Kenya

Country Operational Plan

FY 2017

Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
	GAP	GHP-State	GHP-USAID			
State		1,335,854		**1,335,854**	0	**1,335,854**
USAID		260,878,515		**260,878,515**	56,373,190	**317,251,705**
DOD		17,899,666		**17,899,666**	1,127,860	**19,027,526**
PC		964,428		**964,428**	308,764	**1,273,192**
HHS/CDC	3,320,000	201,447,057		**204,767,057**	0	**204,767,057**
HHS/HRSA		3,634,401		**3,634,401**	0	**3,634,401**
State/AF		50,711		**50,711**	0	**50,711**
State/OGAC		10,000,000		**10,000,000**	0	**10,000,000**
Total	**3,320,000**	**496,210,632**	**0**	**499,530,632**	**57,809,814**	**557,340,446**

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency								Total
	State	DOD	HHS/CDC	HHS/ HRSA	PC	State/ OGAC	USAID	State/AF	
CIRC		1,516,737	6,604,625				2,956,217		**11,077,579**
HBHC	22,163	197,401	206,207				11,648,843		**12,074,614**
HKID	22,163	1,866,466	4,387,033	878,737	24,122		24,795,650	50,711	**32,024,882**
HLAB		833,179	11,171,151	350,000			1,634,071		**13,988,401**
HMBL			1,699,848				850,000		**2,549,848**
HMIN			1,564,088				0		**1,564,088**
HTXD						10,000,000	65,686,810		**75,686,810**
HTXS		6,679,283	79,564,444	550,000			76,864,328		**163,658,055**

Budget Code	Agency								Total
	State	DOD	HHS/CDC	HHS/ HRSA	PC	State/ OGAC	USAID	State/AF	
HVAB		3,394	86,535		29,353		3,838,801		**3,958,083**
HVCT		1,351,806	25,271,140				15,528,217		**42,151,163**
HVMS	1,217,654	991,138	11,897,993		879,855		0		**14,986,640**
HVOP		1,421,957	22,574,257	1,347,664	26,157		17,278,327		**42,648,362**
HVSI	59,099	1,003,138	10,356,162	400,000			10,075,000		**21,893,399**
HVTB		53,937	7,870,714				3,147,400		**11,072,051**
IDUP		0	1,211,896				1,099,983		**2,311,879**
MTCT		1,370,450	8,789,199		4,941		13,096,730		**23,261,320**
OHSS	14,775		3,819,071	108,000			5,415,000		**9,356,846**
PDCS		45,781	126,789				1,318,426		**1,490,996**
PDTX		564,999	7,565,905				5,644,712		**13,775,616**
	1,335,854	**17,899,666**	**204,767,057**	**3,634,401**	**964,428**	**10,000,000**	**260,878,515**	**50,711**	**499,530,632**

Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	11,648,843	0
HKID	31,873,640	0
HVTB	10,746,427	0
PDCS	1,318,426	0
Total Technical Area Planned Funding:	**55,587,336**	**0**

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	13,115,892	0
HVSI	19,960,000	0
OHSS	8,000,000	0
Total Technical Area Planned Funding:	**41,075,892**	**0**

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	10,920,059	0
HMBL	2,500,000	0
HMIN	1,500,000	0
HVAB	3,838,801	0
HVCT	41,752,076	0
HVOP	42,270,817	0
IDUP	2,205,375	0
MTCT	23,025,615	0

Total Technical Area Planned Funding:	**128,012,743**	**0**

Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXD	75,686,810	0
HTXS	162,815,876	0
PDTX	13,603,350	0
Total Technical Area Planned Funding:	**252,106,036**	**0**

Technical Area Summary Indicators and Targets

Indicator Number	Label	2018
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,251,142
	Number of new ANC and L&D clients	
	By Age (Denominator): Unknown Age	108
	By Age (Denominator): <10	3
	By Age (Denominator): 10-14	2,748
	By Age (Denominator): <15-19	148,843
	By Age (Denominator): 20-24	409,101
	By Age (Denominator): 25-49	686,399
	By Age (Denominator): 50+	7,520
	By Number of known positives: Unknown Age	10
	By Number of known positives: <10	0
	By Number of known positives: 10-14	42
	By Number of known positives: 15-19	2,513
	By Number of known positives: 20-24	10,971
	By Number of known positives:	28,753

	25-49	
	By Number of known positives: 50+	361
	By Number of new positives: Unknown Age	7
	By Number of new positives: <10	0
	By Number of new positives: 10-14	28
	By Number of new positives: 15-19	1,730
	By Number of new positives: 20-24	8,467
	By Number of new positives: 25-49	16,572
	By Number of new positives: 50+	208
	By Number of new negative: Unknown Age	158
	By Number of new negative: <10	0
	By Number of new negative: 10-14	1,853
	By Number of new negative: 15-19	144,100
	By Number of new negative: 20-24	388,684
	By Number of new negative: 25-49	633,568
	By Number of new negative: 50+	8,837
	By Age (Numerator): Unknown Age	108
	By Age (Numerator): <10	2
	By Age (Numerator): 10-14	2,647
	By Age (Numerator): 15-19	147,895
	By Age (Numerator): 20-24	405,244
	By Age (Numerator): 25-49	687,562
	By Age (Numerator): 50+	7,524
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	n/a
	Number of pregnant women with known HIV status (includes women who were tested for HIV and	64,669

	received their results)	
	Number of new ANC and L&D clients	
	By Age (Denominator): Unknown Age	0
	By Age (Denominator): <10	0
	By Age (Denominator): 10-14	269
	By Age (Denominator): 15-19	1,891
	By Age (Denominator): 20-24	25,056
	By Age (Denominator): 25-49	37,453
	By Age (Denominator): 50+	0
	By known positives: <Unknown Age	0
	By known positives: <10	0
	By known positives: 10-14	0
	By known positives: 15-19	80
	By known positives: 20-24	111
	By known positives: 25-49	176
	By known positives: 50+	0
	By new positives: Unknown Age	0
	By new positives: <10	0
	By new positives: 10-14	0
	By new positives: 15-19	1
	By new positives: 20-24	92
	By new positives: 25-49	96
	By new positives: 50+	0
	By new negatives: Unknown Age	0
	By new negatives: <10	0
	By new negatives: 10-14	19
	By new negatives: 15-19	1,727
	By new negatives: 20-24	23,965
	By new negatives: 25-49	36,179
	By new negatives: 50+	0

	By Age (Numerator): Unknown Age	0
	By Age (Numerator): <10	0
	By Age (Numerator): 10-14	6
	By Age (Numerator): : 15-19	1,428
	By Age (Numerator): 20-24	24,942
	By Age (Numerator): 25-49	38,293
	By Age (Numerator): 50+	0
PMTCT_ART_DSD	PMTCT_ART_DSD Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	5 %
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	61,964
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,251,142
	New on ART	24,275
	Already on ART at beginning of current pregnancy	37,689
PMTCT_ART_TA	PMTCT_ART_TA Percentage of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1 %
	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	537

	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	64,669
	New on ART	334
	Already on ART at beginning of current pregnancy	203
KP_MAT_DSD	KP_MAT_DSD Percentage of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	n/a
	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	7,949
	Sex: Male	6,449
	Sex: Female	1,500
	Sum of Sex disaggregates	7,949
	Unknown Sex	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	301,834
	By Age: 0-60 days	4,003
	By Age: 2 months - 9 years	0
	By Age: 10-14	119,747
	By Age: 15-19	32,142
	By Age: 20-24	31,998
	By Age: 25-29	58,647
	By Age: 30-49	52,624
	By Age: 50+	2,673
	Sum of age disaggregates (Prior to FY15)	186,560
	Sum of age disaggregates	297,831

	(FY15-Current)	
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	
	By circumcision technique: Surgical VMMC	272,106
	By circumcision technique: Device-based VMMC	8,414
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	
	By follow-up status: Number of device based circumcision clients who returned at least once for follow-up care within 14 days of device placement	
PrEP_NEW_DSD	PrEP_NEW_DSD Number of individuals who have received antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV infection in the reporting period.	n/a
	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	4,496

	Male 10-14	
	Male 15-19	0
	Male 20-24	1
	Male 25-49	3
	Male 50+	0
	Female 10-14	
	Female 15-19	828
	Female 20-24	3,624
	Female 25-49	40
	Female 50+	0
	(15-19)	
	(20-24)	
	FSW	0
	MSM	0
	TG	0
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	n/a
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	522,941
	Total number of people in the target population	
	Age/sex: 10-14 Male	17,617
	Age/sex: 15-19 Male	23,272
	Age/sex: 20-24 Male	41,800
	Age/sex: 25-49 Male	64,786
	Age/sex: 50+ Male	7,088

	Age/sex: 10-14 Female	63,695
	Age/sex: 15-19 Female	115,841
	Age/sex: 20-24 Female	115,586
	Age/sex: 25-49 Female	64,600
	Age/sex: 50+ Female	8,656
	Denominator: Age/sex: 10-14 Male	
	Denominator: Age/sex: 15-19 Male	
	Denominator: Age/sex: 20-24 Male	
	Denominator: Age/sex: 25-49 Male	
	Denominator: Age/sex: 50+ Male	
	Denominator: Age/sex: 10-14 Female	
	Denominator: Age/sex: 15-19 Female	
	Denominator: Age/sex: 20-24 Female	
	Denominator: Age/sex: 25-49 Female	
	Denominator: Age/sex: 50+ Female	
	Service: PP known positive	
	Service: PP tested or referred for testing as part of program	
	New Client: New beneficiary	
	New Client: Returning Beneficiary	
	Aggregated Age/sex: <15 Male	
	Aggregated Age/sex: 15+ Male	
	Aggregated Age/sex: <15 Female	
	Aggregated Age/sex: 15+ Female	
PP_PREV_TA	PP_PREV_TA Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting	n/a

	period (TA-only)	
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	48,120
	Total number of people in the target population	
	Age/sex: 10-14 Male	0
	Age/sex: 15-19 Male	0
	Age/sex: 20-24 Male	0
	Age/sex: 25-49 Male	0
	Age/sex: 50+ Male	0
	Age/sex: 10-14 Female	2,434
	Age/sex: 15-19 Female	27,280
	Age/sex: 20-24 Female	18,406
	Age/sex: 25-49 Female	0
	Age/sex: 50+ Female	0
	Sum of Age/Sex disaggregates	48,120
	Aggregated Age/sex: <15 Male	
	Aggregated Age/sex: 15+ Male	
	Aggregated Age/sex: <15 Female	
	Aggregated Age/sex: 15+ Female	
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a
	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards	177,564

	required	
	Total estimated number of key population in the catchment area	
	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	18,027
	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	12,291
	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	10
	By key population type: Female	132,040

	sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	12,643
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,553
	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: People in	

	prisons and enclosed settings (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men who are sex workers (Denominator: Total estimated number of key population in the catchment area	
	By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Transgender who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Females who inject drugs (Female PWID) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: Men who have sex with men/Transgender	

	(MSM/TG) (Denominator: Total estimated number of key population in the catchment area)	
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)	
	By Service: KP known status	
	By Service: KP was tested as part of the program and/or KP was referred for testing as part of the program	
	By New Client Status: New beneficiary	
	By New Client Status: Returning beneficiary within the current report period	
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	272,291
	By Test Result: Positive	5,818
	Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 10-14, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 10-14, Male, Positive	
	Service Delivery Point (Community)	

	Homebased testing: 15-19, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 15-19, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 15-19, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 15-19, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 20-24, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 20-24, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 20-24, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 20-24, Male, Positive	
	Service Delivery Point (Community) Homebased testing: 25-49, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 25-49, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 25-49, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 25-49, Male, Positive	

	Service Delivery Point (Community) Homebased testing: 50+, Female, Negative	
	Service Delivery Point (Community) Homebased testing: 50+, Female, Positive	
	Service Delivery Point (Community) Homebased testing: 50+, Male, Negative	
	Service Delivery Point (Community) Homebased testing: 50+, Male, Positive	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Homebased testing: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Homebased testing: <1, Negative	
	Service Delivery Point (Community) Homebased testing: <1, Positive	
	Service Delivery Point (Community) Homebased testing: 1-9, Negative	
	Service Delivery Point (Community) Homebased testing: 1-9, Positive	
	Service Delivery Point Agg Age (Community) Homebased testing: <15, Female, Negative	

	Service Delivery Point Agg Age (Community) Homebased testing: <15, Female, Positive	
	Service Delivery Point Agg Age (Community) Homebased testing: <15, Male, Negative	
	Service Delivery Point Agg Age (Community) Homebased testing: <15, Male, Positive	
	Service Delivery Point Agg Age (Community) Homebased testing: 15+, Female, Negative	
	Service Delivery Point Agg Age (Community) Homebased testing: 15+, Female, Positive	
	Service Delivery Point Agg Age (Community) Homebased testing: 15+, Male, Negative	
	Service Delivery Point Agg Age (Community) Homebased testing: 15+, Male, Positive	
	Service Delivery Point Agg Age (Community) Homebased testing: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Community) Homebased testing: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Community) Homebased testing: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Community) Homebased testing: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	22

	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	21
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	55
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	34
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	1
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	85
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	5
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	195
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	5
	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	313
	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	17
	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	235
	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	10
	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	22
	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	0

	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	15
	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	0
	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Inpatient: <1, Negative	6
	Service Delivery Point (Facility) Inpatient: <1, Positive	
	Service Delivery Point (Facility) Inpatient: 1-9, Negative	6
	Service Delivery Point (Facility) Inpatient: 1-9, Positive	
	Service Delivery Point Agg Age (Facility) Inpatient: <15, Female, Negative	54
	Service Delivery Point Agg Age (Facility) Inpatient: <15, Female, Positive	1
	Service Delivery Point Agg Age (Facility) Inpatient: <15, Male, Negative	29
	Service Delivery Point Agg Age (Facility) Inpatient: <15, Male,	

	Positive	
	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Female, Negative	1,012
	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Female, Positive	25
	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Male, Negative	857
	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Male, Positive	24
	Service Delivery Point Agg Age (Facility) Inpatient: Unknown Age, Female, Negative	1
	Service Delivery Point Agg Age (Facility) Inpatient: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Facility) Inpatient: Unknown Age, Male, Negative	1
	Service Delivery Point Agg Age (Facility) Inpatient: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Malnutrition: Negative	3
	Service Delivery Point (Facility) Malnutrition: Positive	
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	

	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 25-49, Female,	

	Positive	
	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Mobile Testing: <1, Negative	
	Service Delivery Point (Community) Mobile Testing: <1, Positive	
	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	

	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	
	Service Delivery Point Agg Age (Community) Mobile Testing: <15, Female, Negative	
	Service Delivery Point Agg Age (Community) Mobile Testing: <15, Female, Positive	
	Service Delivery Point Agg Age (Community) Mobile Testing: <15, Male, Negative	
	Service Delivery Point Agg Age (Community) Mobile Testing: <15, Male, Positive	
	Service Delivery Point Agg Age (Community) Mobile Testing: 15+, Female, Negative	
	Service Delivery Point Agg Age (Community) Mobile Testing: 15+, Female, Positive	
	Service Delivery Point Agg Age (Community) Mobile Testing: 15+, Male, Negative	
	Service Delivery Point Agg Age (Community) Mobile Testing: 15+, Male, Positive	
	Service Delivery Point Agg Age (Community) Mobile Testing: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Community) Mobile Testing: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Community) Mobile Testing: Unknown Age, Male, Negative	

	Service Delivery Point Agg Age (Community) Mobile Testing: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	45
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	1
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	108
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	4
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	642
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	34
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	532
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	51
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	5,355
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	190
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	3,168
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	183
	Service Delivery Point (Facility) Other PITC: 25-49, Female,	15,131

	Negative	
	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	536
	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	5,876
	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	235
	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	579
	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	29
	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	214
	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	6
	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	5
	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Other PITC: <1, Negative	10
	Service Delivery Point (Facility) Other PITC: <1, Positive	
	Service Delivery Point (Facility) Other PITC: 1-9, Negative	22

	Service Delivery Point (Facility) Other PITC: 1-9, Positive	1
	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Negative	11,249
	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Positive	445
	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Negative	5,767
	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Positive	139
	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Negative	109,688
	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Positive	1,961
	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Negative	41,097
	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Positive	1,398
	Service Delivery Point Agg Age (Facility) Other PITC: Unknown Age, Female, Negative	209
	Service Delivery Point Agg Age (Facility) Other PITC: Unknown Age, Female, Positive	10
	Service Delivery Point Agg Age (Facility) Other PITC: Unknown Age, Male, Negative	132

	Service Delivery Point Agg Age (Facility) Other PITC: Unknown Age, Male, Positive	3
	Service Delivery Point (Community) Other: 10-14, Female, Negative	
	Service Delivery Point (Community) Other: 10-14, Female, Positive	
	Service Delivery Point (Community) Other: 10-14, Male, Negative	
	Service Delivery Point (Community) Other: 10-14, Male, Positive	
	Service Delivery Point (Community) Other: 15-19, Female, Negative	
	Service Delivery Point (Community) Other: 15-19, Female, Positive	
	Service Delivery Point (Community) Other: 15-19, Male, Negative	
	Service Delivery Point (Community) Other: 15-19, Male, Positive	
	Service Delivery Point (Community) Other: 20-24, Female, Negative	
	Service Delivery Point (Community) Other: 20-24, Female, Positive	
	Service Delivery Point (Community) Other: 20-24, Male, Negative	
	Service Delivery Point (Community) Other: 20-24, Male, Positive	
	Service Delivery Point (Community) Other: 25-49, Female, Negative	
	Service Delivery Point (Community) Other: 25-49, Female, Positive	
	Service Delivery Point (Community) Other: 25-49, Male, Negative	
	Service Delivery Point (Community)	

	Other: 25-49, Male, Positive	
	Service Delivery Point (Community) Other: 50+, Female, Negative	
	Service Delivery Point (Community) Other: 50+, Female, Positive	
	Service Delivery Point (Community) Other: 50+, Male, Negative	
	Service Delivery Point (Community) Other: 50+, Male, Positive	
	Service Delivery Point (Community) Other: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Other: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Other: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Other: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Other: <1, Negative	
	Service Delivery Point (Community) Other: <1, Positive	
	Service Delivery Point (Community) Other: 1-9, Negative	
	Service Delivery Point (Community) Other: 1-9, Positive	
	Service Delivery Point Agg Age (Community) Other: <15, Female, Negative	
	Service Delivery Point Agg Age (Community) Other: <15, Female,	

	Positive	
	Service Delivery Point Agg Age (Community) Other: <15, Male, Negative	
	Service Delivery Point Agg Age (Community) Other: <15, Male, Positive	
	Service Delivery Point Agg Age (Community) Other: 15+, Female, Negative	
	Service Delivery Point Agg Age (Community) Other: 15+, Female, Positive	
	Service Delivery Point Agg Age (Community) Other: 15+, Male, Negative	
	Service Delivery Point Agg Age (Community) Other: 15+, Male, Positive	
	Service Delivery Point Agg Age (Community) Other: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Community) Other: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Community) Other: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Community) Other: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Pediatric : <5 Negative	
	Service Delivery Point (Facility) Pediatric : <5 Positive	

	Service Delivery Point (Facility) TB: 10-14, Female, Negative	
	Service Delivery Point (Facility) TB: 10-14, Female, Positive	
	Service Delivery Point (Facility) TB: 10-14, Male, Negative	
	Service Delivery Point (Facility) TB: 10-14, Male, Positive	
	Service Delivery Point (Facility) TB: 15-19, Female, Negative	
	Service Delivery Point (Facility) TB: 15-19, Female, Positive	
	Service Delivery Point (Facility) TB: 15-19, Male, Negative	
	Service Delivery Point (Facility) TB: 15-19, Male, Positive	
	Service Delivery Point (Facility) TB: 20-24, Female, Negative	
	Service Delivery Point (Facility) TB: 20-24, Female, Positive	
	Service Delivery Point (Facility) TB: 20-24, Male, Negative	
	Service Delivery Point (Facility) TB: 20-24, Male, Positive	
	Service Delivery Point (Facility) TB: 25-49, Female, Negative	
	Service Delivery Point (Facility) TB: 25-49, Female, Positive	
	Service Delivery Point (Facility) TB: 25-49, Male, Negative	2
	Service Delivery Point (Facility) TB: 25-49, Male, Positive	
	Service Delivery Point (Facility) TB: 50+, Female, Negative	

	Service Delivery Point (Facility) TB: 50+, Female, Positive	
	Service Delivery Point (Facility) TB: 50+, Male, Negative	
	Service Delivery Point (Facility) TB: 50+, Male, Positive	
	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) TB: <1, Negative	
	Service Delivery Point (Facility) TB: <1, Positive	
	Service Delivery Point (Facility) TB: 1-9, Negative	
	Service Delivery Point (Facility) TB: 1-9, Positive	
	Service Delivery Point Agg Age (Facility) TB: <15, Female, Negative	
	Service Delivery Point Agg Age (Facility) TB: <15, Female, Positive	
	Service Delivery Point Agg Age (Facility) TB: <15, Male, Negative	
	Service Delivery Point Agg Age (Facility) TB: <15, Male, Positive	
	Service Delivery Point Agg Age (Facility) TB: 15+, Female, Negative	
	Service Delivery Point Agg Age (Facility) TB: 15+, Female, Positive	

	Service Delivery Point Agg Age (Facility) TB: 15+, Male, Negative	
	Service Delivery Point Agg Age (Facility) TB: 15+, Male, Positive	
	Service Delivery Point Agg Age (Facility) TB: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Facility) TB: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Facility) TB: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Facility) TB: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) VMMC: <1, Negative	
	Service Delivery Point (Facility) VMMC: <1, Positive	
	Service Delivery Point (Facility) VMMC: 10-14, Negative	3
	Service Delivery Point (Facility) VMMC: 10-14, Positive	
	Service Delivery Point (Facility) VMMC: 15-19, Negative	4
	Service Delivery Point (Facility) VMMC: 15-19, Positive	
	Service Delivery Point (Facility) VMMC: 1-9, Negative	3
	Service Delivery Point (Facility) VMMC:	
	Service Delivery Point (Facility) VMMC: 20-24, Negative	6

	Service Delivery Point (Facility) VMMC: 20-24, Positive	
	Service Delivery Point (Facility) VMMC: 25-49, Negative	3
	Service Delivery Point (Facility) VMMC: 25-49, Positive	
	Service Delivery Point (Facility) VMMC: 50+, Negative	
	Service Delivery Point (Facility) VMMC: 50+, Positive	
	Service Delivery Point (Facility) VMMC: Unknown Age, Negative	
	Service Delivery Point (Facility) VMMC: Unknown Age, Positive	
	Service Delivery Point Agg Age (Facility) VMMC: <15, Negative	
	Service Delivery Point Agg Age (Facility) VMMC: <15, Positive	
	Service Delivery Point Agg Age (Facility) VMMC: 15+, Negative	1
	Service Delivery Point Agg Age (Facility) VMMC: 15+, Positive	
	Service Delivery Point Agg Age (Facility) VMMC: Unknown Age, Negative	
	Service Delivery Point Agg Age (Facility) VMMC: Unknown Age, Positive	
	Service Delivery Point (Facility) Index: 10-14, Female, Negative	
	Service Delivery Point (Facility) Index: 10-14, Female, Positive	
	Service Delivery Point (Facility) Index: 10-14, Male, Negative	

	Service Delivery Point (Facility) Index: 10-14, Male, Positive	
	Service Delivery Point (Facility) Index: 15-19, Female, Negative	
	Service Delivery Point (Facility) Index: 15-19, Female, Positive	
	Service Delivery Point (Facility) Index: 15-19, Male, Negative	
	Service Delivery Point (Facility) Index: 15-19, Male, Positive	
	Service Delivery Point (Facility) Index: 20-24, Female, Negative	
	Service Delivery Point (Facility) Index: 20-24, Female, Positive	
	Service Delivery Point (Facility) Index: 20-24, Male, Negative	
	Service Delivery Point (Facility) Index: 20-24, Male, Positive	
	Service Delivery Point (Facility) Index: 25-49, Female, Negative	
	Service Delivery Point (Facility) Index: 25-49, Female, Positive	
	Service Delivery Point (Facility) Index: 25-49, Male, Negative	
	Service Delivery Point (Facility) Index: 25-49, Male, Positive	
	Service Delivery Point (Facility) Index: 50+, Female, Negative	
	Service Delivery Point (Facility) Index: 50+, Female, Positive	
	Service Delivery Point (Facility) Index: 50+, Male, Negative	
	Service Delivery Point (Facility) Index: 50+, Male, Positive	

	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Index: <1, Negative	
	Service Delivery Point (Facility) Index: <1, Positive	
	Service Delivery Point (Facility) Index: 1-9, Negative	
	Service Delivery Point (Facility) Index: 1-9, Positive	
	Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative	
	Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	
	Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative	
	Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive	
	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	
	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	

	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	
	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Positive	
	By Key Population: FSW, Negative	
	By Key Population: FSW, Positive	
	By Key Population: MSM, Negative	
	By Key Population: MSM, Positive	
	By Key Population: People in prisons and other enclosed settings, Negative	
	By Key Population: People in prisons and other enclosed settings, Positive	
	By Key Population: PWID, Negative	
	By Key Population: PWID, Positive	
	By Key Population: TG, Negative	
	By Key Population: TG, Positive	
	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	
	Service Delivery Point (Community)	

	Index Mod: 10-14, Female, Positive	
	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	
	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	
	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	
	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	
	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	
	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	
	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	
	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	
	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	
	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	
	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	
	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	
	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	
	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	
	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	

	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	
	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	
	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	
	Service Delivery Point (Community) Index Mod: Unknown Age, Female, Negative	
	Service Delivery Point (Community) Index Mod: Unknown Age, Female, Positive	
	Service Delivery Point (Community) Index Mod: Unknown Age, Male, Negative	
	Service Delivery Point (Community) Index Mod: Unknown Age, Male, Positive	
	Service Delivery Point (Community) Index Mod: <1, Negative	
	Service Delivery Point (Community) Index Mod: <1, Positive	
	Service Delivery Point (Community) Index Mod: 1-9, Negative	
	Service Delivery Point (Community) Index Mod: 1-9, Positive	
	Service Delivery Point Agg Age (Community) Index Mod: <15, Female, Negative	
	Service Delivery Point Agg Age (Community) Index Mod: <15, Female, Positive	
	Service Delivery Point Agg Age (Community) Index Mod: <15, Male, Negative	

	Service Delivery Point Agg Age (Community) Index Mod: <15, Male, Positive	
	Service Delivery Point Agg Age (Community) Index Mod: 15+, Female, Negative	
	Service Delivery Point Agg Age (Community) Index Mod: 15+, Female, Positive	
	Service Delivery Point Agg Age (Community) Index Mod: 15+, Male, Negative	
	Service Delivery Point Agg Age (Community) Index Mod: 15+, Male, Positive	
	Service Delivery Point Agg Age (Community) Index Mod: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Community) Index Mod: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Community) Index Mod: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Community) Index Mod: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) ANC: <1, Negative	
	Service Delivery Point (Facility) ANC: <1, Positive	
	Service Delivery Point (Facility) ANC: 10-14, Negative	
	Service Delivery Point (Facility) ANC: 10-14, Positive	

	Service Delivery Point (Facility) ANC: 15-19, Negative	
	Service Delivery Point (Facility) ANC: 15-19, Positive	
	Service Delivery Point (Facility) ANC: 1-9, Negative	
	Service Delivery Point (Facility) ANC: 1-9, Positive	
	Service Delivery Point (Facility) ANC: 20-24, Negative	
	Service Delivery Point (Facility) ANC: 20-24, Positive	
	Service Delivery Point (Facility) ANC: 25-49, Negative	
	Service Delivery Point (Facility) ANC: 25-49, Positive	
	Service Delivery Point (Facility) ANC: 50+, Negative	
	Service Delivery Point (Facility) ANC: 50+, Positive	
	Service Delivery Point (Facility) ANC: Unknown Age, Negative	
	Service Delivery Point (Facility) ANC: Unknown Age, Positive	
	Service Delivery Point Agg Age (Facility) ANC: <15, Negative	4,545
	Service Delivery Point Agg Age (Facility) ANC: <15, Positive	27
	Service Delivery Point Agg Age (Facility) ANC: 15+, Negative	60,067
	Service Delivery Point Agg Age (Facility) ANC: 15+, Positive	250
	Service Delivery Point Agg Age (Facility) ANC: Unknown Age,	

	Negative	
	Service Delivery Point Agg Age (Facility) ANC: Unknown Age, Positive	
	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	20
	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	1
	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	15
	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	1
	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	110
	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	3
	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	130
	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	10
	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	726
	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	53
	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	576
	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	28
	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	2,295
	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	106
	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	1,703

	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	62
	Service Delivery Point (Facility) VCT: 50+, Female, Negative	253
	Service Delivery Point (Facility) VCT: 50+, Female, Positive	13
	Service Delivery Point (Facility) VCT: 50+, Male, Negative	148
	Service Delivery Point (Facility) VCT: 50+, Male, Positive	7
	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	
	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	
	Service Delivery Point (Facility) VCT: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) VCT: <1, Negative	2
	Service Delivery Point (Facility) VCT: <1, Positive	
	Service Delivery Point (Facility) VCT: 1-9, Negative	9
	Service Delivery Point (Facility) VCT: 1-9, Positive	0
	Service Delivery Point Agg Age (Facility) VCT: <15, Female, Negative	19
	Service Delivery Point Agg Age (Facility) VCT: <15, Female, Positive	

	Service Delivery Point Agg Age (Facility) VCT: <15, Male, Negative	12
	Service Delivery Point Agg Age (Facility) VCT: <15, Male, Positive	1
	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Negative	4,630
	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Positive	153
	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Negative	4,191
	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Positive	146
	Service Delivery Point Agg Age (Facility) VCT: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Facility) VCT: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Facility) VCT: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Facility) VCT: Unknown Age, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 10-14, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 10-14, Male, Positive	

	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 25-49, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 25-49, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 25-49, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 25-49, Male, Positive	
	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	
	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	
	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	
	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Female,	

	Negative	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Female, Positive	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Male, Negative	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Male, Positive	
	Service Delivery Point (Community) VCT Mod: <1, Negative	
	Service Delivery Point (Community) VCT Mod: <1, Positive	
	Service Delivery Point (Community) VCT Mod: 1-9, Negative	
	Service Delivery Point (Community) VCT Mod: 1-9, Positive	
	Service Delivery Point Agg Age (Community) VCT Mod: <15, Female, Negative	
	Service Delivery Point Agg Age (Community) VCT Mod: <15, Female, Positive	
	Service Delivery Point Agg Age (Community) VCT Mod: <15, Male, Negative	
	Service Delivery Point Agg Age (Community) VCT Mod: <15, Male, Positive	
	Service Delivery Point Agg Age (Community) VCT Mod: 15+, Female, Negative	
	Service Delivery Point Agg Age (Community) VCT Mod: 15+,	

	Female, Positive	
	Service Delivery Point Agg Age (Community) VCT Mod: 15+, Male, Negative	
	Service Delivery Point Agg Age (Community) VCT Mod: 15+, Male, Positive	
	Service Delivery Point Agg Age (Community) VCT Mod: Unknown Age, Female, Negative	
	Service Delivery Point Agg Age (Community) VCT Mod: Unknown Age, Female, Positive	
	Service Delivery Point Agg Age (Community) VCT Mod: Unknown Age, Male, Negative	
	Service Delivery Point Agg Age (Community) VCT Mod: Unknown Age, Male, Positive	
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	96 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	67,573
	Total number of registered new and relapsed TB cases, during the reporting period.	70,344
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	

	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered	

	new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,594
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	32,940
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,363
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with	26,154

	documented HIV status, during the reporting period)	
	Result: Known HIV positive at service entry	
	Result: New HIV positive	
	Result: HIV Negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 10-14	

	(Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Age/Sex: Female 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period.)	
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,701
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	34,171
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,513
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	27,114

TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	81 %
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,937
	Total number of registered new and relapsed TB cases, during the reporting period.	3,623
	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	516
	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	267
	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,616
	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,222
	Age/Sex: <1 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: 1-9 (Numerator: Number of registered new and relapsed TB cases with documented HIV status,	

	during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Male 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	

	Age/Sex: Female 20-24 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Age/Sex: Female 50+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	230
	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	964
	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	433
	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,310
	Result: Known HIV positive at	

	service entry	
	Result: New HIV positive	
	Result: HIV negative	
	Age/Sex: <1 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: 1-9 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Male 50+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	

	Age/Sex: Female 15-19 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	
	By Test Result: Positive	304,369
	Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative	8,031
	Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive	86
	Service Delivery Point (Community) Homebased testing: 10-14, Male, Negative	6,030
	Service Delivery Point (Community) Homebased testing: 10-14, Male, Positive	81
	Service Delivery Point (Community) Homebased testing: 15-19, Female, Negative	35,631
	Service Delivery Point (Community) Homebased testing: 15-19, Female, Positive	527

	Service Delivery Point (Community) Homebased testing: 15-19, Male, Negative	31,138
	Service Delivery Point (Community) Homebased testing: 15-19, Male, Positive	326
	Service Delivery Point (Community) Homebased testing: 20-24, Female, Negative	37,730
	Service Delivery Point (Community) Homebased testing: 20-24, Female, Positive	650
	Service Delivery Point (Community) Homebased testing: 20-24, Male, Negative	27,664
	Service Delivery Point (Community) Homebased testing: 20-24, Male, Positive	377
	Service Delivery Point (Community) Homebased testing: 25-49, Female, Negative	58,644
	Service Delivery Point (Community) Homebased testing: 25-49, Female, Positive	1,182
	Service Delivery Point (Community) Homebased testing: 25-49, Male, Negative	52,235
	Service Delivery Point (Community) Homebased testing: 25-49, Male, Positive	879
	Service Delivery Point (Community) Homebased testing: 50+, Female, Negative	18,669
	Service Delivery Point (Community) Homebased testing: 50+, Female,	320

	Positive	
	Service Delivery Point (Community) Homebased testing: 50+, Male, Negative	11,695
	Service Delivery Point (Community) Homebased testing: 50+, Male, Positive	266
	Service Delivery Point (Community) Homebased testing: Unknown Age, Female, Negative	0
	Service Delivery Point (Community) Homebased testing: Unknown Age, Female, Positive	0
	Service Delivery Point (Community) Homebased testing: Unknown Age, Male, Negative	0
	Service Delivery Point (Community) Homebased testing: Unknown Age, Male, Positive	0
	Service Delivery Point (Community) Homebased testing: <1, Negative	0
	Service Delivery Point (Community) Homebased testing: <1, Positive	0
	Service Delivery Point (Community) Homebased testing: 1-9, Negative	15,102
	Service Delivery Point (Community) Homebased testing: 1-9, Positive	255
	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Negative	277
	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Female, Positive	7
	Service Delivery Point by Agg Age (Community) Homebased testing:	202

	<15, Male, Negative	
	Service Delivery Point by Agg Age (Community) Homebased testing: <15, Male, Positive	4
	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Negative	502
	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive	6
	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Male, Negative	449
	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Male, Positive	4
	Service Delivery Point by Agg Age (Community) Homebased testing: Unknown Age, Female, Negative	0
	Service Delivery Point by Agg Age (Community) Homebased testing: Unknown Age, Female, Positive	0
	Service Delivery Point by Agg Age (Community) Homebased testing: Unknown Age, Male, Negative	0
	Service Delivery Point by Agg Age (Community) by Aggregated Age: Homebased testing: Unknown Age, Male, Positive	0
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	5,810
	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	69
	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	5,929

	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	103
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	19,743
	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	341
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	9,401
	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	147
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	34,534
	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	891
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	12,222
	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	306
	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	74,638
	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	2,662
	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	36,650
	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	1,441
	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	18,464
	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	536
	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	14,249
	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	382

	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	0
	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	0
	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	0
	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	0
	Service Delivery Point (Facility) Inpatient: <1, Negative	1,896
	Service Delivery Point (Facility) Inpatient: <1, Positive	32
	Service Delivery Point (Facility) Inpatient: 1-9, Negative	16,131
	Service Delivery Point (Facility) Inpatient: 1-9, Positive	228
	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	41,974
	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive	190
	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	41,588
	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive	178
	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	243,651

	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	8,737
	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	130,975
	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	5,871
	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Negative	0
	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Positive	0
	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Negative	0
	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Positive	0
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	1,831
	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	7
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	1,996
	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	22
	Service Delivery Point (Community) Mobile Testing: 15-19, Female,	10,813

	Negative	
	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	168
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	9,311
	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	80
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	12,492
	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	431
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	8,677
	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	171
	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	17,410
	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	516
	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	17,065
	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	540
	Service Delivery Point (Community)	3,719

	Mobile Testing: 50+, Female, Negative	
	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	42
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	2,483
	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	54
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Negative	0
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Positive	0
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Negative	0
	Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Positive	0
	Service Delivery Point (Community) Mobile Testing: <1, Negative	29
	Service Delivery Point (Community) Mobile Testing: <1, Positive	2
	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	115
	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	4
	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Negative	825
	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Positive	0

	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Negative	733
	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Positive	0
	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative	6,005
	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Positive	21
	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Negative	5,161
	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive	20
	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Female, Negative	0
	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Female, Positive	0
	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Male, Negative	0
	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Male, Positive	0
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	143,682
	Service Delivery Point (Facility) Other PITC: 10-14, Female,	794

	Positive	
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	114,493
	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	654
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	473,739
	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	7,417
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	285,713
	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	3,078
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	705,480
	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	17,462
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	318,861
	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	6,244
	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	1,257,704
	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	42,986
	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	777,205
	Service Delivery Point (Facility)	29,962

	Other PITC: 25-49, Male, Positive	
	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	213,884
	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	5,187
	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	166,011
	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	4,937
	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	6
	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	0
	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	0
	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0
	Service Delivery Point (Facility)Other PITC: <1, Negative	7,480
	Service Delivery Point (Facility) Other PITC: <1, Positive	133
	Service Delivery Point (Facility) Other PITC: 1-9, Negative	357,187
	Service Delivery Point (Facility) Other PITC: 1-9, Positive	2,171
	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	214,240
	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female,	2,378

	Positive	
	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	190,625
	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	2,206
	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	1,533,359
	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	28,754
	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	1,045,138
	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	14,752
	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Female, Positive	0
	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Negative	1
	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Positive	2
	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1,438
	Service Delivery Point (Community)	4

	Other: 10-14, Female, Positive	
	Service Delivery Point (Community) Other: 10-14, Male, Negative	0
	Service Delivery Point (Community) Other: 10-14, Male, Positive	0
	Service Delivery Point (Community) Other: 15-19, Female, Negative	26,397
	Service Delivery Point (Community) Other: 15-19, Female, Positive	207
	Service Delivery Point (Community) Other: 15-19, Male, Negative	0
	Service Delivery Point (Community) Other: 15-19, Male, Positive	0
	Service Delivery Point (Community) Other: 20-24, Female, Negative	18,442
	Service Delivery Point (Community) Other: 20-24, Female, Positive	530
	Service Delivery Point (Community) Other: 20-24, Male, Negative	0
	Service Delivery Point (Community) Other: 20-24, Male, Positive	0
	Service Delivery Point (Community) Other: 25-49, Female, Negative	0
	Service Delivery Point (Community) Other: 25-49, Female, Positive	0
	Service Delivery Point (Community) Other: 25-49, Male, Negative	0
	Service Delivery Point (Community) Other: 25-49, Male, Positive	0
	Service Delivery Point (Community) Other: 50+, Female, Negative	0
	Service Delivery Point (Community) Other: 50+, Female, Positive	0
	Service Delivery Point (Community)	0

	Other: 50+, Male, Negative	
	Service Delivery Point (Community) Other: 50+, Male, Positive	0
	Service Delivery Point (Community) Other: Unknown Age, Female, Negative	0
	Service Delivery Point (Community) Other: Unknown Age, Female, Positive	0
	Service Delivery Point (Community) Other: Unknown Age, Male, Negative	0
	Service Delivery Point (Community) Other: Unknown Age, Male, Positive	0
	Service Delivery Point (Community) Other: <1, Negative	0
	Service Delivery Point (Community) Other: <1, Positive	0
	Service Delivery Point (Community) Other: 1-9, Negative	0
	Service Delivery Point (Community) Other: 1-9, Positive	0
	Service Delivery Point by Agg Age (Community) Other: <15, Female, Negative	
	Service Delivery Point by Agg Age (Community) Other: <15, Female, Positive	
	Service Delivery Point by Agg Age (Community) Other: <15, Male, Negative	
	Service Delivery Point by Agg Age (Community) Other: <15, Male, Positive	

	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Negative	
	Service Delivery Point by Agg Age (Community) Other: 15+, Female, Positive	
	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Negative	
	Service Delivery Point by Agg Age (Community) Other: 15+, Male, Positive	
	Service Delivery Point by Agg Age (Community) Other: Unknown Age, Female, Negative	
	Service Delivery Point by Agg Age (Community) Other: Unknown Age, Female, Positive	
	Service Delivery Point by Agg Age (Community) Other: Unknown Age, Male, Negative	
	Service Delivery Point by Agg Age (Community) Other: Unknown Age, Male, Positive	
	Service Delivery Point (Facility) Pediatric : <5 Negative	224,454
	Service Delivery Point (Facility) Pediatric : <5 Positive	2,593
	Service Delivery Point (Facility) TB: 10-14, Female, Negative	219
	Service Delivery Point (Facility) TB: 10-14, Female, Positive	19
	Service Delivery Point (Facility) TB: 10-14, Male, Negative	185
	Service Delivery Point (Facility) TB:	29

	10-14, Male, Positive	
	Service Delivery Point (Facility) TB: 15-19, Female, Negative	1,123
	Service Delivery Point (Facility) TB: 15-19, Female, Positive	92
	Service Delivery Point (Facility) TB: 15-19, Male, Negative	841
	Service Delivery Point (Facility) TB: 15-19, Male, Positive	84
	Service Delivery Point (Facility) TB: 20-24, Female, Negative	1,807
	Service Delivery Point (Facility) TB: 20-24, Female, Positive	219
	Service Delivery Point (Facility) TB: 20-24, Male, Negative	1,294
	Service Delivery Point (Facility) TB: 20-24, Male, Positive	132
	Service Delivery Point (Facility) TB: 25-49, Female, Negative	6,360
	Service Delivery Point (Facility) TB: 25-49, Female, Positive	1,307
	Service Delivery Point (Facility) TB: 25-49, Male, Negative	5,882
	Service Delivery Point (Facility) TB: 25-49, Male, Positive	1,228
	Service Delivery Point (Facility) TB: 50+, Female, Negative	1,491
	Service Delivery Point (Facility) TB: 50+, Female, Positive	134
	Service Delivery Point (Facility) TB: 50+, Male, Negative	1,146
	Service Delivery Point (Facility) TB: 50+, Male, Positive	160
	Service Delivery Point (Facility) TB:	0

	Unknown Age, Female, Negative	
	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	1
	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	1
	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	1
	Service Delivery Point (Facility) TB: <1, Negative	35
	Service Delivery Point (Facility) TB: <1, Positive	0
	Service Delivery Point (Facility) TB: 1-9, Negative	516
	Service Delivery Point (Facility) TB: 1-9, Positive	121
	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	7,691
	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	58
	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	8,337
	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Positive	52
	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	49,916
	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	1,783
	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	29,866
	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	1,096
	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Negative	1

	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Positive	12
	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Negative	0
	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Positive	0
	Service Delivery Point (Facility) VMMC: <1, Negative	1,946
	Service Delivery Point (Facility) VMMC: <1, Positive	10
	Service Delivery Point (Facility) VMMC: 10-14, Negative	74,716
	Service Delivery Point (Facility) VMMC: 10-14, Positive	607
	Service Delivery Point (Facility) VMMC: 15-19, Negative	20,253
	Service Delivery Point (Facility) VMMC: 15-19, Positive	442
	Service Delivery Point (Facility) VMMC: 1-9, Negative	58
	Service Delivery Point (Facility) VMMC: 1-9, Positive	0
	Service Delivery Point (Facility) VMMC: 20-24, Negative	19,033
	Service Delivery Point (Facility) VMMC: 20-24, Positive	273
	Service Delivery Point (Facility) VMMC: 25-49, Negative	70,072
	Service Delivery Point (Facility) VMMC: 25-49, Positive	399
	Service Delivery Point (Facility)	1,797

	VMMC: 50+, Negative	
	Service Delivery Point (Facility) VMMC: 50+, Positive	26
	Service Delivery Point (Facility) VMMC: Unknown Age, Negative	0
	Service Delivery Point (Facility) VMMC: Unknown Age, Positive	0
	Service Delivery Point (Facility) VMMC: <15, Negative	16,757
	Service Delivery Point by Agg Age (Facility) VMMC: <15, Positive	11
	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Negative	27,865
	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Positive	352
	Service Delivery Point by Agg Age (Facility) VMMC: Unknown Age, Negative	0
	Service Delivery Point by Agg Age (Facility) VMMC: Unknown Age, Positive	0
	Service Delivery Point (Facility) Index: 10-14, Female, Negative	6,384
	Service Delivery Point (Facility) Index: 10-14, Female, Positive	55
	Service Delivery Point (Facility) Index: 10-14, Male, Negative	4,815
	Service Delivery Point (Facility) Index: 10-14, Male, Positive	32
	Service Delivery Point (Facility) Index: 15-19, Female, Negative	36,183
	Service Delivery Point (Facility) Index: 15-19, Female, Positive	704
	Service Delivery Point (Facility)	21,149

	Index: 15-19, Male, Negative	
	Service Delivery Point (Facility) Index: 15-19, Male, Positive	496
	Service Delivery Point (Facility) Index: 20-24, Female, Negative	22,322
	Service Delivery Point (Facility) Index: 20-24, Female, Positive	889
	Service Delivery Point (Facility) Index: 20-24, Male, Negative	11,607
	Service Delivery Point (Facility) Index: 20-24, Male, Positive	341
	Service Delivery Point (Facility) Index: 25-49, Female, Negative	41,520
	Service Delivery Point (Facility) Index: 25-49, Female, Positive	2,009
	Service Delivery Point (Facility) Index: 25-49, Male, Negative	26,409
	Service Delivery Point (Facility) Index: 25-49, Male, Positive	1,407
	Service Delivery Point (Facility) Index: 50+, Female, Negative	6,669
	Service Delivery Point (Facility) Index: 50+, Female, Positive	263
	Service Delivery Point (Facility) Index: 50+, Male, Negative	5,512
	Service Delivery Point (Facility) Index: 50+, Male, Positive	221
	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	41
	Service Delivery Point (Facility)	1

	Index: Unknown Age, Male, Negative	
	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
	Service Delivery Point (Facility) Index: <1, Negative	386
	Service Delivery Point (Facility) Index: <1, Positive	4
	Service Delivery Point (Facility) Index: 1-9, Negative	17,996
	Service Delivery Point (Facility) Index: 1-9, Positive	138
	Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative	29,094
	Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	196
	Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative	28,419
	Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive	242
	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	145,672
	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	3,295
	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	78,058
	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	2,030
	Service Delivery Point Agg Age (Facility) Index: Unknown Age,	0

	Female, Negative	
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Positive	0
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Negative	0
	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Positive	0
	By Key Population: FSW, Negative	66,003
	By Key Population: FSW, Positive	2,348
	By Key Population: MSM, Negative	11,508
	By Key Population: MSM, Positive	491
	By Key Population: People in prisons and other enclosed settings, Negative	61,322
	By Key Population: People in prisons and other enclosed settings, Positive	2,201
	By Key Population: PWID, Negative	12,500
	By Key Population: PWID, Positive	578
	By Key Population: TG, Negative	1,329
	By Key Population: TG, Positive	12
	Service Delivery Point (Facility) Malnutrition: Negative	25,919
	Service Delivery Point (Facility) Malnutrition: Positive	262
	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	0
	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	0
	Service Delivery Point (Community)	0

	Index Mod: 10-14, Male, Negative	
	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	0
	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	3
	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	0
	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	15
	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	0
	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	24
	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	8
	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	30
	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	2
	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	54
	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	18
	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	54
	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	12
	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	0
	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	2

	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	2
	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	2
	Service Delivery Point (Community) Index Mod: Unknown Age, Female, Negative	0
	Service Delivery Point (Community) Index Mod: Unknown Age, Female, Positive	0
	Service Delivery Point (Community) Index Mod: Unknown Age, Male, Negative	0
	Service Delivery Point (Community) Index Mod: Unknown Age, Male, Positive	0
	Service Delivery Point (Community) Index Mod: <1, Negative	2
	Service Delivery Point (Community) Index Mod: <1, Positive	0
	Service Delivery Point (Community) Index Mod: 1-9, Negative	0
	Service Delivery Point (Community) Index Mod: 1-9, Positive	0
	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Negative	508
	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Positive	5
	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Negative	426
	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male,	6

	Positive	
	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Negative	219
	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Positive	6
	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Negative	287
	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Positive	2
	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Female, Negative	0
	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Female, Positive	0
	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Male, Negative	0
	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Male, Positive	0
	Service Delivery Point (Facility) ANC: <1, Negative	4
	Service Delivery Point (Facility) ANC: <1, Positive	0
	Service Delivery Point (Facility) ANC: 10-14, Negative	1,166
	Service Delivery Point (Facility) ANC: 10-14, Positive	25
	Service Delivery Point (Facility) ANC: 15-19, Negative	42,970

	Service Delivery Point (Facility) ANC: 15-19, Positive	1,257
	Service Delivery Point (Facility) ANC: 1-9, Negative	5
	Service Delivery Point (Facility) ANC: 1-9, Positive	1
	Service Delivery Point (Facility) ANC: 20-24, Negative	119,953
	Service Delivery Point (Facility) ANC: 20-24, Positive	5,108
	Service Delivery Point (Facility) ANC: 25-49, Negative	190,532
	Service Delivery Point (Facility) ANC: 25-49, Positive	11,586
	Service Delivery Point (Facility) ANC: 50+, Negative	1,758
	Service Delivery Point (Facility) ANC: 50+, Positive	180
	Service Delivery Point (Facility) ANC: Unknown Age, Negative	0
	Service Delivery Point (Facility) ANC: Unknown Age, Positive	0
	Service Delivery Point by Agg Age (Facility) ANC: <15, Negative	13,975
	Service Delivery Point by Agg Age (Facility) ANC: <15, Positive	236
	Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative	740,323
	Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive	16,210
	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Negative	1
	Service Delivery Point by Agg Age	0

	(Facility) ANC: Unknown Age, Positive	
	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	9,892
	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	181
	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	10,109
	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	133
	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	55,655
	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	896
	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	35,597
	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	496
	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	110,465
	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	3,239
	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	74,419
	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	1,486
	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	194,757
	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	9,147
	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	148,485
	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	6,949

	Service Delivery Point (Facility) VCT: 50+, Female, Negative	21,148
	Service Delivery Point (Facility) VCT: 50+, Female, Positive	905
	Service Delivery Point (Facility) VCT: 50+, Male, Negative	18,424
	Service Delivery Point (Facility) VCT: 50+, Male, Positive	932
	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	0
	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	0
	Service Delivery Point (Facility) VCT:	0
	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
	Service Delivery Point (Facility) VCT: <1, Negative	1,940
	Service Delivery Point (Facility) VCT: <1, Positive	132
	Service Delivery Point (Facility) VCT: 1-9, Negative	20,022
	Service Delivery Point (Facility) VCT: 1-9, Positive	376
	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	81,022
	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	784
	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	65,101

	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	474
	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	506,938
	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	14,231
	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	342,321
	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	8,528
	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Negative	0
	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Positive	0
	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Negative	0
	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Positive	0
	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	1
	Service Delivery Point (Community) VCT Mod: 10-14, Female, Positive	0
	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	1
	Service Delivery Point (Community) VCT Mod: 10-14, Male, Positive	0
	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	212

	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	2
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	105
	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	3
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	986
	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	27
	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	391
	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	17
	Service Delivery Point (Community) VCT Mod: 25-49, Female, Negative	1,761
	Service Delivery Point (Community) VCT Mod: 25-49, Female, Positive	53
	Service Delivery Point (Community) VCT Mod: 25-49, Male, Negative	436
	Service Delivery Point (Community) VCT Mod: 25-49, Male, Positive	11
	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	21
	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	0
	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	13
	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	0
	Service Delivery Point (Community) VCT Mod: Unknown Age, Female, Negative	0
	Service Delivery Point (Community)	0

	VCT Mod: Unknown Age, Female, Positive	
	Service Delivery Point (Community) VCT Mod: Unknown Age, Male, Negative	0
	Service Delivery Point (Community) VCT Mod: Unknown Age, Male, Positive	0
	Service Delivery Point (Community) VCT Mod: <1, Negative	1
	Service Delivery Point (Community) VCT Mod: <1, Positive	0
	Service Delivery Point (Community) VCT Mod: 1-9, Negative	2
	Service Delivery Point (Community) VCT Mod: 1-9, Positive	0
	Service Delivery Point by Agg Age (Community) VCT Mod: <15, Female, Negative	938
	Service Delivery Point by Agg Age (Community) VCT Mod: <15, Female, Positive	0
	Service Delivery Point by Agg Age (Community) VCT Mod: <15, Male, Negative	897
	Service Delivery Point by Agg Age (Community) VCT Mod: <15, Male, Positive	0
	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Female, Negative	6,209
	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Female, Positive	23
	Service Delivery Point by Agg Age	5,205

	(Community) VCT Mod: 15+, Male, Negative	
	Service Delivery Point by Agg Age (Community) VCT Mod: 15+, Male, Positive	18
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Female, Negative	0
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Female, Positive	0
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Male, Negative	0
	Service Delivery Point by Agg Age (Community) VCT Mod: Unknown Age, Male, Positive	0
GEND_GBV_DSD	Number of people receiving post-GBV care	874,793
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	691,330
	By type of service: Sexual Violence (Post-Rape Care)	182,940
	By PEP service provision (related to sexual violence services provided)	56,828
	<10, Female, Physical and/or Emotional Violence	13,055
	<10, Female, Sexual Violence (Post-Rape Care)	4,190
	<10, Male, Physical and/or Emotional Violence	12,248
	<10, Male, Sexual Violence (Post-Rape Care)	1,940

	10-14, Female, Physical and/or Emotional Violence	40,011
	10-14, Female, Sexual Violence (Post-Rape Care)	11,413
	10-14, Male, Physical and/or Emotional Violence	17,101
	10-14, Male, Sexual Violence (Post-Rape Care)	2,519
	15-19, Female, Physical and/or Emotional Violence	42,438
	15-19, Female, Sexual Violence (Post-Rape Care)	12,924
	15-19, Male, Physical and/or Emotional Violence	16,526
	15-19, Male, Sexual Violence (Post-Rape Care)	3,026
	20-24, Female, Physical and/or Emotional Violence	45,577
	20-24, Female, Sexual Violence (Post-Rape Care)	18,592
	20-24, Male, Physical and/or Emotional Violence	14,249
	20-24, Male, Sexual Violence (Post-Rape Care)	3,751
	25-49, Female, Physical and/or Emotional Violence	70,115
	25-49, Female, Sexual Violence (Post-Rape Care)	29,646
	25-49, Male, Physical and/or Emotional Violence	30,668
	25-49, Male, Sexual Violence (Post-Rape Care)	7,335
	50+, Female, Physical and/or Emotional Violence	9,249

	50+, Female, Sexual Violence (Post-Rape Care)	3,385
	50+, Male, Physical and/or Emotional Violence	4,663
	50+, Male, Sexual Violence (Post-Rape Care)	1,625
	Unknown Age, Female, Physical and/or Emotional Violence	173
	Unknown Age, Female, Sexual Violence (Post-Rape Care)	17
	Unknown Age, Male, Physical and/or Emotional Violence	1,490
	Unknown Age, Male, Sexual Violence (Post-Rape Care)	200
GEND_GBV_TA	Number of people receiving post-GBV care	1,789
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	2,271
	By type of service: Sexual Violence (Post-Rape Care)	959
	By PEP service provision (related to sexual violence services provided)	156
	<10, Female, Physical and/or Emotional Violence	
	<10, Female, Sexual Violence (Post-Rape Care)	
	<10, Male, Physical and/or Emotional Violence	
	<10, Male, Sexual Violence (Post-Rape Care)	
	10-14, Female, Physical and/or Emotional Violence	
	10-14, Female, Sexual Violence	

	(Post-Rape Care)	
	10-14, Male, Physical and/or Emotional Violence	
	10-14, Male, Sexual Violence (Post-Rape Care)	
	15-19, Female, Physical and/or Emotional Violence	180
	15-19, Female, Sexual Violence (Post-Rape Care)	
	15-19, Male, Physical and/or Emotional Violence	
	15-19, Male, Sexual Violence (Post-Rape Care)	
	20-24, Female, Physical and/or Emotional Violence	270
	20-24, Female, Sexual Violence (Post-Rape Care)	
	20-24, Male, Physical and/or Emotional Violence	
	20-24, Male, Sexual Violence (Post-Rape Care)	
	25-49, Female, Physical and/or Emotional Violence	
	25-49, Female, Sexual Violence (Post-Rape Care)	
	25-49, Male, Physical and/or Emotional Violence	
	25-49, Male, Sexual Violence (Post-Rape Care)	
	50+, Female, Physical and/or Emotional Violence	
	50+, Female, Sexual Violence (Post-Rape Care)	
	50+, Male, Physical and/or	

	Emotional Violence	
	50+, Male, Sexual Violence (Post-Rape Care)	
	Unknown Age, Female, Physical and/or Emotional Violence	
	Unknown Age, Female, Sexual Violence (Post-Rape Care)	
	Unknown Age, Male, Physical and/or Emotional Violence	
	Unknown Age, Male, Sexual Violence (Post-Rape Care)	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	817,207
	Age/Sex: 10-14 Male	108,351
	Age/Sex: 15-17 Male	82,941
	By: Age/sex: Male 18-24	29,318
	By: Age/sex: Male 25+	0
	Age/Sex: 18+ Male	
	Age/Sex: 10-14 Female	193,282
	Age/Sex: 15-17 Female	179,757
	By: Age/sex: 18-24 Female	45,762
	By: Age/sex: 25+ Female	843
	Age/Sex: 18+ Female	
	Sum of Age/Sex disaggregates	564,331
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	35,324
	Required only for DREAMS countries - By service, age and sex:	58,196

	Education Support Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	5,278
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	53
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1	
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	877
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	457
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	351
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	0
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	9,346
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	12,417
	Required only for DREAMS	757

	countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	0
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	1,775
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	960
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	721
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	0
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	999
	Required only for DREAMS countries - By service, age and sex:	6,520

	Social Protection Female 15-17	
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	7,531
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	127
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1	
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	891
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	460
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	356
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	939
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	25,296
	Required only for DREAMS countries - By service, age and sex:	22,892

	Economic Strengthening Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	172
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	778
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	420
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	333
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	0
	Required only for DREAMS countries - By service, age and sex: Other Services Female <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	42,361
	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	77,424
	Required only for DREAMS countries - By service, age and sex:	32,635

	Other Services Female 18-24	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	843
	Required only for DREAMS countries - By service, age and sex: Other Services Male <1	
	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	152
	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	82
	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	77
	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	0
	Age/Sex: <1	3,101
	Age/Sex: 1-9	176,240
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Male	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Male 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-9	

	Required only for DREAMS countries - By service, age and sex: Other Services Male 1-9	
	Program Completion: Active	803,520
	Program Completion: Graduation	13,103
	Program Completion: Transferred	286
	Program Completion: Exited without graduation	298
	By Aggregated Age/Sex: <18 Male	
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Social Protection Programs Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9	
	Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9	
OVC_SERV_TA	Number of active beneficiaries served by PEPFAR OVC programs	

	for children and families affected by HIV/AIDS	
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-9 Male	
	Age/Sex: 10-14 Male	
	Age/Sex: 15-17 Male	
	By age/sex: 18-24 Male	
	By age/sex: 25+ Male	
	Age/Sex: 18+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-9 Female	
	Age/Sex: 10-14 Female	
	Age/Sex: 15-17 Female	
	By age/sex: 18-24 Female	
	By age/sex: 25+ Female	
	Age/Sex: 18+ Female	
	Sum of Age/Sex disaggregates	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 10-14	
	Required only for DREAMS	

	countries: By Service Area, age and sex: Education Support Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Female 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support Male 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female <1	

	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Female 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program	

	Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program Male 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 15-17	
	Required only for DREAMS	

	countries: By Service Area, age and sex: Social Protection Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Female 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection Male 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 1-4	

	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Female 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male <1	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male	

	10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening Male 25+	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female <1	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 1-4	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 5-9	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 10-14	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 15-17	3,657
	Required only for DREAMS countries: By Service Area, age and	5,486

	sex: Other Service Areas Female 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 25+	
	Age/Sex: <1	
	Age/Sex: 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Education Support 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Parenting/Caregiver Program 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Social Protection 1-9	
	Required only for DREAMS countries: By Service Area, age and sex: Economic Strengthening 1-9	
	Program Completion: Active	
	Program Completion: Graduated	
	Program Completion: Transferred	
	Program Completion: Exited without graduation	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas <1	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 10-14	
	Required only for DREAMS	

	countries: By Service Area, age and sex: Other Service Areas Male 15-17	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 18-24	
	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Male 25+	
	By Aggregated Age/Sex: <18 Male	
	By Aggregated Age/Sex: 18+ Male	
	By Aggregated Age/Sex: <18 Female	
	By Aggregated Age/Sex: 18+ Female	
	Required only for DREAMS countries - By service, age and sex: Education Support 1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Program 1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening 1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Other Service Areas 1-9 Female	
	Required only for DREAMS countries - By service, age and sex: Social Protection 1-9 Female	
	Required only for DREAMS countries: By Service Area, age and	

	sex: Other Service Areas 1-9	
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	100 %
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	22,914
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	22,936
	Age/Sex: <1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented	

	HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24	

	(Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	821
	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	11,178
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB	709

	cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	10,199
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: >1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting	

	period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB	

	cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	817
	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	11,201
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented	733

	HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	10,205
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	137 %
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	395
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	288
	Age/Sex: <1 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	

	Age/Sex: Male 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the	

	reporting period)	
	Age/Sex: Female 15-19 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	11
	Aggregated Age/Sex: Male 15+	196

	(Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	8
	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	180
	On ART: Already on ART	
	On ART: New on ART	
	Age/Sex: <1 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: 1-9 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 10-14 (Denominator: The number of registered new and	

	relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 15-19 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Male 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 10-14 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 15-19	

	(Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 20-24 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 25-49 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Age/Sex: Female 50+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	9
	Aggregated Age/Sex: Male 15+ (Denominator: The number of	142

	registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	6
	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	131
TB_PREV_DSD	TB_PREV_DSD TB_PREV_DSD	90 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	127,715
	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	141,602

	By Age/Sex (Denominator): <15, Female	3,020
	By Age/Sex (Denominator): <15, Male	2,592
	By Age/Sex (Denominator): 15+, Female	87,445
	By Age/Sex (Denominator): 15+, Male	45,489
	By Therapy type (Denominator): 6-12 Month IPT	129,034
	By Therapy type (Denominator): Alternative Regimen	0
	By Therapy type (Denominator): Continuous IPT	234
	By Age/Sex (Numerator): <15, Female	2,684
	By Age/Sex (Numerator): <15, Male	2,311
	By Age/Sex (Numerator): 15+, Female	78,876
	By Age/Sex (Numerator): 15+, Male	40,955
	By Therapy type (Numerator): 6-12 Month IPT	116,734
	By Therapy type (Numerator): Alternative Regimen	0
	By Therapy type (Numerator): Continuous IPT	221
TB_PREV_TA	TB_PREV_TA TB_PREV_TA	90 %
	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	318
	The number of ART patients who	353

	were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	
	By Age/Sex (Denominator): <15, Female	4
	By Age/Sex (Denominator): <15, Male	4
	By Age/Sex (Denominator): 15+, Female	68
	By Age/Sex (Denominator): 15+, Male	32
	By Therapy type (Denominator): 6-12 Month IPT	
	By Therapy type (Denominator):Alternative Regimen	
	By Therapy type (Denominator):Continuous IPT	
	By Age/Sex (Numerator): <15, Female	4
	By Age/Sex (Numerator): <15, Male	3
	By Age/Sex (Numerator): 15+, Female	61
	By Age/Sex (Numerator): 15+, Male	29
	By Therapy type (Numerator): 6-12 Month IPT	
	By Therapy type (Numerator): Alternative Regimen	
	By Therapy type (Numerator):	

	Continuous IPT	
TX_TB_DSD	TX_TB_DSD The proportion of ART patients who were screened who are receiving TB treatment	1 %
	Number of ART patients who were started on TB treatment during the reporting period.	9,314
	Number of ART patients who were screened for TB at least once during the reporting period	1,138,976
	Numerator: By Aggregated Age/Sex: <15, Female	312
	Numerator: By Aggregated Age/Sex: <15, Male	334
	Numerator: By Aggregated Age/Sex: 15+, Female	4,113
	Numerator: By Aggregated Age/Sex: 15+, Male	4,493
	Denominator: By Aggregated Age/Sex: <15, Female	39,768
	Denominator: By Aggregated Age/Sex: <15, Male	34,743
	Denominator: By Aggregated Age/Sex:15+, Female	634,884
	Denominator: By Aggregated Age/Sex:15+, Male	304,715
	Denominator: By Screen Result: Negative	906,121
	Denominator: By Screen Result: Positive	218,253
	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	215,241

	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	9,477
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	33,587
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	170,150
TX_TB_TA	TX_TB_TA The proportion of ART patients who were screened who are receiving TB treatment	3 %
	Number of ART patients who were started on TB treatment during the reporting period.	162
	Number of ART patients who were screened for TB at least once during the reporting period	4,737
	Numerator: By Aggregated Age/Sex: <15, Female	2
	Numerator: By Aggregated Age/Sex: <15, Male	1
	Numerator: By Aggregated Age/Sex: 15+, Female	52
	Numerator: By Aggregated Age/Sex: 15+, Male	49
	Denominator: By Aggregated Age/Sex: <15, Female	257
	Denominator: By Aggregated Age/Sex: <15, Male	114
	Denominator: By Aggregated Age/Sex: 15+, Female	2,972
	Denominator: By Aggregated Age/Sex: 15+, Male	1,338

	Denominator: By Screen Result: Negative	3,743
	Denominator: By Screen Result: Positive	937
	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	887
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	470
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	141
	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	746
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	62,200
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	
	By infants who received their first virologic HIV test between 2 and 12 months of age	
	Sum of Infant Age disaggregates	

	By infants with a positive virologic test result within 12 months of birth	
	Number of infants with a positive virological test result within 2 months of birth	1,525
	Number of infants with a positive virological test result within 12 months of birth	
	Unknown, <= 2 months	410
	Unknown, 2 - 12 months	200
	Number of infants with a negative virological test result within 2 months of birth	37,702
	Number of infants with a positive virological test result between 2 and 12 months of birth	3,020
	Number of infants with a negative virological test result between 2 and 12 months of birth	19,343
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a
	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	537
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	
	By infants who received a virologic test within 2 months of birth	
	By infants who received their first virologic HIV test between 2 and 12	

	months of age	
	Sum of Infant Age disaggregates	
	By infants with a positive virologic test result within 12 months of birth	
	Unknown, <= 2 months	0
	Unknown, 2 - 12 months	0
	Number of infants with a positive virological test result within 2 months of birth	19
	Number of infants with a negative virological test result within 2 months of birth	266
	Number of infants with a positive virological test result between 2 and 12 months of birth	110
	Number of infants with a negative virological test result between 2 and 12 months of birth	142
	Number of infants with a positive virological test result within 12 months of birth	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,310,158
	Age/Sex: 15-19 Male	12,531
	Age/Sex: 15-19 Female	19,456
	Age/Sex: 20+ Female	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	13,905
	Aggregated Age/Sex: 15+ Male	118,917
	Aggregated Age/Sex: <15 Female	15,883
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	242,274

	Sum of Aggregated Age/Sex <15	29,788
	Sum of Aggregated Age/Sex 15+	361,191
	Sum of Aggregated Age/Sex disaggregates	390,979
	Age/Sex: <1	1,868
	Age/Sex: <1-9	33,202
	Age/Sex: 10-14 Male	12,335
	Age/Sex: 10-14 Female	14,234
	Aggregated Age/Sex: 1-14 Male	
	Age/Sex: 20-24 Male	19,842
	Age/Sex: 25-49 Male	183,181
	Age/Sex: 50+ Male	57,673
	Age/Sex: 20-24 Female	59,769
	Age/Sex: 25-49 Female	421,311
	Age/Sex: 50+ Female	84,210
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	8,745
	Age/Sex: <1 Male	
	Age/Sex: 1-4 Male	
	Age/Sex: 5-14 Male	
	Age/Sex: 15-19 Male	
	Age/Sex: 20+ Male	
	Age/Sex: <1 Female	
	Age/Sex: 1-4 Female	
	Age/Sex: 5-14 Female	
	Age/Sex: 15-19 Female	
	Age/Sex: 20+ Female	
	Sum of Age/Sex disaggregations	
	Aggregated Age/Sex: <1 Male	
	Aggregated Age/Sex: <1 Female	
	Aggregated Age/Sex: <15 Male	238

	Aggregated Age/Sex: 1-14 Male	
	Aggregated Age/Sex: 15+ Male	2,503
	Aggregated Age/Sex: <15 Female	476
	Aggregated Age/Sex: 1-14 Female	
	Aggregated Age/Sex: 15+ Female	5,528
	Sum of Aggregated Age/Sex <15	714
	Sum of Aggregated Age/Sex 15+	8,031
	Sum of Aggregated Age/Sex disaggregates	8,745
	Age/Sex: <1	
	Age/Sex: 1-9	
	Age/Sex: 10-14 Male	
	Age/Sex: 10-14 Female	
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	
	Age/Sex: 20-24 Male	
	Age/Sex: 25-49 Male	
	Age/Sex: 50+ Male	
	Age/Sex: 20-24 Female	
	Age/Sex: 25-49 Female	
	Age/Sex: 50+ Female	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	272,596
	By Age/Sex: <1	760
	By Age/Sex: 1-9	3,021
	By Age/Sex: 10-14 Male	1,007
	By Age/Sex: 15-19 Male	1,761
	By Age/Sex: 20-24 Male	4,785
	By Age/Sex: 25-49 Male	38,549
	By Age/Sex: 50+ Male	8,731
	By Age/Sex: 10-14 Female	1,108

	By Age/Sex: 15-19 Female	4,862
	By Age/Sex: 20-24 Female	17,725
	By Age/Sex: 25-49 Female	72,162
	By Age/Sex: 50+ Female	10,499
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	4,200
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	33,922
	Aggregated Grouping by Age/Sex: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	5,083
	Aggregated Grouping by Age/Sex: 15+ Female	64,170
	Pregnancy status	16,962
	Breastfeeding status	2,174
	FSW	487
	MSM	86
	People in prisons and other enclosed settings	779
	TG	0
	Aggregated Grouping by Age/Sex: 1-14 Female	
	By Key populations: People who inject drugs (PWID)	57
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,278

	By Age/Sex: <1	
	By Age/Sex: 1-9	
	By Age/Sex: <1 Male	
	By Age/Sex: 1-4 Male	
	By Age/Sex: 5-9 Male	
	By Age/Sex: 10-14 Male	
	By Age/Sex: 15-19 Male	
	By Age/Sex: 20-24 Male	
	By Age/Sex: 25-49 Male	
	By Age/Sex: 50+ Male	
	By Age/Sex: <1 Female	
	By Age/Sex: 1-4 Female	
	By Age/Sex: 5-9 Female	
	By Age/Sex: 10-14 Female	
	By Age/Sex: 15-19 Female	
	By Age/Sex: 20-24 Female	
	By Age/Sex: 25-49 Female	
	By Age/Sex: 50+ Female	
	Sum of Age/Sex disaggregates	
	Aggregated Grouping by Age: <1	
	Aggregated Grouping by Age: <1 Male	
	Aggregated Grouping by Age/Sex: <15 Male	78
	Aggregated Grouping by Age/Sex: 1-14 Male	
	Aggregated Grouping by Age/Sex: 15+ Male	654
	Aggregated Grouping by Age: <1 Female	
	Aggregated Grouping by Age/Sex: <15 Female	140
	Aggregated Grouping by Age/Sex:	

	1-14 Female	
	Aggregated Grouping by Age/Sex: 15+ Female	1,442
	Sum of Aggregated Age/Sex disaggregates	2,314
	Pregnancy status	17
	Breastfeeding status	2
	FSW	
	MSM	
	People in prisons and other enclosed settings	
	TG	
	By Key populations: People who inject drugs (PWID)	
TX_PVLS_DSD	TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml)	89 %
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,210,601
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,363,490
	Numerator: Indication: Routine	1,097,808
	Numerator: Indication: Targeted	111,671

	Numerator: Preg/BF by Indication: Pregnant Routine	29,186
	Numerator: Preg/BF by Indication: Breastfeeding Routine	24,905
	Numerator: Preg/BF by Indication: Pregnant Targeted	5,920
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	3,709
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	

	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	3,245
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	33,409
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	4,535
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	69,940
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	31,826
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	327,166

	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	40,095
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	695,460
	Denominator: Indication: Routine	1,227,059
	Denominator: Indication: Targeted	126,413
	Denominator: Preg/BF by Indication: Pregnant Routine	30,418
	Denominator: Preg/BF by Indication: Breastfeeding Routine	26,792
	Denominator: Preg/BF by Indication: Pregnant Targeted	5,918
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	5,740
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	

	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	4,423
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	37,488
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	6,118

	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	77,738
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	39,583
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	365,431
	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	49,564
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	775,566
	Numerator Aggregated Age/Sex: <15 Male	
	Numerator Aggregated Age/Sex: 15+ Male	
	Numerator Aggregated Age/Sex: <15 Female	
	Numerator Aggregated Age/Sex: 15+ Female	
	Denominator Aggregated Age/Sex: <15 Male	
	Denominator Aggregated Age/Sex: 15+ Male	
	Denominator Aggregated Age/Sex: <15 Female	
	Denominator Aggregated Age/Sex: 15+ Female	
	<15, Routine, Unknown Sex	129
	<15, Targeted, Unknown Sex	19
	<15, Undocumented Test Indication, Female	245
	<15, Undocumented Test Indication, Male	112
	<15, Undocumented Test Indication, Unknown Sex	0

	15+, Routine, Unknown Sex	1,763
	15+, Targeted, Unknown Sex	264
	15+, Undocumented Test Indication, Female	517
	15+, Undocumented Test Indication, Male	393
	15+, Undocumented Test Indication, Unknown Sex	0
	Unknown Age, Routine, Female	0
	Unknown Age, Routine, Male	0
	Unknown Age, Routine, Unknown Sex	0
	Unknown Age, Targeted, Female	60
	Unknown Age, Targeted, Male	59
	Unknown Age, Targeted, Unknown Sex	0
	Unknown Age, Undocumented Test Indication, Female	1
	Unknown Age, Undocumented Test Indication, Male	6
	Unknown Age, Undocumented Test Indication, Unknown Sex	0
	Breastfeeding, Undocumented Test Indication	65
	Pregnant, Undocumented Test Indication	12
	Undocumented Test Indication	1,267
	<15, Routine, Unknown Sex	5
	<15, Targeted, Unknown Sex	1
	<15, Undocumented Test Indication, Female	212
	<15, Undocumented Test Indication, Male	111

	<15, Undocumented Test Indication, Unknown Sex	0
	15+, Routine, Unknown Sex	142
	15+, Targeted, Unknown Sex	21
	15+, Undocumented Test Indication, Female	454
	15+, Undocumented Test Indication, Male	340
	15+, Undocumented Test Indication, Unknown Sex	0
	Unknown Age, Routine, Female	1
	Unknown Age, Routine, Male	0
	Unknown Age, Routine, Unknown Sex	0
	Unknown Age, Targeted, Female	26
	Unknown Age, Targeted, Male	22
	Unknown Age, Targeted, Unknown Sex	0
	Unknown Age, Undocumented Test Indication, Female	0
	Unknown Age, Undocumented Test Indication, Male	0
	Unknown Age, Undocumented Test Indication, Unknown Sex	0
	Breastfeeding, Undocumented Test Indication	64
	Pregnant, Undocumented Test Indication	10
	Undocumented Test Indication	1,122
TX_PVLS_TA	TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12	58 %

	months with a suppressed viral load (<1000 copies/ml)	
	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	5,088
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	8,731
	Numerator: Age/Sex by Indication: <1 Routine	
	Numerator: Age/Sex by Indication: <1 Targeted	
	Numerator: Age/Sex by Indication: 1-9 Routine	
	Numerator: Age/Sex by Indication: 1-9 Targeted	
	Numerator: Age/Sex by Indication: 10-14 Female Routine	
	Numerator: Age/Sex by Indication: 10-14 Female Targeted	
	Numerator: Age/Sex by Indication: 10-14 Male Routine	
	Numerator: Age/Sex by Indication: 10-14 Male Targeted	
	Numerator: Age/Sex by Indication: 15-19 Female Routine	
	Numerator: Age/Sex by Indication: 15-19 Female Targeted	
	Numerator: Age/Sex by Indication: 15-19 Male Routine	

	Numerator: Age/Sex by Indication: 15-19 Male Targeted	
	Numerator: Age/Sex by Indication: 20-24 Female Routine	
	Numerator: Age/Sex by Indication: 20-24 Female Targeted	
	Numerator: Age/Sex by Indication: 20-24 Male Routine	
	Numerator: Age/Sex by Indication: 20-24 Male Targeted	
	Numerator: Age/Sex by Indication: 25-49 Female Routine	
	Numerator: Age/Sex by Indication: 25-49 Female Targeted	
	Numerator: Age/Sex by Indication: 25-49 Male Routine	
	Numerator: Age/Sex by Indication: 25-49 Male Targeted	
	Numerator: Age/Sex by Indication: 50+ Female Routine	
	Numerator: Age/Sex by Indication: 50+ Female Targeted	
	Numerator: Age/Sex by Indication: 50+ Male Routine	
	Numerator: Age/Sex by Indication: 50+ Male Targeted	
	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	701
	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	106
	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	373
	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	48

	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	2,254
	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	320
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,107
	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	138
	Numerator: Indication: Routine	4,425
	Numerator: Indication: Targeted	663
	Numerator: Preg/BF by Indication: Breastfeeding Routine	20
	Numerator: Preg/BF by Indication: Breastfeeding Targeted	4
	Numerator: Preg/BF by Indication: Pregnant Routine	10
	Numerator: Preg/BF by Indication: Pregnant Targeted	2
	Denominator: Indication: Routine	7,518
	Denominator: Indication: Targeted	1,213
	Denominator: Age/Sex by Indication: <1 Routine	
	Denominator: Age/Sex by Indication: <1 Targeted	
	Denominator: Age/Sex by Indication: 1-9 Routine	
	Denominator: Age/Sex by Indication: 1-9 Targeted	
	Denominator: Age/Sex by Indication: 10-14 Female Routine	
	Denominator: Age/Sex by Indication: 10-14 Female Targeted	
	Denominator: Age/Sex by Indication: 10-14 Male Routine	

	Denominator: Age/Sex by Indication: 10-14 Male Targeted	
	Denominator: Age/Sex by Indication: 15-19 Female Routine	
	Denominator: Age/Sex by Indication: 15-19 Female Targeted	
	Denominator: Age/Sex by Indication: 15-19 Male Routine	
	Denominator: Age/Sex by Indication: 15-19 Male Targeted	
	Denominator: Age/Sex by Indication: 20-24 Female Routine	
	Denominator: Age/Sex by Indication: 20-24 Female Targeted	
	Denominator: Age/Sex by Indication: 20-24 Male Routine	
	Denominator: Age/Sex by Indication: 20-24 Male Targeted	
	Denominator: Age/Sex by Indication: 25-49 Female Routine	
	Denominator: Age/Sex by Indication: 25-49 Female Targeted	
	Denominator: Age/Sex by Indication: 25-49 Male Routine	
	Denominator: Age/Sex by Indication: 25-49 Male Targeted	
	Denominator: Age/Sex by Indication: 50+ Female Routine	
	Denominator: Age/Sex by Indication: 50+ Female Targeted	
	Denominator: Age/Sex by Indication: 50+ Male Routine	
	Denominator: Age/Sex by Indication: 50+ Male Targeted	

	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,268
	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	234
	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	624
	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	116
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	3,847
	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	583
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,763
	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	281
	Denominator: Preg/BF by Indication: Breastfeeding Routine	23
	Denominator: Preg/BF by Indication: Breastfeeding Targeted	5
	Denominator: Preg/BF by Indication: Pregnant Routine	11
	Denominator: Preg/BF by Indication: Pregnant Targeted	2
	Numerator Aggregated Age/Sex: <15 Male	
	Numerator Aggregated Age/Sex: 15+ Male	
	Numerator Aggregated Age/Sex: <15 Female	
	Numerator Aggregated Age/Sex: 15+ Female	
	Denominator Aggregated Age/Sex: <15 Male	

	Denominator Aggregated Age/Sex: 15+ Male	
	Denominator Aggregated Age/Sex: <15 Female	
	Denominator Aggregated Age/Sex: 15+ Female	
	<15, Routine, Unknown Sex	
	<15, Targeted, Unknown Sex	
	<15, Undocumented Test Indication, Female	0
	<15, Undocumented Test Indication, Male	
	<15, Undocumented Test Indication, Unknown Sex	
	15+, Routine, Unknown Sex	
	15+, Targeted, Unknown Sex	
	15+, Undocumented Test Indication, Female	
	15+, Undocumented Test Indication, Male	
	15+, Undocumented Test Indication, Unknown Sex	
	Unknown Age, Routine, Female	7
	Unknown Age, Routine, Male	4
	Unknown Age, Routine, Unknown Sex	
	Unknown Age, Targeted, Female	2
	Unknown Age, Targeted, Male	1
	Unknown Age, Targeted, Unknown Sex	
	Unknown Age, Undocumented Test Indication, Female	
	Unknown Age, Undocumented Test Indication, Male	

	Unknown Age, Undocumented Test Indication, Unknown Sex	
	Breastfeeding, Undocumented Test Indication	
	Pregnant, Undocumented Test Indication	
	Undocumented Test Indication	0
	<15, Routine, Unknown Sex	
	<15, Targeted, Unknown Sex	
	<15, Undocumented Test Indication, Female	2
	<15, Undocumented Test Indication, Male	1
	<15, Undocumented Test Indication, Unknown Sex	
	15+, Routine, Unknown Sex	1
	15+, Targeted, Unknown Sex	
	15+, Undocumented Test Indication, Female	5
	15+, Undocumented Test Indication, Male	2
	15+, Undocumented Test Indication, Unknown Sex	
	Unknown Age, Routine, Female	
	Unknown Age, Routine, Male	
	Unknown Age, Routine, Unknown Sex	
	Unknown Age, Targeted, Female	
	Unknown Age, Targeted, Male	
	Unknown Age, Targeted, Unknown Sex	
	Unknown Age, Undocumented Test Indication, Female	

	Unknown Age, Undocumented Test Indication, Male	
	Unknown Age, Undocumented Test Indication, Unknown Sex	
	Breastfeeding, Undocumented Test Indication	
	Pregnant, Undocumented Test Indication	
	Undocumented Test Indication	0
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	84 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	254,715
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	303,734
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	

	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sed: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	

	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART	
	Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children	

	who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died,	

	those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of	

	adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	15,454
	Numerator by Status: Breastfeeding	2,070
	Denominator by Status: Pregnant	16,001
	Denominator by Status: Breastfeeding	2,077
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7,027
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	79,478
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,018
	Aggregated Age/Sex: 15+ Female	160,366

	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,750
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	92,895
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10,195
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	190,720

TX_RET_TA	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	92 %
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,070
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,258
	Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Male (Numerator:	

	Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Age/Sex: <1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have	

	died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months	

	prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and	

	those lost to follow-up)	
	Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	
	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated	

	ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
	Numerator by Status: Pregnant	17
	Numerator by Status: Breastfeeding	10
	Denominator by Status: Pregnant	17
	Denominator by Status: Breastfeeding	10
	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	171
	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	474
	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	376
	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,046
	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	188

	including those who have died, those who have stopped ART, and those lost to follow-up)	
	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	522
	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	414
	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,133
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	1,567
	By Graduates: Doctors	6
	By Graduates: Nurses	994
	By Graduates: Midwives	0

	By Graduates: Social service workers	1
	By Graduates: Laboratory professionals	90
	By Graduates: Other	476
	Sum of Graduates disaggreagtes	1,567

Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
2866	CENTERS FOR HEALTH SOLUTIONS	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
7139	Palladium Group	NGO	U.S. Agency for International Development	GHP-State	1,200,000
7305	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-State	345,000
9108	American International Health Alliance Twinning Center	NGO	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	2,684,401
9110	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	776,667
9136	International Medical Corps	NGO	U.S. Department of Health and	GHP-State	0

			Human Services/Centers for Disease Control and Prevention		
9143	Henry Jackson Foundation	Private Contractor	U.S. Department of Defense	GHP-State	0
9171	Henry Jackson Foundation	Private Contractor	U.S. Department of Defense	GHP-State	0
11406	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	50,711
12054	CHF International	NGO	U.S. Agency for International Development	GHP-State	2,673,864
12056	Ananda Marga Universal Relief Teams	NGO	U.S. Agency for International Development	GHP-State	576,290
12083	Liverpool VCT and Care	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12530	Nyanza Reproductive Health Society	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12540	University of North Carolina	University	U.S. Agency for International Development	GHP-State	0

12551	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12555	University of Nairobi	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12585	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12598	International Rescue Committee	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12605	Care International	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12637	Futures Group	Private Contractor	U.S. Department	GHP-State	0

			of Health and Human Services/Centers for Disease Control and Prevention		
12656	Eastern Deanery AIDS Relief Program	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12658	Mkomani Society Clinic	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
12664	African Medical and Research Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13025	Impact Research and Development Organization	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13050	Coptic Hospital	FBO	U.S. Department of Health and	GHP-State	0

			Human Services/Centers for Disease Control and Prevention		
13061	MINISTRY OF PUBLIC HEALTH AND SANITATION	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13179	Association of Schools of Public Health	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13302	Hope Worldwide	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13307	Impact Research and Development Organization	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13340	FHI 360	NGO	U.S. Agency for International Development	GHP-State	0

13346	World Health Organization	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	250,000
13354	Kenya Episcopal Conference	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13366	Christian Health Association of Kenya	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13385	University of Manitoba	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13399	University of Maryland	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13474	Hope Worldwide	FBO	U.S. Department	GHP-State	0

			of Health and Human Services/Centers for Disease Control and Prevention		
13481	University of Nairobi	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13543	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13545	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	0
13546	Henry Jackson Foundation	Private Contractor	U.S. Department of Defense	GHP-State	0
13588	Program for Appropriate Technology in Health	NGO	U.S. Agency for International Development	GHP-State	0
13636	JHPIEGO	University	U.S. Agency for International Development	GHP-State	0
13701	Kenya Medical Supplies Agency	Host Country Government Agency	U.S. Agency for International Development	GHP-State	107,669,451
13802	University of	University	U.S. Department	GHP-State	0

	Nairobi		of Health and Human Services/Centers for Disease Control and Prevention		
13868	New Partner	TBD	U.S. Agency for International Development	GHP-State	5,886,680
13882	Children of God Relief Institute	FBO	U.S. Agency for International Development	GHP-State	1,443,097
13919	Clinical and Laboratory Standards Institute	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	575,525
14009	FHI 360	NGO	U.S. Agency for International Development	GHP-State	2,952,941
14012	Moi Teaching and Referral Hospital	Parastatal	U.S. Agency for International Development	GHP-State	16,117,337
14015	IntraHealth International, Inc	NGO	U.S. Agency for International Development	GHP-State	0
14022	African Medical and Research Foundation	NGO	U.S. Agency for International Development	GHP-State	1,857,180
14034	Equity Group Foundation	NGO	U.S. Agency for International Development	GHP-State	0
16450	Kenya Community	NGO	U.S. Agency for	GHP-State	0

	Development Foundation		International Development		
16670	University of Nairobi	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	850,000
16679	International Business & Technical Consultants Inc.	Private Contractor	U.S. Agency for International Development	GHP-State	350,000
16684	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,478,673
16687	Health Strat Kenya	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,950,977
16705	United Nations Office on Drug and Crime (UNODC)	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	1,695,173
16709	Center for Health Solutions (CHS)	NGO	U.S. Agency for International Development	GHP-State	1,500,000
16710	Equity Group Foundation	NGO	U.S. Agency for International Development	GHP-State	0

17190	Life Skills Promoters	NGO	U.S. Agency for International Development	GHP-State	1,068,232
17191	Reformed Church of East Africa	FBO	U.S. Agency for International Development	GHP-State	379,566
17707	PLAN International	NGO	U.S. Agency for International Development	GHP-State	7,659,688
17709	IntraHealth International, Inc	NGO	U.S. Agency for International Development	GHP-State	4,020,000
17711	National Blood Transfusion Service, Kenya	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	850,000
17712	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,960,000
17718	Interchurch Medical Assistance	FBO	U.S. Agency for International Development	GHP-State	8,475,481
17719	Pathfinder International	NGO	U.S. Agency for International Development	GHP-State	9,926,262
17944	FHI 360	NGO	U.S. Agency for International Development	GHP-State	3,931,219

17945	mHealth Kenya	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	850,000
17947	African Medical and Research Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,267,392
17948	African Society for Laboratory Medicine	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	100,000
17950	University of Maryland	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,695,387
17951	FHI 360	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,475,736
17954	Global	Implementing	U.S. Department	GHP-State	3,175,208

	Implementation Solutions	Agency	of Health and Human Services/Centers for Disease Control and Prevention		
17956	JHPIEGO	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
17958	Palladium Group	NGO	U.S. Agency for International Development	GHP-State	2,850,000
17959	University of Nairobi	University	U.S. Agency for International Development	GHP-State	1,500,000
17960	Population Council	NGO	U.S. Agency for International Development	GHP-State	300,000
17964	University of North Carolina	University	U.S. Agency for International Development	GHP-State	200,000
18203	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	18,162,015
18204	University of Nairobi	University	U.S. Department of Health and Human Services/Centers	GHP-State	4,381,085

			for Disease Control and Prevention		
18205	University of Maryland Baltimore	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	7,083,122
18206	Kenya Conference of Catholic Bishops	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	11,141,713
18207	Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,242,218
18208	Impact Research and Development Organization	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	10,783,836
18209	Liverpool VCT and Care	NGO	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	5,626,931

			Control and Prevention		
18213	Ministry of Health (MOH)	Implementing Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,516,289
18214	Palladium Group	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,495,000
18215	Coptic Hospital	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,200,517
18216	University of Maryland Baltimore	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	600,000
18217	County Government of Siaya	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	1,927,704

			Prevention		
18223	University of Maryland	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,500,000
18260	University of Washington	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	650,000
18261	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	300,000
18262	UNAIDS - Joint United Nations Programme on HIV/AIDS	Multi-lateral Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	200,000
18281	Chemonics. Inc	Private Contractor	U.S. Agency for International Development	GHP-State	895,000
18283	TBD	TBD	Redacted	Redacted	Redacted
18284	TBD	TBD	Redacted	Redacted	Redacted
18285	Catholic Relief	FBO	U.S. Agency for	GHP-State	1,600,000

	Services		International Development		
18317	Columbia University Mailman School of Public Health	University	U.S. Department of Health and Human Services/Health Resources and Services Administration	GHP-State	0
18318	Palladium Group	NGO	U.S. Agency for International Development	GHP-State	3,850,000
18490	TBD	TBD	Redacted	Redacted	Redacted
18491	TBD	TBD	Redacted	Redacted	Redacted
18492	TBD	TBD	Redacted	Redacted	Redacted
18493	TBD	TBD	Redacted	Redacted	Redacted
18494	TBD	TBD	Redacted	Redacted	Redacted
18495	TBD	TBD	Redacted	Redacted	Redacted
18496	TBD	TBD	Redacted	Redacted	Redacted
18497	TBD	TBD	Redacted	Redacted	Redacted
18498	TBD	TBD	Redacted	Redacted	Redacted
18499	TBD	TBD	Redacted	Redacted	Redacted
18504	University of Maryland Baltimore	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	11,467,637
18505	Center for Health Solutions (CHS)	NGO	U.S. Department of Health and Human Services/Centers for Disease	GHP-State	15,251,051

			Control and Prevention		
18506	University of California at San Francisco	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	10,584,812
18507	Center for Health Solutions (CHS)	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,014,012
18508	Center for Health Solutions (CHS)	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	10,669,097
18509	African Medical and Research Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,468,513
18511	Christian Health Association of Kenya	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and	GHP-State	8,009,304

			Prevention		
18512	University of Nairobi	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	3,269,141
18513	Liverpool VCT and Care	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,128,258
18514	Hope Worldwide	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,531,005
18515	Eastern Deanery AIDS Relief Program	FBO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	6,389,279
18516	Mkomani Society Clinic	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	4,151,888

18517	University of Washington	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	950,000
18670	TBD	TBD	Redacted	Redacted	Redacted

Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 2866	**Mechanism Name: DUMISHA/TEGEMEZA**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: CENTERS FOR HEALTH SOLUTIONS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**2866**		
Mechanism Name:	**DUMISHA/TEGEMEZA**		
Prime Partner Name:	**CENTERS FOR HEALTH SOLUTIONS**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**

Care	HVTB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 7139	**Mechanism Name: HP Plus**
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Palladium Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,200,000	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,200,000	
Funding Source	**Funding Amount**

GHP-State	1,200,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 7139 Mechanism Name: HP Plus Prime Partner Name: Palladium Group			
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	OHSS	1,200,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 7305	**Mechanism Name: Applying Science to Strengthen and Improve Systems-ASSIST**
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 345,000	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 345,000	

Funding Source	Funding Amount
GHP-State	345,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	7305		
Mechanism Name:	Applying Science to Strengthen and Improve Systems-ASSIST		
Prime Partner Name:	University Research Corporation, LLC		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	OHSS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	115,000	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	230,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 9108	**Mechanism Name: AIHA**
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: American International Health Alliance Twinning Center	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,684,401	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,684,401	
Funding Source	**Funding Amount**
GHP-State	2,684,401

Cross-Cutting Budget Attribution(s)

Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	100,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	250,000

Budget Code Information

Mechanism ID:	9108		
Mechanism Name:	AIHA		
Prime Partner Name:	American International Health Alliance Twinning Center		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	878,737	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HLAB	350,000	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	OHSS	108,000	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	1,347,664	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	16,951
PP_PREV_DSD	Age/sex: 10-14 Male	7,146
PP_PREV_DSD	Age/sex: 10-14 Female	9,805
PP_PREV_DSD	Sum of Age/Sex disaggregates	16,951
GEND_GBV_DSD	Number of people receiving post-GBV care	8,264
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	7,058
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,206
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	483
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	7,058

GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	1,206
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	16,773
OVC_SERV_DSD	Age/Sex: 10-14 Female	16,773
OVC_SERV_DSD	Sum of Age/Sex disaggregates	16,773
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	16,773
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	3,355
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	16,773
OVC_SERV_DSD	Program Completion: Active	16,773

Implementing Mechanism Details

Mechanism ID: 9110	**Mechanism Name: APHL**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 776,667	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 776,667	
Funding Source	**Funding Amount**
GHP-State	776,667

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	9110		
Mechanism Name:	APHL		
Prime Partner Name:	Association of Public Health Laboratories		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HLAB	546,667	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	OHSS	150,000	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HMBL	80,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 9136	**Mechanism Name: IMC MARPS**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Medical Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	9136		
Mechanism Name:	IMC MARPS		
Prime Partner Name:	International Medical Corps		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	IDUP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 9143	**Mechanism Name: Kenya Department of Defense**
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: Henry Jackson Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**

Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**9143**		
Mechanism Name:	**Kenya Department of Defense**		
Prime Partner Name:	**Henry Jackson Foundation**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HVSI	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	CIRC	0	0

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 9171	**Mechanism Name: South Rift Valley**
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: Henry Jackson Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**9171**		
Mechanism Name:	**South Rift Valley**		
Prime Partner Name:	**Henry Jackson Foundation**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HLAB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HVSI	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	CIRC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**

Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	IDUP	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	0
PMTCT_ART_DSD	New on ART	0
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	0
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 50+	0
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	0
PMTCT_STAT_DSD	By Number of known positives: 15-19	0

PMTCT_STAT_DSD	By Number of known positives: 20-24	0
PMTCT_STAT_DSD	By Number of known positives: 25-49	0
PMTCT_STAT_DSD	By Number of known positives: 50+	0
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	0
PMTCT_STAT_DSD	By Number of new positives: 15-19	0
PMTCT_STAT_DSD	By Number of new positives: 20-24	0
PMTCT_STAT_DSD	By Number of new positives: 25-49	0
PMTCT_STAT_DSD	By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	0
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 50+	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Homebased testing: 15+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	0

HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative	0

HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: <15, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: 15+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Community) Index Mod: Unknown Age, Male, Positive	0

HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: <15, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: <15, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Negative	0
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	0
PMTCT_EID_DSD	Unknown, 2 - 12 months	0
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	0
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	0
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	0
TX_NEW_DSD	Breastfeeding status	0

TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_RET_DSD	Numerator by Status: Breastfeeding	0
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TB_PREV_DSD	By Therapy type (Denominator): Alternative Regimen	0
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	0
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	5

Implementing Mechanism Details

Mechanism ID: 11406	**Mechanism Name: Community Grants Program**
Funding Agency: State/AF	Procurement Type: Grant
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 50,711	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 50,711	
Funding Source	**Funding Amount**
GHP-State	50,711

Cross-Cutting Budget Attribution(s)

Economic Strengthening	30,000

Education	20,000

Budget Code Information

Mechanism ID:	11406		
Mechanism Name:	Community Grants Program		
Prime Partner Name:	U.S. Department of State		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	50,711	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12054	**Mechanism Name: Healthy Outcomes through Prevention Education (HOPE)**
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: CHF International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,673,864	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,673,864	
Funding Source	**Funding Amount**

GHP-State	2,673,864

Cross-Cutting Budget Attribution(s)

Gender: GBV	73,728
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	GBV Prevention
Sub Area:	Implementation

Budget Code Information

Mechanism ID:	**12054**		
Mechanism Name:	**Healthy Outcomes through Prevention Education (HOPE)**		
Prime Partner Name:	**CHF International**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVAB	1,571,449	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	1,102,415	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	23,691

PP_PREV_DSD	Age/sex: 10-14 Male	0
PP_PREV_DSD	Age/sex: 15-19 Male	0
PP_PREV_DSD	Age/sex: 20-24 Male	0
PP_PREV_DSD	Age/sex: 25-49 Male	0
PP_PREV_DSD	Age/sex: 50+ Male	0
PP_PREV_DSD	Age/sex: 10-14 Female	4,319
PP_PREV_DSD	Age/sex: 15-19 Female	11,009
PP_PREV_DSD	Age/sex: 20-24 Female	8,363
PP_PREV_DSD	Age/sex: 25-49 Female	0
PP_PREV_DSD	Age/sex: 50+ Female	0
PP_PREV_DSD	Sum of Age/Sex disaggregates	23,691

Implementing Mechanism Details

Mechanism ID: 12056	**Mechanism Name: Inuka Community Based OVC Project (ICOP)**
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Ananda Marga Universal Relief Teams	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 576,290	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 576,290	
Funding Source	**Funding Amount**
GHP-State	576,290

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12056		
Mechanism Name:	Inuka Community Based OVC Project (ICOP)		
Prime Partner Name:	Ananda Marga Universal Relief Teams		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	576,290	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
GEND_GBV_DSD	Number of people receiving post-GBV care	5,485
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	4,694
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	791
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	120
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	11,000
OVC_SERV_DSD	Age/Sex: 10-14 Male	1,716
OVC_SERV_DSD	Age/Sex: 15-17 Male	1,185
OVC_SERV_DSD	By: Age/sex: Male 18-24	1,243
OVC_SERV_DSD	By: Age/sex: Male 25+	0
OVC_SERV_DSD	Age/Sex: 10-14 Female	1,622
OVC_SERV_DSD	Age/Sex: 15-17 Female	1,135
OVC_SERV_DSD	By: Age/sex: 18-24 Female	1,092
OVC_SERV_DSD	By: Age/sex: 25+ Female	0
OVC_SERV_DSD	Sum of Age/Sex disaggregates	5,658
OVC_SERV_DSD	Age/Sex: <1	0
OVC_SERV_DSD	Age/Sex: 1-9	3,007

OVC_SERV_DSD	Program Completion: Active	11,000

Implementing Mechanism Details

Mechanism ID: 12083	**Mechanism Name: Community HTC**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Liverpool VCT and Care	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**12083**		
Mechanism Name:	**Community HTC**		
Prime Partner Name:	**Liverpool VCT and Care**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVAB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	0	0

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12530	**Mechanism Name: Provision of VMMC**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Nyanza Reproductive Health Society	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**12530**
Mechanism Name:	**Provision of VMMC**
Prime Partner Name:	**Nyanza Reproductive Health Society**

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12540	**Mechanism Name: MEASURE Evaluation**
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of North Carolina	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**12540**
Mechanism Name:	**MEASURE Evaluation**
Prime Partner Name:	**University of North Carolina**

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12551	**Mechanism Name: Clinical Services**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at San Francisco	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12551		
Mechanism Name:	Clinical Services		
Prime Partner Name:	University of California at San Francisco		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HLAB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	CIRC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12555	**Mechanism Name: Clinical Services/Centers of Excellence**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Nairobi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**12555**		
Mechanism Name:	**Clinical Services/Centers of Excellence**		
Prime Partner Name:	**University of Nairobi**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**

Care	PDCS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HLAB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12585	**Mechanism Name: Eastern and Western Kenya**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University Mailman School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	

Funding Source	Funding Amount
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12585		
Mechanism Name:	Eastern and Western Kenya		
Prime Partner Name:	Columbia University Mailman School of Public Health		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	CIRC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	0	0

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	0
VMMC_CIRC_DSD	By Age: 0-60 days	0

Implementing Mechanism Details

Mechanism ID: 12598	**Mechanism Name: HIV Prevention in the General Population and Youth**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Rescue Committee	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12598		
Mechanism Name:	HIV Prevention in the General Population and Youth		
Prime Partner Name:	International Rescue Committee		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVAB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12605	**Mechanism Name: Clinical Services**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Care International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12605		
Mechanism Name:	Clinical Services		
Prime Partner Name:	Care International		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12637	**Mechanism Name: Strengthening Strategic Information in Kenya**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Futures Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**12637**		
Mechanism Name:	**Strengthening Strategic Information in Kenya**		
Prime Partner Name:	**Futures Group**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HVSI	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12656	**Mechanism Name: Clinical Services**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Eastern Deanery AIDS Relief Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**12656**		
Mechanism Name:	**Clinical Services**		
Prime Partner Name:	**Eastern Deanery AIDS Relief Program**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**

Care	HVTB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	CIRC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12658	**Mechanism Name: Clinical Services**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Mkomani Society Clinic	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**

Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**12658**		
Mechanism Name:	**Clinical Services**		
Prime Partner Name:	**Mkomani Society Clinic**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	IDUP	0	0

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 12664	**Mechanism Name: Clinical Services**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Medical and Research Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	12664		
Mechanism Name:	Clinical Services		
Prime Partner Name:	African Medical and Research Foundation		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13025	**Mechanism Name: Integrated HIV Prevention Interventions Including Male Circumcision**

Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Impact Research and Development Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**13025**		
Mechanism Name:	**Integrated HIV Prevention Interventions Including Male Circumcision**		
Prime Partner Name:	**Impact Research and Development Organization**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	CIRC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	IDUP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13050	**Mechanism Name: Coptic Hospital / University of Washington Collaborative HIV Care Program**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Coptic Hospital	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: **Mechanism Name:** **Prime Partner Name:**	**13050** **Coptic Hospital / University of Washington Collaborative HIV Care Program** **Coptic Hospital**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**

Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13061	**Mechanism Name: Advancement of Public Health Practices in Kenya**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: MINISTRY OF PUBLIC HEALTH AND SANITATION	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**13061**		
Mechanism Name:	**Advancement of Public Health Practices in Kenya**		
Prime Partner Name:	**MINISTRY OF PUBLIC HEALTH AND SANITATION**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HLAB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HVSI	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**

Governance and Systems	OHSS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	CIRC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HMIN	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	IDUP	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13179	**Mechanism Name: Emory University**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Schools of Public Health	

Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**13179**		
Mechanism Name:	**Emory University**		
Prime Partner Name:	**Association of Schools of Public Health**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	OHSS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13302	**Mechanism Name: HIV Prevention Activities for Youth and General Population**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement

Prime Partner Name: Hope Worldwide	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**13302**		
Mechanism Name:	**HIV Prevention Activities for Youth and General Population**		
Prime Partner Name:	**Hope Worldwide**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVAB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13307	**Mechanism Name: Prevention for Youth and General Population**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Impact Research and Development Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**13307**		
Mechanism Name:	**Prevention for Youth and General Population**		
Prime Partner Name:	**Impact Research and Development Organization**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**

Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13340	**Mechanism Name: APHIAPlus Rift Valley**
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**13340**		
Mechanism Name:	**APHIAPlus Rift Valley**		
Prime Partner Name:	**FHI 360**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**

Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HVSI	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	CIRC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13346	**Mechanism Name: Support Services for HIV Pandemic**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: World Health Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 250,000	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 250,000	
Funding Source	**Funding Amount**
GHP-State	250,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	7,500
Focus Area:	GBV Prevention
Sub Area:	Capacity building

Budget Code Information

Mechanism ID:	**13346**		
Mechanism Name:	**Support Services for HIV Pandemic**		
Prime Partner Name:	**World Health Organization**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**

Treatment	HTXS	250,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13354	**Mechanism Name: Kenya Conference of Catholic Bishops (KCCB)**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Kenya Episcopal Conference	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**13354**		
Mechanism Name:	**Kenya Conference of Catholic Bishops (KCCB)**		
Prime Partner Name:	**Kenya Episcopal Conference**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**

Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	2,336
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	14,373
PMTCT_ART_DSD	New on ART	747
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,589
PMTCT_STAT_DSD	Number of pregnant women with known HIV status	14,373

	(includes women who were tested for HIV and received their results)	
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Denominator): <10	3
PMTCT_STAT_DSD	By Age (Denominator): 10-14	210
PMTCT_STAT_DSD	By Age (Denominator): <15-19	540
PMTCT_STAT_DSD	By Age (Denominator): 20-24	1,396
PMTCT_STAT_DSD	By Age (Denominator): 25-49	9,742
PMTCT_STAT_DSD	By Age (Denominator): 50+	2,482
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	30
PMTCT_STAT_DSD	By Number of known positives: 15-19	65
PMTCT_STAT_DSD	By Number of known positives: 20-24	234
PMTCT_STAT_DSD	By Number of known positives: 25-49	1,015
PMTCT_STAT_DSD	By Number of known positives: 50+	241
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	9
PMTCT_STAT_DSD	By Number of new positives: 15-19	32
PMTCT_STAT_DSD	By Number of new positives: 20-24	124
PMTCT_STAT_DSD	By Number of new positives: 25-49	577
PMTCT_STAT_DSD	By Number of new positives: 50+	119
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	0
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	170
PMTCT_STAT_DSD	By Number of new negative: 15-19	1,162
PMTCT_STAT_DSD	By Number of new negative: 20-24	2,143
PMTCT_STAT_DSD	By Number of new negative: 25-49	6,815
PMTCT_STAT_DSD	By Number of new negative: 50+	1,637
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0

PMTCT_STAT_DSD	By Age (Numerator): 10-14	210
PMTCT_STAT_DSD	By Age (Numerator): 15-19	540
PMTCT_STAT_DSD	By Age (Numerator): 20-24	1,399
PMTCT_STAT_DSD	By Age (Numerator): 25-49	9,742
PMTCT_STAT_DSD	By Age (Numerator): 50+	2,482
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	384,741
HTC_TST_DSD	By Test Result: Positive	11,265
HTC_TST_DSD	Sum of Test Result disaggregates	11,265
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	344
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	498
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	1,409
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	1,675
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	3,179
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	1,611
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	24

HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	11,749
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	175
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	5,469
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	117
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	5,306
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	51
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	5,330
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	215
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	2,603
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	7
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	1,145
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive	13
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	1,169

HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive	7
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	7,788
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	189
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	5,217
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	141
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	2,897
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	2,544
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	9,795
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	181
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	6,848
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	160

HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	14,850
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	601
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	8,237
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	486
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	49,190
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	1,950
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	32,141
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	1,545
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	14,260
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	400
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	13,048
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	327
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	0

HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	8,278
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	45
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	4,665
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	73
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	4,392
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	52
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	32,406
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	967
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	22,607
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	739
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	11,715
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	15
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	3

HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	38
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	169
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	122
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	218
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	102
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	21
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0

HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	88
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	10
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	21
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	8
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	14
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Positive	3
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	89
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	61
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	98
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	56
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	765
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	578

HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	801
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	568
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	936
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	699
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	1,249
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	56
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	1,067
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	453
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	267
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	3

HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	1,323
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	14
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative	885
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	11
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative	767
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive	5
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	1,000
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	33
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	763
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	75

HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	178
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	296
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	1,976
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	499
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: <15, Negative	971
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: <15, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative	8,761
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	507
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	487

HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	3,566
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	46
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	2,459
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	4,761
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	166
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	3,589
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	84
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	11,150
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	767
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	7,328
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	422
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	2,986
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	47
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	2,392
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	57
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age,	0

	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT:	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	1,489
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	28
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	771
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	16
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	754
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	15
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	7,724
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	335
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	5,272
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	195
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,639
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,687
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	80
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of	514

	registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	161
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	884
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	76
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	524
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	165
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	922
GEND_GBV_DSD	Number of people receiving post-GBV care	31,097
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	22,503
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	8,590
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	3,446
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	434
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	174
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	411
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	161
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	206
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	80
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	195
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	75

GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	175
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	71
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	101
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	39
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	728
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	294
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	182
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	78
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	6,256
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	2,489
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	2,715
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	1,080
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	1,206
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	487
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	934
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	370
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,155
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,155
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	50

TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	359
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	101
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	635
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	50
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	362
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	102
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	641
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,341
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	47
PMTCT_EID_DSD	Unknown, <= 2 months	0
PMTCT_EID_DSD	Unknown, 2 - 12 months	0
PMTCT_EID_DSD	Number of infants with a negative virological test result	1,687

	within 2 months of birth	
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	19
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	588
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	90,578
TX_CURR_DSD	Age/Sex: 15-19 Male	549
TX_CURR_DSD	Age/Sex: 15-19 Female	682
TX_CURR_DSD	Sum of age/sex disaggregates	1,231
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,078
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	13,516
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,509
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	19,498
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,587
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	33,014
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	35,601
TX_CURR_DSD	Age/Sex: <1	30
TX_CURR_DSD	Age/Sex: <1-9	1,504
TX_CURR_DSD	Age/Sex: 10-14 Male	707
TX_CURR_DSD	Age/Sex: 10-14 Female	1,385
TX_CURR_DSD	Age/Sex: 20-24 Male	1,688
TX_CURR_DSD	Age/Sex: 25-49 Male	11,077
TX_CURR_DSD	Age/Sex: 50+ Male	3,892
TX_CURR_DSD	Age/Sex: 20-24 Female	2,848
TX_CURR_DSD	Age/Sex: 25-49 Female	24,191
TX_CURR_DSD	Age/Sex: 50+ Female	6,424
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	19,262
TX_NEW_DSD	By Age/Sex: <1	2
TX_NEW_DSD	By Age/Sex: 1-9	398
TX_NEW_DSD	By Age/Sex: 10-14 Male	46

TX_NEW_DSD	By Age/Sex: 15-19 Male	129
TX_NEW_DSD	By Age/Sex: 20-24 Male	355
TX_NEW_DSD	By Age/Sex: 25-49 Male	3,102
TX_NEW_DSD	By Age/Sex: 50+ Male	1,185
TX_NEW_DSD	By Age/Sex: 10-14 Female	57
TX_NEW_DSD	By Age/Sex: 15-19 Female	207
TX_NEW_DSD	By Age/Sex: 20-24 Female	922
TX_NEW_DSD	By Age/Sex: 25-49 Female	6,843
TX_NEW_DSD	By Age/Sex: 50+ Female	1,473
TX_NEW_DSD	Sum of Age/Sex disaggregates	14,319
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	135
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,683
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	224
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,501
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	4,543
TX_NEW_DSD	Pregnancy status	677
TX_NEW_DSD	Breastfeeding status	73
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	80,939
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	90,590
TX_PVLS_DSD	Numerator: Indication: Routine	75,267
TX_PVLS_DSD	Numerator: Indication: Targeted	5,672
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	1,272
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	168
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	80
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	6
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male	252

	Targeted	
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	1,815
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	345
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	3,242
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	1,946
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	25,510
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	3,228
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	44,583
TX_PVLS_DSD	Denominator: Indication: Routine	84,245
TX_PVLS_DSD	Denominator: Indication: Targeted	6,344
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	1,356
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	170
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	85
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Targeted	8
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	279
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	2,023
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	384
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	3,635
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	2,170
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+	28,562

	Male Routine	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	3,612
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	49,901
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	12
TX_PVLS_DSD	Unknown Age, Targeted, Male	11
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	1
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0

TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	9
TX_PVLS_DSD	Unknown Age, Targeted, Male	9
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	1
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	18,301
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	19,264
TX_RET_DSD	Numerator by Status: Pregnant	646
TX_RET_DSD	Numerator by Status: Breastfeeding	67
TX_RET_DSD	Denominator by Status: Pregnant	663
TX_RET_DSD	Denominator by Status: Breastfeeding	72
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	318
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of	6,442

	adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	495
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11,046
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	379
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,696
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	584
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11,605
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	461
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	86,335
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	33
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	13
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	267

TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	148
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	3,665
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	3,030
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	50,452
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	29,188
TX_TB_DSD	Denominator: By Screen Result: Negative	69,067
TX_TB_DSD	Denominator: By Screen Result: Positive	17,268
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	17,254
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	859
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	6,444
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	9,964

Implementing Mechanism Details

Mechanism ID: 13366	**Mechanism Name: Expanding High Quality HIV Prevention, Care and Treatment within Faith-Based Health Facilities**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Christian Health Association of Kenya	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**13366**		
Mechanism Name:	**Expanding High Quality HIV Prevention, Care and Treatment within Faith-Based Health Facilities**		
Prime Partner Name:	**Christian Health Association of Kenya**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13385	**Mechanism Name: Prevention for MARPS**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Manitoba	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**13385**		
Mechanism Name:	**Prevention for MARPS**		
Prime Partner Name:	**University of Manitoba**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**

Care	HVTB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	IDUP	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13399	**Mechanism Name: Partnership for Advanced Care and Treatment (PACT)**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland	
Agreement Start Date: Redacted	Agreement End Date: Redacted

TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**13399**		
Mechanism Name:	**Partnership for Advanced Care and Treatment (PACT)**		
Prime Partner Name:	**University of Maryland**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**

Prevention	IDUP	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13474	**Mechanism Name: HIV Prevention for MARPS**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Hope Worldwide	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13474		
Mechanism Name:	HIV Prevention for MARPS		
Prime Partner Name:	Hope Worldwide		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	IDUP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13481	**Mechanism Name: Prevention for MARPS-Central and Eastern**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Nairobi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	

Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**13481**		
Mechanism Name:	**Prevention for MARPS-Central and Eastern**		
Prime Partner Name:	**University of Nairobi**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	IDUP	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**

Treatment	HTXS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13543	**Mechanism Name: PAMOJA**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**13543**

Mechanism Name:	PAMOJA		
Prime Partner Name:	Elizabeth Glaser Pediatric AIDS Foundation		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HLAB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13545	**Mechanism Name: Peace Corps**
Funding Agency: PC	Procurement Type: USG Core
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 308,764	
Total All Funding Sources and Applied Pipeline Amount: 308,764	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**13545**		
Mechanism Name:	**Peace Corps**		
Prime Partner Name:	**U.S. Peace Corps**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**

Prevention	HVAB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13546	**Mechanism Name: Kisumu West**
Funding Agency: DOD	Procurement Type: Cooperative Agreement
Prime Partner Name: Henry Jackson Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**13546**

Mechanism Name:	Kisumu West		
Prime Partner Name:	Henry Jackson Foundation		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HVSI	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVAB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13588	**Mechanism Name: APHIAplus Nyanza/Western**
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Program for Appropriate Technology in Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**13588**		
Mechanism Name:	**APHIAplus Nyanza/Western**		
Prime Partner Name:	**Program for Appropriate Technology in Health**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**

Care	HKID	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HVSI	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	CIRC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVAB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
GEND_GBV_DSD	Number of people receiving post-GBV care	10
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	5
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	5
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	2

Implementing Mechanism Details

Mechanism ID: 13636	**Mechanism Name: APHIAplus Central/Eastern**
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**13636**

Mechanism Name:	APHIAplus Central/Eastern		
Prime Partner Name:	JHPIEGO		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HVSI	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Negative	1
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Positive	12

Implementing Mechanism Details

Mechanism ID: 13701	**Mechanism Name: KEMSA Medical Commodities Program**
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Kenya Medical Supplies Agency	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 107,669,451	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 28,099,194	
Total All Funding Sources and Applied Pipeline Amount: 135,768,645	
Funding Source	**Funding Amount**
GHP-State	107,669,451

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**13701**
Mechanism Name:	**KEMSA Medical Commodities Program**

Prime Partner Name:	Kenya Medical Supplies Agency		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	11,648,843	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	1,647,400	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	1,318,426	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HLAB	761,258	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	CIRC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HMBL	850,000	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HMIN	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	1,559,772	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	450,000	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	2,723,231	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXD	65,686,810	0

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	21,023,711	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13802	**Mechanism Name: Central Province Response Integration, Strengthening & Sustainability Project (CRISSP)**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Nairobi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13802		
Mechanism Name:	Central Province Response Integration, Strengthening & Sustainability Project (CRISSP)		
Prime Partner Name:	University of Nairobi		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Positive	0

Implementing Mechanism Details

Mechanism ID: 13868	**Mechanism Name: Health Communication & Marketing**
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: New Partner	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 5,886,680	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 5,886,680	
Funding Source	**Funding Amount**
GHP-State	5,886,680

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**13868**		
Mechanism Name:	**Health Communication & Marketing**		
Prime Partner Name:	**New Partner**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HLAB	250,000	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	CIRC	1,000,000	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**

Prevention	HVAB	2,267,352	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	534,325	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	569,657	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	1,250,829	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	14,517	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	282
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,611
PMTCT_ART_DSD	New on ART	89
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	193
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	4,611
PMTCT_STAT_DSD	By Age (Denominator): <15-19	968
PMTCT_STAT_DSD	By Age (Denominator): 20-24	1,105
PMTCT_STAT_DSD	By Age (Denominator): 25-49	2,538
PMTCT_STAT_DSD	By Number of known positives: 25-49	21

PMTCT_STAT_DSD	By Number of new positives: 20-24	1
PMTCT_STAT_DSD	By Number of new positives: 25-49	1
PMTCT_STAT_DSD	By Number of new negative: 15-19	968
PMTCT_STAT_DSD	By Number of new negative: 20-24	1,104
PMTCT_STAT_DSD	By Number of new negative: 25-49	2,516
PMTCT_STAT_DSD	By Age (Numerator): 15-19	968
PMTCT_STAT_DSD	By Age (Numerator): 20-24	1,105
PMTCT_STAT_DSD	By Age (Numerator): 25-49	2,538
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	81,543
HTC_TST_DSD	By Test Result: Positive	2,474
HTC_TST_DSD	Sum of Test Result disaggregates	2,474
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	26
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	102
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	4

HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	94
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	197
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	130
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	42
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	29
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	667
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	20
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	514

HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	713
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	367
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	66
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	3,853
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	178
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	2,440
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	121
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	5,124
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	203
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	2,780
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	93

HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	514
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	190
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	39
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	203
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	10
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	72
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	21,587
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	603
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	10,978
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	301
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	1
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	38

HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	1,592
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	4,345
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	61
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative	9,923
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive	205
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	341
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	321
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	1,180
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	67
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	1,094
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	60

HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	156
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	145
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	6
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	2
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	3
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	1
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	1,868
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	53
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	1,700
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	47
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	101,136
HTC_TST_TA	By Test Result: Positive	3,292
HTC_TST_TA	Sum of Test Result disaggregates	3,292
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	22
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	21
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	55

HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	34
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	85
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	195
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	5
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	313
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	17
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	235
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	10
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	22
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	15
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	0
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: <1, Negative	6
HTC_TST_TA	Service Delivery Point (Facility) Inpatient: 1-9, Negative	6
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: <15, Female, Negative	54
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: <15, Female, Positive	1

HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: <15, Male, Negative	29
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Female, Negative	1,012
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Female, Positive	25
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Male, Negative	856
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Male, Positive	23
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: Unknown Age, Female, Negative	1
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: Unknown Age, Male, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) Malnutrition: Negative	3
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	45
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	108
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	4
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	642
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	34
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	532
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	51
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	5,355
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24,	190

	Female, Positive	
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	3,168
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	183
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	15,131
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	536
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	5,876
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	235
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	579
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	29
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	214
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	6
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	5
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: <1, Negative	10
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Negative	22
HTC_TST_TA	Service Delivery Point (Facility) Other PITC: 1-9, Positive	1
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Negative	65
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Positive	2
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC:	67

	<15, Male, Negative	
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Positive	3
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Negative	28,968
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Positive	856
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Negative	16,368
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Positive	505
HTC_TST_TA	Service Delivery Point (Facility) TB: 25-49, Male, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 10-14, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 15-19, Negative	4
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 1-9, Negative	3
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 20-24, Negative	6
HTC_TST_TA	Service Delivery Point (Facility) VMMC: 25-49, Negative	3
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VMMC: 15+, Negative	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	20
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	15
HTC_TST_TA	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	1
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	110
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	3
HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	130

HTC_TST_TA	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	10
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	726
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	53
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	576
HTC_TST_TA	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	28
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	2,295
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	106
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	1,703
HTC_TST_TA	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	62
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Negative	253
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Female, Positive	13
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Negative	148
HTC_TST_TA	Service Delivery Point (Facility) VCT: 50+, Male, Positive	7
HTC_TST_TA	Service Delivery Point (Facility) VCT: <1, Negative	2
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Negative	9
HTC_TST_TA	Service Delivery Point (Facility) VCT: 1-9, Positive	0
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: <15, Female, Negative	19
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: <15, Male, Negative	12
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: <15, Male, Positive	1

HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Negative	4,630
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Female, Positive	153
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Negative	4,191
HTC_TST_TA	Service Delivery Point Agg Age (Facility) VCT: 15+, Male, Positive	146
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	683
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	735
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	298
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	382
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	322
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	411
GEND_GBV_DSD	Number of people receiving post-GBV care	1,459

GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,080
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	379
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	56
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	1
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	22
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	9
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	41
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	5
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	125
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	71
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	75
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	22
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	194
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	104
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	8
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	4
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	178
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	178
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	98
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with	1

	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	75
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	4
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	98
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	75
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	269
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	1
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	5
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	9
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	254
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	6,627
TX_CURR_DSD	Age/Sex: 15-19 Male	11

TX_CURR_DSD	Age/Sex: 15-19 Female	9
TX_CURR_DSD	Sum of age/sex disaggregates	20
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	34
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,713
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	62
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	2,371
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	96
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	4,084
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	4,180
TX_CURR_DSD	Age/Sex: <1	2
TX_CURR_DSD	Age/Sex: <1-9	17
TX_CURR_DSD	Age/Sex: 10-14 Male	3
TX_CURR_DSD	Age/Sex: 10-14 Female	12
TX_CURR_DSD	Age/Sex: 20-24 Male	35
TX_CURR_DSD	Age/Sex: 25-49 Male	936
TX_CURR_DSD	Age/Sex: 50+ Male	94
TX_CURR_DSD	Age/Sex: 20-24 Female	90
TX_CURR_DSD	Age/Sex: 25-49 Female	1,153
TX_CURR_DSD	Age/Sex: 50+ Female	85
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	590
TX_NEW_DSD	By Age/Sex: <1	0
TX_NEW_DSD	By Age/Sex: 1-9	0
TX_NEW_DSD	By Age/Sex: 10-14 Male	0
TX_NEW_DSD	By Age/Sex: 15-19 Male	0
TX_NEW_DSD	By Age/Sex: 20-24 Male	1
TX_NEW_DSD	By Age/Sex: 25-49 Male	38
TX_NEW_DSD	By Age/Sex: 50+ Male	0
TX_NEW_DSD	By Age/Sex: 10-14 Female	0
TX_NEW_DSD	By Age/Sex: 15-19 Female	0
TX_NEW_DSD	By Age/Sex: 20-24 Female	2
TX_NEW_DSD	By Age/Sex: 25-49 Female	33

TX_NEW_DSD	By Age/Sex: 50+ Female	0
TX_NEW_DSD	Sum of Age/Sex disaggregates	74
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	204
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	7
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	305
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	516
TX_NEW_DSD	Pregnancy status	1
TX_NEW_DSD	Breastfeeding status	32
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	5,932
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	6,627
TX_PVLS_DSD	Numerator: Indication: Routine	895
TX_PVLS_DSD	Numerator: Indication: Targeted	5,037
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	74
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	2,077
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	55
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	2,797
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	5
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	398
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	5
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	518

TX_PVLS_DSD	Denominator: Indication: Routine	996
TX_PVLS_DSD	Denominator: Indication: Targeted	5,631
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	52
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	2,364
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	68
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	3,150
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	5
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	425
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	5
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	558
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	3
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	531
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	590
TX_RET_DSD	Numerator by Status: Pregnant	1
TX_RET_DSD	Numerator by Status: Breastfeeding	33
TX_RET_DSD	Denominator by Status: Pregnant	1
TX_RET_DSD	Denominator by Status: Breastfeeding	33
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at	228

	12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	297
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	248
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	336
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	71
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	2,743
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	29
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	42

TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	29
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	28
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	1,534
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	1,152
TX_TB_DSD	Denominator: By Screen Result: Negative	2,197
TX_TB_DSD	Denominator: By Screen Result: Positive	546
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	519
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	27
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	82
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	437

Implementing Mechanism Details

Mechanism ID: 13882	**Mechanism Name: Integrated Program for both HIV infected and affected children and their households**
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Children of God Relief Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,443,097	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,443,097	
Funding Source	**Funding Amount**
GHP-State	1,443,097

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**13882**		
Mechanism Name:	**Integrated Program for both HIV infected and affected children and their households**		
Prime Partner Name:	**Children of God Relief Institute**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	785,169	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	23,719	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	1,467	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	150,433	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**

Treatment	PDTX	482,309	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	7,371
HTC_TST_DSD	By Test Result: Positive	377
HTC_TST_DSD	Sum of Test Result disaggregates	377
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	447
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	460
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	413
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	329
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	647
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	276
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male,	4

	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	1,060
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	618
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	63
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	83
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	418
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	80
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	2,180
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	117
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	35
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	35
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	16
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number	14

	of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	16
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	14
GEND_GBV_DSD	Number of people receiving post-GBV care	8,925
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	7,588
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,337
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	201
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	967
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	220
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	1,267
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	130
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	1,541
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	367
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	1,084
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	132
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	1,248
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	296
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	951
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	112
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	271

GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	57
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	253
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	23
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	0
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	14,987
OVC_SERV_DSD	Age/Sex: 10-14 Male	1,839
OVC_SERV_DSD	Age/Sex: 15-17 Male	1,585
OVC_SERV_DSD	By: Age/sex: Male 18-24	417
OVC_SERV_DSD	By: Age/sex: Male 25+	0
OVC_SERV_DSD	Age/Sex: 10-14 Female	3,529
OVC_SERV_DSD	Age/Sex: 15-17 Female	2,860
OVC_SERV_DSD	By: Age/sex: 18-24 Female	613
OVC_SERV_DSD	By: Age/sex: 25+ Female	0
OVC_SERV_DSD	Sum of Age/Sex disaggregates	9,813
OVC_SERV_DSD	Age/Sex: <1	110
OVC_SERV_DSD	Age/Sex: 1-9	4,034
OVC_SERV_DSD	Program Completion: Active	14,987
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	32
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	32
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with	2

	documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	16
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	14
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	16
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	14
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	3,347
TX_CURR_DSD	Age/Sex: 15-19 Male	480
TX_CURR_DSD	Age/Sex: 15-19 Female	539
TX_CURR_DSD	Sum of age/sex disaggregates	1,019

TX_CURR_DSD	Age/Sex: <1	12
TX_CURR_DSD	Age/Sex: <1-9	812
TX_CURR_DSD	Age/Sex: 10-14 Male	594
TX_CURR_DSD	Age/Sex: 10-14 Female	624
TX_CURR_DSD	Age/Sex: 20-24 Male	116
TX_CURR_DSD	Age/Sex: 25-49 Male	9
TX_CURR_DSD	Age/Sex: 50+ Male	6
TX_CURR_DSD	Age/Sex: 20-24 Female	132
TX_CURR_DSD	Age/Sex: 25-49 Female	14
TX_CURR_DSD	Age/Sex: 50+ Female	9
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	167
TX_NEW_DSD	By Age/Sex: <1	4
TX_NEW_DSD	By Age/Sex: 1-9	42
TX_NEW_DSD	By Age/Sex: 10-14 Male	40
TX_NEW_DSD	By Age/Sex: 15-19 Male	14
TX_NEW_DSD	By Age/Sex: 20-24 Male	0
TX_NEW_DSD	By Age/Sex: 25-49 Male	0
TX_NEW_DSD	By Age/Sex: 50+ Male	0
TX_NEW_DSD	By Age/Sex: 10-14 Female	43
TX_NEW_DSD	By Age/Sex: 15-19 Female	24
TX_NEW_DSD	By Age/Sex: 20-24 Female	0
TX_NEW_DSD	By Age/Sex: 25-49 Female	0
TX_NEW_DSD	By Age/Sex: 50+ Female	0
TX_NEW_DSD	Sum of Age/Sex disaggregates	121
TX_NEW_DSD	Pregnancy status	0
TX_NEW_DSD	Breastfeeding status	0
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	2,683
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral	3,347

	load result documented in the patient medical record and /or laboratory records in the past 12 months.	
TX_PVLS_DSD	Numerator: Indication: Routine	2,683
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	797
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	488
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	840
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	558
TX_PVLS_DSD	Denominator: Indication: Routine	3,347
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	995
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	611
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,047
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	694
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	150
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	167
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	55
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	13
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment	59

	at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	23
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	62
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	14
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	67
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	24
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	12
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	3,347
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	1
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	5
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	6
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	1,047
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	995

TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	694
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	611
TX_TB_DSD	Denominator: By Screen Result: Negative	2,680
TX_TB_DSD	Denominator: By Screen Result: Positive	667
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	634
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	33
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	101
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	534

Implementing Mechanism Details

Mechanism ID: 13919	**Mechanism Name: Laboratory Regulatory Support**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Clinical and Laboratory Standards Institute	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 575,525	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 575,525	
Funding Source	**Funding Amount**
GHP-State	575,525

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	13919		
Mechanism Name:	Laboratory Regulatory Support		
Prime Partner Name:	Clinical and Laboratory Standards Institute		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HLAB	575,525	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14009	**Mechanism Name: Kenya Nutrition and HIV Program Plus**
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,952,941	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,952,941	
Funding Source	**Funding Amount**
GHP-State	2,952,941

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14009		
Mechanism Name:	Kenya Nutrition and HIV Program Plus		
Prime Partner Name:	FHI 360		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	452,941	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	1,500,000	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	1,000,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14012	**Mechanism Name: AMPATHplus**
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Moi Teaching and Referral Hospital	

Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 16,117,337	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 16,117,337	
Funding Source	**Funding Amount**
GHP-State	16,117,337

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**14012**		
Mechanism Name:	**AMPATHplus**		
Prime Partner Name:	**Moi Teaching and Referral Hospital**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	446,100	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	0	0

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	422,686	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HVSI	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVAB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	1,874,419	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	125,061	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	1,796,273	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	10,566,100	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	886,698	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	4,155
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received	155,500

	their results)	
PMTCT_ART_DSD	New on ART	2,081
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,074
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	155,500
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	2
PMTCT_STAT_DSD	By Age (Denominator): <15-19	29,796
PMTCT_STAT_DSD	By Age (Denominator): 20-24	45,217
PMTCT_STAT_DSD	By Age (Denominator): 25-49	78,342
PMTCT_STAT_DSD	By Age (Denominator): 50+	0
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	0
PMTCT_STAT_DSD	By Number of known positives: 15-19	316
PMTCT_STAT_DSD	By Number of known positives: 20-24	646
PMTCT_STAT_DSD	By Number of known positives: 25-49	1,291
PMTCT_STAT_DSD	By Number of known positives: 50+	0
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	0
PMTCT_STAT_DSD	By Number of new positives: 15-19	279
PMTCT_STAT_DSD	By Number of new positives: 20-24	617
PMTCT_STAT_DSD	By Number of new positives: 25-49	1,179
PMTCT_STAT_DSD	By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	0
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	2
PMTCT_STAT_DSD	By Number of new negative: 15-19	29,802
PMTCT_STAT_DSD	By Number of new negative: 20-24	44,614

PMTCT_STAT_DSD	By Number of new negative: 25-49	76,706
PMTCT_STAT_DSD	By Number of new negative: 50+	48
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	2
PMTCT_STAT_DSD	By Age (Numerator): 15-19	30,221
PMTCT_STAT_DSD	By Age (Numerator): 20-24	45,862
PMTCT_STAT_DSD	By Age (Numerator): 25-49	79,415
PMTCT_STAT_DSD	By Age (Numerator): 50+	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	805,855
HTC_TST_DSD	By Test Result: Positive	17,103
HTC_TST_DSD	Sum of Test Result disaggregates	17,103
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	14,922
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive	30
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	14,173
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive	20
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	140,428
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	3,952
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	72,847
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	2,076
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient:	0

	Unknown Age, Female, Positive	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	10,779
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	5
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	9,427
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	1
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	35,885
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	1,134
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	36,618
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	571
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	43
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	3
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	6,753
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15,	5

	Female, Positive	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	7,423
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Positive	1
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	39,757
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	1,073
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	23,213
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	519
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative	13,944
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	4
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative	13,957
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive	3
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	45,789
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	966
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+,	25,094

	Male, Negative	
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	481
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: <15, Negative	3,473
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: <15, Positive	23
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative	145,652
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive	2,047
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	28,444
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	25
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	24,197
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	14
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+,	100,516

	Female, Negative	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	2,724
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	56,305
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	1,404
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Positive	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	5,739
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	6,038
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	328
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,187
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	312
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,912
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	343

TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3,344
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	328
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,020
GEND_GBV_DSD	Number of people receiving post-GBV care	30,041
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	23,396
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	6,645
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	997
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	7
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	12
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	3
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	59
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	10
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	22
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	6
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	80
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	16
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	36
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	10
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	52
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	56
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	37
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	10
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	1,225
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	507

GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	342
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	96
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	374
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	155
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	186
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	52
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	8,515
OVC_SERV_DSD	Age/Sex: 10-14 Male	960
OVC_SERV_DSD	Age/Sex: 15-17 Male	899
OVC_SERV_DSD	By: Age/sex: Male 18-24	816
OVC_SERV_DSD	By: Age/sex: Male 25+	0
OVC_SERV_DSD	Age/Sex: 10-14 Female	1,773
OVC_SERV_DSD	Age/Sex: 15-17 Female	1,416
OVC_SERV_DSD	By: Age/sex: 18-24 Female	400
OVC_SERV_DSD	By: Age/sex: 25+ Female	0
OVC_SERV_DSD	Sum of Age/Sex disaggregates	5,048
OVC_SERV_DSD	Age/Sex: <1	53
OVC_SERV_DSD	Age/Sex: 1-9	2,198
OVC_SERV_DSD	Program Completion: Active	8,515
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,532
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,533

TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	31
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	821
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	30
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	651
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	31
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	821
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	45
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	636
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	4,155
PMTCT_EID_DSD	Number of infants with a positive virological test result	0

	within 2 months of birth	
PMTCT_EID_DSD	Unknown, <= 2 months	0
PMTCT_EID_DSD	Unknown, 2 - 12 months	0
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	0
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	208
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	3,947
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	97,641
TX_CURR_DSD	Age/Sex: 15-19 Male	110
TX_CURR_DSD	Age/Sex: 15-19 Female	145
TX_CURR_DSD	Sum of age/sex disaggregates	255
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	3,374
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	24,924
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	3,935
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	55,897
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	7,309
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	80,821
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	88,130
TX_CURR_DSD	Age/Sex: <1	22
TX_CURR_DSD	Age/Sex: <1-9	234
TX_CURR_DSD	Age/Sex: 10-14 Male	119
TX_CURR_DSD	Age/Sex: 10-14 Female	143
TX_CURR_DSD	Age/Sex: 20-24 Male	63
TX_CURR_DSD	Age/Sex: 25-49 Male	1,685
TX_CURR_DSD	Age/Sex: 50+ Male	916
TX_CURR_DSD	Age/Sex: 20-24 Female	189
TX_CURR_DSD	Age/Sex: 25-49 Female	4,505
TX_CURR_DSD	Age/Sex: 50+ Female	1,380
TX_NEW_DSD	Number of adults and children newly enrolled on	18,439

	antiretroviral therapy (ART)	
TX_NEW_DSD	By Age/Sex: <1	0
TX_NEW_DSD	By Age/Sex: 1-9	10
TX_NEW_DSD	By Age/Sex: 10-14 Male	14
TX_NEW_DSD	By Age/Sex: 15-19 Male	26
TX_NEW_DSD	By Age/Sex: 20-24 Male	14
TX_NEW_DSD	By Age/Sex: 25-49 Male	434
TX_NEW_DSD	By Age/Sex: 50+ Male	220
TX_NEW_DSD	By Age/Sex: 10-14 Female	14
TX_NEW_DSD	By Age/Sex: 15-19 Female	35
TX_NEW_DSD	By Age/Sex: 20-24 Female	45
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,087
TX_NEW_DSD	By Age/Sex: 50+ Female	332
TX_NEW_DSD	Sum of Age/Sex disaggregates	2,221
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	821
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	4,461
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	859
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	10,017
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	16,158
TX_NEW_DSD	Pregnancy status	0
TX_NEW_DSD	Breastfeeding status	0
TX_NEW_DSD	FSW	0
TX_NEW_DSD	MSM	0
TX_NEW_DSD	People in prisons and other enclosed settings	0
TX_NEW_DSD	TG	0
TX_NEW_DSD	By Key populations: People who inject drugs (PWID)	0
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	100,823
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record	112,866

	and /or laboratory records in the past 12 months.	
TX_PVLS_DSD	Numerator: Indication: Routine	87,106
TX_PVLS_DSD	Numerator: Indication: Targeted	13,717
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	436
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	3,952
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	489
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	8,844
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	2,868
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	24,754
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	3,166
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	56,268
TX_PVLS_DSD	Denominator: Indication: Routine	97,478
TX_PVLS_DSD	Denominator: Indication: Targeted	15,388
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	0
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	0
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	0
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Targeted	0

TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	563
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	4,386
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	624
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	9,823
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	3,616
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	27,570
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	3,996
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	62,284
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0

TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	17,534
TX_RET_DSD	Total number of adults and children who initiated ART in	18,440

	the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	
TX_RET_DSD	Numerator by Status: Pregnant	0
TX_RET_DSD	Numerator by Status: Breastfeeding	0
TX_RET_DSD	Denominator by Status: Pregnant	0
TX_RET_DSD	Denominator by Status: Breastfeeding	0
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	797
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,878
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	829
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11,024
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	869
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,086
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	910
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total	11,574

	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	604
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	88,130
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	21
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	34
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	224
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	314
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	3,934
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	3,373
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	55,899
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	24,922
TX_TB_DSD	Denominator: By Screen Result: Negative	70,504
TX_TB_DSD	Denominator: By Screen Result: Positive	17,626
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	16,801
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	847
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	2,547
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	13,560

Implementing Mechanism Details

Mechanism ID: 14015	**Mechanism Name: FUNZO Kenya**
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No

Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**14015**		
Mechanism Name:	**FUNZO Kenya**		
Prime Partner Name:	**IntraHealth International, Inc**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HLAB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**

Governance and Systems	OHSS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0
HRH_PRE	By Graduates: Doctors	0
HRH_PRE	By Graduates: Nurses	0
HRH_PRE	By Graduates: Midwives	0
HRH_PRE	By Graduates: Social service workers	0
HRH_PRE	By Graduates: Laboratory professionals	0
HRH_PRE	By Graduates: Other	0
HRH_PRE	Sum of Graduates disaggreagtes	0

Implementing Mechanism Details

Mechanism ID: 14022	**Mechanism Name: APHIAplus Imarisha**
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: African Medical and Research Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,857,180	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,857,180	
Funding Source	**Funding Amount**
GHP-State	1,857,180

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**14022**		
Mechanism Name:	**APHIAplus Imarisha**		
Prime Partner Name:	**African Medical and Research Foundation**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	0	0

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	CIRC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVAB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	399,896	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	614,046	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	767,870	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	75,368	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	0
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	0
PMTCT_ART_TA	Number of HIV-positive pregnant women who received	436

	ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	63,529
PMTCT_ART_TA	New on ART	300
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	136
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	0
PMTCT_STAT_DSD	By Number of known positives: 20-24	0
PMTCT_STAT_DSD	By Number of known positives: 50+	0
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	0
PMTCT_STAT_DSD	By Age (Numerator): 50+	0
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	63,529
PMTCT_STAT_TA	By Age (Denominator): Unknown Age	0
PMTCT_STAT_TA	By Age (Denominator): <10	0
PMTCT_STAT_TA	By Age (Denominator): 10-14	264
PMTCT_STAT_TA	By Age (Denominator): 15-19	1,768
PMTCT_STAT_TA	By Age (Denominator): 20-24	24,679
PMTCT_STAT_TA	By Age (Denominator): 25-49	36,818
PMTCT_STAT_TA	By Age (Denominator): 50+	0
PMTCT_STAT_TA	By known positives: <Unknown Age	0
PMTCT_STAT_TA	By known positives: <10	0
PMTCT_STAT_TA	By known positives: 10-14	0
PMTCT_STAT_TA	By known positives: 15-19	38
PMTCT_STAT_TA	By known positives: 20-24	94
PMTCT_STAT_TA	By known positives: 25-49	136
PMTCT_STAT_TA	By known positives: 50+	0
PMTCT_STAT_TA	By new positives: Unknown Age	0

PMTCT_STAT_TA	By new positives: <10	0
PMTCT_STAT_TA	By new positives: 10-14	0
PMTCT_STAT_TA	By new positives: 15-19	0
PMTCT_STAT_TA	By new positives: 20-24	90
PMTCT_STAT_TA	By new positives: 25-49	89
PMTCT_STAT_TA	By new positives: 50+	0
PMTCT_STAT_TA	By new negatives: Unknown Age	0
PMTCT_STAT_TA	By new negatives: <10	0
PMTCT_STAT_TA	By new negatives: 10-14	14
PMTCT_STAT_TA	By new negatives: 15-19	1,640
PMTCT_STAT_TA	By new negatives: 20-24	23,607
PMTCT_STAT_TA	By new negatives: 25-49	35,599
PMTCT_STAT_TA	By new negatives: 50+	0
PMTCT_STAT_TA	By Age (Numerator): Unknown Age	0
PMTCT_STAT_TA	By Age (Numerator): <10	0
PMTCT_STAT_TA	By Age (Numerator): 10-14	1
PMTCT_STAT_TA	By Age (Numerator): : 15-19	1,305
PMTCT_STAT_TA	By Age (Numerator): 20-24	24,565
PMTCT_STAT_TA	By Age (Numerator): 25-49	37,658
PMTCT_STAT_TA	By Age (Numerator): 50+	0
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	201,426
HTC_TST_TA	By Test Result: Positive	2,008
HTC_TST_TA	Sum of Test Result disaggregates	2,008
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Male, Negative	1
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Inpatient: 15+, Male, Positive	1
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Negative	10,971
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Positive	435

HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Negative	5,496
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Positive	104
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Negative	75,585
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Positive	881
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Negative	21,565
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Positive	367
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: Unknown Age, Female, Negative	209
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: Unknown Age, Female, Positive	10
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: Unknown Age, Male, Negative	132
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: Unknown Age, Male, Positive	3
HTC_TST_TA	Service Delivery Point Agg Age (Facility) ANC: <15, Negative	4,539
HTC_TST_TA	Service Delivery Point Agg Age (Facility) ANC: <15, Positive	27
HTC_TST_TA	Service Delivery Point Agg Age (Facility) ANC: 15+, Negative	59,041
HTC_TST_TA	Service Delivery Point Agg Age (Facility) ANC: 15+, Positive	142
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,922
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	2,263
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during	477

	the reporting period)	
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	214
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,084
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	486
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	189
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	415
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	406
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	912
GEND_GBV_TA	Number of people receiving post-GBV care	1,237
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,000
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	227
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	33
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	252
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	252

TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	8
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	124
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	114
TB_ART_TA	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	8
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	124
TB_ART_TA	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	6
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	114
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	436
PMTCT_EID_TA	Unknown, <= 2 months	0

PMTCT_EID_TA	Unknown, 2 - 12 months	0
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	18
PMTCT_EID_TA	Number of infants with a negative virological test result within 2 months of birth	188
PMTCT_EID_TA	Number of infants with a positive virological test result between 2 and 12 months of birth	109
PMTCT_EID_TA	Number of infants with a negative virological test result between 2 and 12 months of birth	121
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	7,403
TX_CURR_TA	Aggregated Age/Sex: <15 Male	182
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	2,113
TX_CURR_TA	Aggregated Age/Sex: <15 Female	415
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	4,693
TX_CURR_TA	Sum of Aggregated Age/Sex <15	597
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	6,806
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	7,403
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,925
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	75
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	543
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	135
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	1,209
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	1,962
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting	3,901

	laboratory results within the past 12 months.	
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	7,403
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	660
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	102
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	336
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	46
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	1,549
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	268
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	787
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	112
TX_PVLS_TA	Numerator: Indication: Routine	3,322
TX_PVLS_TA	Numerator: Indication: Targeted	579
TX_PVLS_TA	Denominator: Indication: Routine	6,284
TX_PVLS_TA	Denominator: Indication: Targeted	1,119
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,219
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	230
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	579
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	113
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	3,062

TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	523
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,408
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	254
TX_PVLS_TA	<15, Undocumented Test Indication, Female	0
TX_PVLS_TA	Unknown Age, Routine, Female	7
TX_PVLS_TA	Unknown Age, Routine, Male	4
TX_PVLS_TA	Unknown Age, Targeted, Female	2
TX_PVLS_TA	Unknown Age, Targeted, Male	1
TX_PVLS_TA	Undocumented Test Indication	0
TX_PVLS_TA	<15, Undocumented Test Indication, Female	2
TX_PVLS_TA	<15, Undocumented Test Indication, Male	1
TX_PVLS_TA	15+, Routine, Unknown Sex	1
TX_PVLS_TA	15+, Undocumented Test Indication, Female	5
TX_PVLS_TA	15+, Undocumented Test Indication, Male	2
TX_PVLS_TA	Undocumented Test Indication	0
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,734
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,922
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	168
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	370
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	369
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number	824

	of adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	185
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	418
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	407
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	911
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	0
TX_TB_TA	Number of ART patients who were started on TB treatment during the reporting period.	104
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	4,681
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Female	2
TX_TB_TA	Numerator: By Aggregated Age/Sex: <15, Male	1

TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Female	52
TX_TB_TA	Numerator: By Aggregated Age/Sex: 15+, Male	49
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Female	257
TX_TB_TA	Denominator: By Aggregated Age/Sex: <15, Male	114
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Female	2,972
TX_TB_TA	Denominator: By Aggregated Age/Sex: 15+, Male	1,338
TX_TB_TA	Denominator: By Screen Result: Negative	3,743
TX_TB_TA	Denominator: By Screen Result: Positive	937
TX_TB_TA	Denominator: By Specimen Sent: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	887
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	470
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	141
TX_TB_TA	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	746

Implementing Mechanism Details

Mechanism ID: 14034	**Mechanism Name: The OVC Scholarship and Leadership Program**
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: Equity Group Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	14034		
Mechanism Name:	The OVC Scholarship and Leadership Program		
Prime Partner Name:	Equity Group Foundation		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16450	**Mechanism Name: Global Give Back Circle**
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Kenya Community Development Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	16450		
Mechanism Name:	Global Give Back Circle		
Prime Partner Name:	Kenya Community Development Foundation		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16670	**Mechanism Name: HIV Fellowship Program**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Nairobi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 850,000	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 850,000	
Funding Source	**Funding Amount**
GHP-State	850,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	425,000

Budget Code Information

Mechanism ID:	**16670**		
Mechanism Name:	**HIV Fellowship Program**		
Prime Partner Name:	**University of Nairobi**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	OHSS	850,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	12
HRH_PRE	By Graduates: Doctors	6
HRH_PRE	By Graduates: Nurses	1
HRH_PRE	By Graduates: Midwives	0
HRH_PRE	By Graduates: Social service workers	1
HRH_PRE	By Graduates: Laboratory professionals	0
HRH_PRE	By Graduates: Other	4
HRH_PRE	Sum of Graduates disaggreagtes	12

Implementing Mechanism Details

Mechanism ID: 16679	**Mechanism Name: Program Support Services**

Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: International Business & Technical Consultants Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 350,000	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 350,000	
Funding Source	**Funding Amount**
GHP-State	350,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**16679**		
Mechanism Name:	**Program Support Services**		
Prime Partner Name:	**International Business & Technical Consultants Inc.**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HVSI	250,000	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVAB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**

Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	100,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16684	**Mechanism Name: Kenya Disciplined Services ZUIA**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,478,673	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,478,673	
Funding Source	**Funding Amount**
GHP-State	1,478,673

Cross-Cutting Budget Attribution(s)

Human Resources for Health	107,640

Budget Code Information

Mechanism ID:	16684		
Mechanism Name:	Kenya Disciplined Services ZUIA		
Prime Partner Name:	Elizabeth Glaser Pediatric AIDS Foundation		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	32,362	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	OHSS	190,000	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	96,566	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	700,439	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	89,378	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	348,371	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	21,557	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission	321

	(MTCT) during pregnancy	
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	5,759
PMTCT_ART_DSD	New on ART	147
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	174
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	5,759
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	7
PMTCT_STAT_DSD	By Age (Denominator): <15-19	537
PMTCT_STAT_DSD	By Age (Denominator): 20-24	1,922
PMTCT_STAT_DSD	By Age (Denominator): 25-49	3,230
PMTCT_STAT_DSD	By Age (Denominator): 50+	0
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	0
PMTCT_STAT_DSD	By Number of known positives: 15-19	8
PMTCT_STAT_DSD	By Number of known positives: 20-24	50
PMTCT_STAT_DSD	By Number of known positives: 25-49	117
PMTCT_STAT_DSD	By Number of known positives: 50+	0
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	0
PMTCT_STAT_DSD	By Number of new positives: 15-19	5
PMTCT_STAT_DSD	By Number of new positives: 20-24	40
PMTCT_STAT_DSD	By Number of new positives: 25-49	103
PMTCT_STAT_DSD	By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	0
PMTCT_STAT_DSD	By Number of new negative: <10	0

PMTCT_STAT_DSD	By Number of new negative: 10-14	7
PMTCT_STAT_DSD	By Number of new negative: 15-19	529
PMTCT_STAT_DSD	By Number of new negative: 20-24	1,849
PMTCT_STAT_DSD	By Number of new negative: 25-49	3,041
PMTCT_STAT_DSD	By Number of new negative: 50+	10
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	7
PMTCT_STAT_DSD	By Age (Numerator): 15-19	543
PMTCT_STAT_DSD	By Age (Numerator): 20-24	1,943
PMTCT_STAT_DSD	By Age (Numerator): 25-49	3,166
PMTCT_STAT_DSD	By Age (Numerator): 50+	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	33,545
PP_PREV_DSD	Age/sex: 10-14 Male	58
PP_PREV_DSD	Age/sex: 15-19 Male	449
PP_PREV_DSD	Age/sex: 20-24 Male	7,882
PP_PREV_DSD	Age/sex: 25-49 Male	585
PP_PREV_DSD	Age/sex: 50+ Male	32
PP_PREV_DSD	Age/sex: 10-14 Female	49
PP_PREV_DSD	Age/sex: 15-19 Female	3,422
PP_PREV_DSD	Age/sex: 20-24 Female	7,997
PP_PREV_DSD	Age/sex: 25-49 Female	12,420
PP_PREV_DSD	Age/sex: 50+ Female	651
PP_PREV_DSD	Sum of Age/Sex disaggregates	33,545
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	77,174
HTC_TST_DSD	By Test Result: Positive	2,093
HTC_TST_DSD	Sum of Test Result disaggregates	2,093
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14,	1,390

	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	1,166
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	6,028
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	177
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	3,627
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	101
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	9,248
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	275
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	4,059
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	112
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	14,962
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	445
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	11,846
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	334
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	1,424
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+,	45

	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,570
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	50
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1, Negative	79
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	5,054
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	65
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	16
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	33
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male,	3

	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	35
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	42
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	46
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	74
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	16
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	8

HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	12
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	1,034
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	1,802
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	47
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	2,588
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	72
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	1,466
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	62
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	1,276

HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	1,444
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	1,645
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	48
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	1,182
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	48
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	1,686
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	44
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	121
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT:	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	0

HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	1
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	391
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	406
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	8
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	257
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	0
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	126
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	9
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	265
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	131
GEND_GBV_DSD	Number of people receiving post-GBV care	853
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	616
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	237

GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	94
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	2
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	28
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	10
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	4
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	1
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	76
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	27
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	18
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	5
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	140
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	55
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	33
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	11
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	173
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	66
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	41
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	14
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	76
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	32
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	25
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	16
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	0

GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	102
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	102
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	68
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	34
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	68
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	0

TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	34
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	321
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	15
PMTCT_EID_DSD	Unknown, <= 2 months	0
PMTCT_EID_DSD	Unknown, 2 - 12 months	0
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	241
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	0
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	65
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	3,058
TX_CURR_DSD	Age/Sex: 15-19 Male	19
TX_CURR_DSD	Age/Sex: 15-19 Female	39
TX_CURR_DSD	Sum of age/sex disaggregates	58
TX_CURR_DSD	Age/Sex: <1	15
TX_CURR_DSD	Age/Sex: <1-9	97
TX_CURR_DSD	Age/Sex: 10-14 Male	30
TX_CURR_DSD	Age/Sex: 10-14 Female	22
TX_CURR_DSD	Age/Sex: 20-24 Male	56
TX_CURR_DSD	Age/Sex: 25-49 Male	597
TX_CURR_DSD	Age/Sex: 50+ Male	199
TX_CURR_DSD	Age/Sex: 20-24 Female	184
TX_CURR_DSD	Age/Sex: 25-49 Female	1,518
TX_CURR_DSD	Age/Sex: 50+ Female	282
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	606

TX_NEW_DSD	By Age/Sex: <1	12
TX_NEW_DSD	By Age/Sex: 1-9	5
TX_NEW_DSD	By Age/Sex: 10-14 Male	9
TX_NEW_DSD	By Age/Sex: 15-19 Male	0
TX_NEW_DSD	By Age/Sex: 20-24 Male	13
TX_NEW_DSD	By Age/Sex: 25-49 Male	124
TX_NEW_DSD	By Age/Sex: 50+ Male	44
TX_NEW_DSD	By Age/Sex: 10-14 Female	0
TX_NEW_DSD	By Age/Sex: 15-19 Female	5
TX_NEW_DSD	By Age/Sex: 20-24 Female	39
TX_NEW_DSD	By Age/Sex: 25-49 Female	301
TX_NEW_DSD	By Age/Sex: 50+ Female	54
TX_NEW_DSD	Sum of Age/Sex disaggregates	589
TX_NEW_DSD	Pregnancy status	140
TX_NEW_DSD	Breastfeeding status	5
TX_NEW_DSD	FSW	0
TX_NEW_DSD	MSM	0
TX_NEW_DSD	People in prisons and other enclosed settings	0
TX_NEW_DSD	TG	0
TX_NEW_DSD	By Key populations: People who inject drugs (PWID)	0
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	2,725
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	3,040
TX_PVLS_DSD	Numerator: Indication: Routine	2,532
TX_PVLS_DSD	Numerator: Indication: Targeted	193
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	145
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	4
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	0

TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	1
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	57
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	7
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	128
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	47
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	727
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	65
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	1,693
TX_PVLS_DSD	Denominator: Indication: Routine	2,828
TX_PVLS_DSD	Denominator: Indication: Targeted	212
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	140
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	4
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	0
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	1
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	63
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	7
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	141

TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	62
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	810
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	76
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	1,880
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	<15, Routine, Unknown Sex	0

TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	573
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	604
TX_RET_DSD	Numerator by Status: Pregnant	133
TX_RET_DSD	Numerator by Status: Breastfeeding	4
TX_RET_DSD	Denominator by Status: Pregnant	136
TX_RET_DSD	Denominator by Status: Breastfeeding	4

TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	163
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	16
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	385
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	12
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	171
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	17
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	406
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	563

TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	622
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	21
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	21
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	398
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	182
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	622
TB_PREV_DSD	By Therapy type (Denominator): Alternative Regimen	0
TB_PREV_DSD	By Therapy type (Denominator): Continuous IPT	0
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	21
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	21
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	355
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	165
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	563
TB_PREV_DSD	By Therapy type (Numerator): Alternative Regimen	0
TB_PREV_DSD	By Therapy type (Numerator): Continuous IPT	0
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	37
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	3,055
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	10
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	27
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	23
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	10
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	403
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	175

TX_TB_DSD	Denominator: By Screen Result: Negative	2,447
TX_TB_DSD	Denominator: By Screen Result: Positive	611
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	611
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	25
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	94
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	492

Implementing Mechanism Details

Mechanism ID: 16687	**Mechanism Name: Kenya Prison Services**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Health Strat Kenya	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,950,977	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,950,977	
Funding Source	**Funding Amount**
GHP-State	1,950,977

Cross-Cutting Budget Attribution(s)

Gender: GBV	3,854
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building

Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	3,854
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	308,303

Budget Code Information

Mechanism ID:	**16687**		
Mechanism Name:	**Kenya Prison Services**		
Prime Partner Name:	**Health Strat Kenya**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	52,415	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	OHSS	160,000	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	327,781	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	701,226	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	115,495	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	564,232	0

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	29,828	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	514
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	7,470
PMTCT_ART_DSD	New on ART	251
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	263
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	7,470
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	0
PMTCT_STAT_DSD	By Age (Denominator): <15-19	519
PMTCT_STAT_DSD	By Age (Denominator): 20-24	1,941
PMTCT_STAT_DSD	By Age (Denominator): 25-49	5,010
PMTCT_STAT_DSD	By Age (Denominator): 50+	0
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	0
PMTCT_STAT_DSD	By Number of known positives: 15-19	16
PMTCT_STAT_DSD	By Number of known positives: 20-24	70
PMTCT_STAT_DSD	By Number of known positives: 25-49	177
PMTCT_STAT_DSD	By Number of known positives: 50+	0

PMTCT_STAT_DSD	By Number of new positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	0
PMTCT_STAT_DSD	By Number of new positives: 15-19	17
PMTCT_STAT_DSD	By Number of new positives: 20-24	66
PMTCT_STAT_DSD	By Number of new positives: 25-49	176
PMTCT_STAT_DSD	By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	0
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	0
PMTCT_STAT_DSD	By Number of new negative: 15-19	486
PMTCT_STAT_DSD	By Number of new negative: 20-24	1,805
PMTCT_STAT_DSD	By Number of new negative: 25-49	4,657
PMTCT_STAT_DSD	By Number of new negative: 50+	0
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	0
PMTCT_STAT_DSD	By Age (Numerator): 15-19	519
PMTCT_STAT_DSD	By Age (Numerator): 20-24	1,941
PMTCT_STAT_DSD	By Age (Numerator): 25-49	5,010
PMTCT_STAT_DSD	By Age (Numerator): 50+	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	27,472
PP_PREV_DSD	Age/sex: 10-14 Male	0
PP_PREV_DSD	Age/sex: 15-19 Male	787
PP_PREV_DSD	Age/sex: 20-24 Male	2,983
PP_PREV_DSD	Age/sex: 25-49 Male	10,209
PP_PREV_DSD	Age/sex: 50+ Male	2,409
PP_PREV_DSD	Age/sex: 10-14 Female	0
PP_PREV_DSD	Age/sex: 15-19 Female	441
PP_PREV_DSD	Age/sex: 20-24 Female	1,155

PP_PREV_DSD	Age/sex: 25-49 Female	7,298
PP_PREV_DSD	Age/sex: 50+ Female	2,190
PP_PREV_DSD	Sum of Age/Sex disaggregates	27,472
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	117,586
HTC_TST_DSD	By Test Result: Positive	5,168
HTC_TST_DSD	Sum of Test Result disaggregates	5,168
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	60,617
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	2,135
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	142
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	525
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	1,354
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	141
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: <15, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: <15,	0

	Positive	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative	4,927
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive	358
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	590
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	446
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	886
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	1,432
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	2,303
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	145
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	4,975
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	203
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female,	3,744

	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	577
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	14,667
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	774
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	267
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	1,168
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	75
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT:	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	592
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	17
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	8,010
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	150
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	4,583
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	94
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+,	13,288

	Female, Negative	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	908
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	48,516
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	1,619
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Positive	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,300
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,359
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	16
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,080
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	10
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	194
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	16

TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,130
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	10
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	203
GEND_GBV_DSD	Number of people receiving post-GBV care	2,462
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,794
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	668
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	267
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	4
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	2
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	36
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	13
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	57
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	23
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	141
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	62
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	228
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	97
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	156
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	66

GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	237
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	102
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	46
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	17
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	50
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	18
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	360
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	360
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	277
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	79

	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	277
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	3
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	79
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	514
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	0
PMTCT_EID_DSD	Unknown, <= 2 months	0
PMTCT_EID_DSD	Unknown, 2 - 12 months	0
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	154
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	12
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	348
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	9,245
TX_CURR_DSD	Age/Sex: 15-19 Male	243
TX_CURR_DSD	Age/Sex: 15-19 Female	186
TX_CURR_DSD	Sum of age/sex disaggregates	429

TX_CURR_DSD	Aggregated Age/Sex: <15 Male	77
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	2,470
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	91
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	2,223
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	168
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	4,693
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	4,861
TX_CURR_DSD	Age/Sex: <1	6
TX_CURR_DSD	Age/Sex: <1-9	13
TX_CURR_DSD	Age/Sex: 10-14 Male	31
TX_CURR_DSD	Age/Sex: 10-14 Female	41
TX_CURR_DSD	Age/Sex: 20-24 Male	972
TX_CURR_DSD	Age/Sex: 25-49 Male	973
TX_CURR_DSD	Age/Sex: 50+ Male	243
TX_CURR_DSD	Age/Sex: 20-24 Female	743
TX_CURR_DSD	Age/Sex: 25-49 Female	746
TX_CURR_DSD	Age/Sex: 50+ Female	187
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,711
TX_NEW_DSD	By Age/Sex: <1	0
TX_NEW_DSD	By Age/Sex: 1-9	0
TX_NEW_DSD	By Age/Sex: 10-14 Male	5
TX_NEW_DSD	By Age/Sex: 15-19 Male	59
TX_NEW_DSD	By Age/Sex: 20-24 Male	239
TX_NEW_DSD	By Age/Sex: 25-49 Male	240
TX_NEW_DSD	By Age/Sex: 50+ Male	58
TX_NEW_DSD	By Age/Sex: 10-14 Female	6
TX_NEW_DSD	By Age/Sex: 15-19 Female	42
TX_NEW_DSD	By Age/Sex: 20-24 Female	169
TX_NEW_DSD	By Age/Sex: 25-49 Female	172
TX_NEW_DSD	By Age/Sex: 50+ Female	43
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,033

TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	12
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	329
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	15
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	322
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	678
TX_NEW_DSD	Pregnancy status	208
TX_NEW_DSD	Breastfeeding status	23
TX_NEW_DSD	People in prisons and other enclosed settings	779
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	8,277
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	9,222
TX_PVLS_DSD	Numerator: Indication: Routine	7,699
TX_PVLS_DSD	Numerator: Indication: Targeted	578
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	6
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	311
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	8
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	253
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	84
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	4,109
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	95
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	3,411
TX_PVLS_DSD	Denominator: Indication: Routine	8,576

TX_PVLS_DSD	Denominator: Indication: Targeted	646
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	7
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	347
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	10
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	282
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	103
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	4,560
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	119
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	3,794
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0

TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,626
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,805
TX_RET_DSD	Numerator by Status: Pregnant	208

TX_RET_DSD	Numerator by Status: Breastfeeding	22
TX_RET_DSD	Denominator by Status: Pregnant	208
TX_RET_DSD	Denominator by Status: Breastfeeding	22
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	16
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	888
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	20
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	702
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	16
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	988
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	20
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	781

TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,542
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	1,711
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	21
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	16
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	747
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	927
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	1,711
TB_PREV_DSD	By Therapy type (Denominator): Alternative Regimen	0
TB_PREV_DSD	By Therapy type (Denominator): Continuous IPT	0
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	19
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	15
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	671
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	837
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	1,542
TB_PREV_DSD	By Therapy type (Numerator): Alternative Regimen	0
TB_PREV_DSD	By Therapy type (Numerator): Continuous IPT	0
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	143
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	8,832
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	1
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	1
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	29
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	112
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	144

TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	113
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	3,872
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	4,703
TX_TB_DSD	Denominator: By Screen Result: Negative	7,069
TX_TB_DSD	Denominator: By Screen Result: Positive	1,763
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,763
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	90
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	262
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	1,411

Implementing Mechanism Details

Mechanism ID: 16705	**Mechanism Name: IDU - HIV Combination Prevention**
Funding Agency: USAID	Procurement Type: Grant
Prime Partner Name: United Nations Office on Drug and Crime (UNODC)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,695,173	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,695,173	
Funding Source	**Funding Amount**
GHP-State	1,695,173

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	16705		
Mechanism Name:	IDU - HIV Combination Prevention		
Prime Partner Name:	United Nations Office on Drug and Crime (UNODC)		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	595,190	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	IDUP	1,099,983	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	4,589
KP_MAT_DSD	Sex: Male	3,648
KP_MAT_DSD	Sex: Female	941
KP_MAT_DSD	Sum of Sex disaggregates	4,589
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,808
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	2,248
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations	560

	reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
GEND_GBV_DSD	Number of people receiving post-GBV care	1,829
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	1,613
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	216
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	33
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	137
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	17
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	1,490
GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	200

Implementing Mechanism Details

Mechanism ID: 16709	**Mechanism Name: Accelerating Progress Against TB**
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Center for Health Solutions (CHS)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,500,000	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,500,000	
Funding Source	**Funding Amount**
GHP-State	1,500,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	16709		
Mechanism Name:	Accelerating Progress Against TB		
Prime Partner Name:	Center for Health Solutions (CHS)		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	1,500,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16710	**Mechanism Name: Expanding Health Insurance Coverage**
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Equity Group Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	16710		
Mechanism Name:	Expanding Health Insurance Coverage		
Prime Partner Name:	Equity Group Foundation		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17190	**Mechanism Name: Wezesha Project**
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Life Skills Promoters	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,068,232	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,068,232	
Funding Source	**Funding Amount**
GHP-State	1,068,232

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17190		
Mechanism Name:	Wezesha Project		
Prime Partner Name:	Life Skills Promoters		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	1,068,232	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
GEND_GBV_DSD	Number of people receiving post-GBV care	9,985
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	8,519
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,466
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	859
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	194
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	657
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	75
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	1,623
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	315
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	1,165
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	134
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	1,748
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	344
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	1,373

GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	190
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	341
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	151
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	753
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	63
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	20,389
OVC_SERV_DSD	Age/Sex: 10-14 Male	2,945
OVC_SERV_DSD	Age/Sex: 15-17 Male	2,766
OVC_SERV_DSD	By: Age/sex: Male 18-24	327
OVC_SERV_DSD	By: Age/sex: Male 25+	0
OVC_SERV_DSD	Age/Sex: 10-14 Female	5,341
OVC_SERV_DSD	Age/Sex: 15-17 Female	4,578
OVC_SERV_DSD	By: Age/sex: 18-24 Female	416
OVC_SERV_DSD	By: Age/sex: 25+ Female	0
OVC_SERV_DSD	Sum of Age/Sex disaggregates	15,630
OVC_SERV_DSD	Age/Sex: <1	3

OVC_SERV_DSD	Age/Sex: 1-9	4,013
OVC_SERV_DSD	Program Completion: Active	20,389

Implementing Mechanism Details

Mechanism ID: 17191	**Mechanism Name: Watoto Wazima Initiative)**
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Reformed Church of East Africa	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 379,566	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 379,566	
Funding Source	**Funding Amount**
GHP-State	379,566

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**17191**		
Mechanism Name:	**Watoto Wazima Initiative)**		
Prime Partner Name:	**Reformed Church of East Africa**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	379,566	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**

Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
GEND_GBV_DSD	Number of people receiving post-GBV care	3,503
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	2,982
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	521
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	78
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	7,245
OVC_SERV_DSD	Age/Sex: 10-14 Male	822
OVC_SERV_DSD	Age/Sex: 15-17 Male	643
OVC_SERV_DSD	By: Age/sex: Male 18-24	364
OVC_SERV_DSD	Age/Sex: 10-14 Female	1,748
OVC_SERV_DSD	Age/Sex: 15-17 Female	1,450
OVC_SERV_DSD	By: Age/sex: 18-24 Female	364
OVC_SERV_DSD	Sum of Age/Sex disaggregates	4,663
OVC_SERV_DSD	Age/Sex: <1	22
OVC_SERV_DSD	Age/Sex: 1-9	1,832
OVC_SERV_DSD	Program Completion: Active	7,245

Implementing Mechanism Details

Mechanism ID: 17707	**Mechanism Name: Nilinde Project**
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: PLAN International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 7,659,688	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 913,674	
Total All Funding Sources and Applied Pipeline Amount: 8,573,362	
Funding Source	**Funding Amount**
GHP-State	7,659,688

Cross-Cutting Budget Attribution(s)

Gender: GBV	605,345
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID:	**17707**		
Mechanism Name:	**Nilinde Project**		
Prime Partner Name:	**PLAN International**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	7,659,688	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
GEND_GBV_DSD	Number of people receiving post-GBV care	83,885

GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	72,102
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	11,767
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1,770
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	3,436
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	583
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	2,858
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	485
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	529
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	90
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	163,645
OVC_SERV_DSD	Age/Sex: 10-14 Male	20,202
OVC_SERV_DSD	Age/Sex: 15-17 Male	15,304
OVC_SERV_DSD	By: Age/sex: Male 18-24	5,067
OVC_SERV_DSD	By: Age/sex: Male 25+	0
OVC_SERV_DSD	Age/Sex: 10-14 Female	37,992
OVC_SERV_DSD	Age/Sex: 15-17 Female	31,667
OVC_SERV_DSD	By: Age/sex: 18-24 Female	6,456
OVC_SERV_DSD	By: Age/sex: 25+ Female	0
OVC_SERV_DSD	Sum of Age/Sex disaggregates	105,165
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	3,832
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	3,185
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	585
OVC_SERV_DSD	Age/Sex: <1	1,316
OVC_SERV_DSD	Age/Sex: 1-9	45,641
OVC_SERV_DSD	Program Completion: Active	152,122
OVC_SERV_DSD	Program Completion: Graduation	11,523

Implementing Mechanism Details

Mechanism ID: 17709	**Mechanism Name: HRH Kenya**
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: IntraHealth International, Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 4,020,000	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 4,020,000	
Funding Source	**Funding Amount**
GHP-State	4,020,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**17709**		
Mechanism Name:	**HRH Kenya**		
Prime Partner Name:	**IntraHealth International, Inc**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**

Governance and Systems	HLAB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	OHSS	3,320,000	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	700,000	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	1,555
HRH_PRE	By Graduates: Nurses	993
HRH_PRE	By Graduates: Laboratory professionals	90
HRH_PRE	By Graduates: Other	472
HRH_PRE	Sum of Graduates disaggreagtes	1,555

Implementing Mechanism Details

Mechanism ID: 17711	**Mechanism Name: Implementation and expansion of blood safety**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: National Blood Transfusion Service, Kenya	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 850,000	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 850,000	
Funding Source	**Funding Amount**
GHP-State	850,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	425,000

Budget Code Information

Mechanism ID:	**17711**		
Mechanism Name:	**Implementation and expansion of blood safety**		
Prime Partner Name:	**National Blood Transfusion Service, Kenya**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HMBL	850,000	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	0
HRH_PRE	By Graduates: Doctors	0
HRH_PRE	By Graduates: Nurses	0
HRH_PRE	By Graduates: Midwives	0
HRH_PRE	By Graduates: Social service workers	0
HRH_PRE	By Graduates: Laboratory professionals	0
HRH_PRE	By Graduates: Other	0
HRH_PRE	Sum of Graduates disaggreagtes	0

Implementing Mechanism Details

Mechanism ID: 17712	**Mechanism Name: Strengthening Strategic Information in Kenya**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at San Francisco	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,960,000	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,960,000	
Funding Source	**Funding Amount**
GHP-State	3,960,000

Cross-Cutting Budget Attribution(s)

Key Populations: FSW	350,000
Focus Area:	Collection and use of strategic information on SWs

	and clients
Focus Area:	Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients
Focus Area:	Monitoring and evaluation of SW programs
Key Populations: MSM and TG	250,000
Focus Area:	Collection and use of strategic information
Focus Area:	Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners
Focus Area:	Monitoring and evaluation of MSM/TG programs
Human Resources for Health	1,110,000

Budget Code Information

Mechanism ID:	**17712**		
Mechanism Name:	**Strengthening Strategic Information in Kenya**		
Prime Partner Name:	**University of California at San Francisco**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HVSI	3,560,000	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	400,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17718	**Mechanism Name: Afya Jijini**
Funding Agency: USAID	Procurement Type: Contract

Prime Partner Name: Interchurch Medical Assistance	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 8,475,481	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 8,475,481	
Funding Source	**Funding Amount**
GHP-State	8,475,481

Cross-Cutting Budget Attribution(s)

Gender: GBV	73,728
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Water	150,000

Budget Code Information

Mechanism ID:	**17718**		
Mechanism Name:	**Afya Jijini**		
Prime Partner Name:	**Interchurch Medical Assistance**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	0	0

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	336,096	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	689,044	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	1,704,766	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	952,595	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	4,594,740	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	198,240	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	3,178
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	69,221
PMTCT_ART_DSD	New on ART	808
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,370
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	69,221

PMTCT_STAT_DSD	By Age (Denominator): 10-14	5
PMTCT_STAT_DSD	By Age (Denominator): <15-19	3,059
PMTCT_STAT_DSD	By Age (Denominator): 20-24	20,553
PMTCT_STAT_DSD	By Age (Denominator): 25-49	45,572
PMTCT_STAT_DSD	By Age (Denominator): 50+	32
PMTCT_STAT_DSD	By Number of known positives: 15-19	7
PMTCT_STAT_DSD	By Number of known positives: 20-24	324
PMTCT_STAT_DSD	By Number of known positives: 25-49	2,068
PMTCT_STAT_DSD	By Number of new positives: 15-19	19
PMTCT_STAT_DSD	By Number of new positives: 20-24	194
PMTCT_STAT_DSD	By Number of new positives: 25-49	733
PMTCT_STAT_DSD	By Number of new negative: 10-14	5
PMTCT_STAT_DSD	By Number of new negative: 15-19	2,923
PMTCT_STAT_DSD	By Number of new negative: 20-24	18,687
PMTCT_STAT_DSD	By Number of new negative: 25-49	44,229
PMTCT_STAT_DSD	By Number of new negative: 50+	32
PMTCT_STAT_DSD	By Age (Numerator): 10-14	5
PMTCT_STAT_DSD	By Age (Numerator): 15-19	2,950
PMTCT_STAT_DSD	By Age (Numerator): 20-24	19,206
PMTCT_STAT_DSD	By Age (Numerator): 25-49	47,028
PMTCT_STAT_DSD	By Age (Numerator): 50+	32
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	6,224
VMMC_CIRC_DSD	By Age: 10-14	2,490
VMMC_CIRC_DSD	By Age: 15-19	622
VMMC_CIRC_DSD	By Age: 20-24	622
VMMC_CIRC_DSD	By Age: 25-29	1,245
VMMC_CIRC_DSD	By Age: 30-49	1,183
VMMC_CIRC_DSD	By Age: 50+	62
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	3,796
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	6,224

VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	6,224
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	17,951
PP_PREV_DSD	Age/sex: 10-14 Male	310
PP_PREV_DSD	Age/sex: 15-19 Male	702
PP_PREV_DSD	Age/sex: 20-24 Male	784
PP_PREV_DSD	Age/sex: 10-14 Female	7,038
PP_PREV_DSD	Age/sex: 15-19 Female	6,326
PP_PREV_DSD	Age/sex: 20-24 Female	2,791
PP_PREV_DSD	Sum of Age/Sex disaggregates	17,951
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	3,730
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,543
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	187
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	288,361
HTC_TST_DSD	By Test Result: Positive	12,573
HTC_TST_DSD	Sum of Test Result disaggregates	12,573
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	68
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	63

HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	113
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	191
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	414
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	294
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	36
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	656
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	63
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	412
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	98
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	51
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	50
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	315

HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	866
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	974
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	2,387
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	59
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	3,063
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	7,816
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	319
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	3,805
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	106
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	13,931
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	1,087
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	10,995
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	586
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	803

HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	82
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,281
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	86
HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1, Negative	193
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	2,359
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	684
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	60
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	90
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	114
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	156
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male,	12

	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	1,332
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	462
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	2,075
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	522
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	109
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	66
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	36
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	3,471
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	672
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	1,035
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Negative	1,046
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	2,923
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	18,687
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	191
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	44,235
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	731
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	32
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	2,764
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female,	72

	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	2,169
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	44
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	8,004
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	155
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	3,648
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	64
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	26,438
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	1,458
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	15,493
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	476
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	48,022
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	3,369
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	27,479
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	1,719
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	4,415
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	195
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male,	3,510

	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	307
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	1,052
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	4,729
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	89
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	5,202
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	5,456
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	57
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,947
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	51
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	2,147
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	61
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3,087
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	53
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	2,255
GEND_GBV_DSD	Number of people receiving post-GBV care	8,338

GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	7,088
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,250
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	188
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	38
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	35
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	33
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	4
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	564
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	106
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	532
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	59
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	752
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	176
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	665
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	74
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	865
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	202
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	765
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	85
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	1,354
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	317
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	1,197
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	129
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	188
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	44
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	133
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	18
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,575

TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,575
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	54
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	782
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	50
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	689
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	54
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	782
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	50
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	689

PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3,178
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	97
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	75
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	1,708
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	1,298
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	41,631
TX_CURR_DSD	Age/Sex: 15-19 Male	464
TX_CURR_DSD	Age/Sex: 15-19 Female	758
TX_CURR_DSD	Sum of age/sex disaggregates	1,222
TX_CURR_DSD	Age/Sex: <1	172
TX_CURR_DSD	Age/Sex: <1-9	653
TX_CURR_DSD	Age/Sex: 10-14 Male	441
TX_CURR_DSD	Age/Sex: 10-14 Female	487
TX_CURR_DSD	Age/Sex: 20-24 Male	1,005
TX_CURR_DSD	Age/Sex: 25-49 Male	9,469
TX_CURR_DSD	Age/Sex: 50+ Male	2,136
TX_CURR_DSD	Age/Sex: 20-24 Female	3,411
TX_CURR_DSD	Age/Sex: 25-49 Female	20,351
TX_CURR_DSD	Age/Sex: 50+ Female	2,284
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	10,587
TX_NEW_DSD	By Age/Sex: <1	105
TX_NEW_DSD	By Age/Sex: 1-9	97
TX_NEW_DSD	By Age/Sex: 10-14 Male	35
TX_NEW_DSD	By Age/Sex: 15-19 Male	48
TX_NEW_DSD	By Age/Sex: 20-24 Male	271
TX_NEW_DSD	By Age/Sex: 25-49 Male	2,562

TX_NEW_DSD	By Age/Sex: 50+ Male	368
TX_NEW_DSD	By Age/Sex: 10-14 Female	42
TX_NEW_DSD	By Age/Sex: 15-19 Female	151
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,187
TX_NEW_DSD	By Age/Sex: 25-49 Female	5,491
TX_NEW_DSD	By Age/Sex: 50+ Female	230
TX_NEW_DSD	Sum of Age/Sex disaggregates	10,385
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	37,288
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	41,631
TX_PVLS_DSD	Numerator: Indication: Routine	37,288
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	687
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	11,755
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	721
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	24,125
TX_PVLS_DSD	Denominator: Indication: Routine	41,631
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	878
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	13,044
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	972
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	26,737
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	9,526

TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	10,587
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	118
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,922
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	127
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,359
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	133
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,251
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	143
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped	7,060

	ART, and those lost to follow-up)	
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	630
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	41,631
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	21
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	20
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	275
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	314
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	895
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	857
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	26,808
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	13,071
TX_TB_DSD	Denominator: By Screen Result: Negative	33,304
TX_TB_DSD	Denominator: By Screen Result: Positive	8,326
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	7,911
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	415
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	1,251
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	6,464

Implementing Mechanism Details

Mechanism ID: 17719	**Mechanism Name: APHIAPlus Pwani**
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Pathfinder International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 9,926,262	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 9,926,262	
Funding Source	**Funding Amount**
GHP-State	9,926,262

Cross-Cutting Budget Attribution(s)

Gender: GBV	140,088
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation

Budget Code Information

Mechanism ID:	**17719**		
Mechanism Name:	**APHIAPlus Pwani**		
Prime Partner Name:	**Pathfinder International**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HBHC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**

Governance and Systems	HLAB	200,127	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	CIRC	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVAB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	615,894	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	1,077,370	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	1,429,150	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	6,111,444	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	492,277	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	4,596
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	109,663

PMTCT_ART_DSD	New on ART	1,751
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,845
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	109,663
PMTCT_STAT_DSD	By Age (Denominator): 10-14	501
PMTCT_STAT_DSD	By Age (Denominator): <15-19	2,541
PMTCT_STAT_DSD	By Age (Denominator): 20-24	33,446
PMTCT_STAT_DSD	By Age (Denominator): 25-49	69,372
PMTCT_STAT_DSD	By Age (Denominator): 50+	3,860
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	4
PMTCT_STAT_DSD	By Number of known positives: 15-19	42
PMTCT_STAT_DSD	By Number of known positives: 20-24	811
PMTCT_STAT_DSD	By Number of known positives: 25-49	1,625
PMTCT_STAT_DSD	By Number of known positives: 50+	93
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	1
PMTCT_STAT_DSD	By Number of new positives: 15-19	26
PMTCT_STAT_DSD	By Number of new positives: 20-24	644
PMTCT_STAT_DSD	By Number of new positives: 25-49	1,302
PMTCT_STAT_DSD	By Number of new positives: 50+	72
PMTCT_STAT_DSD	By Number of new negative: 10-14	478
PMTCT_STAT_DSD	By Number of new negative: 15-19	2,229
PMTCT_STAT_DSD	By Number of new negative: 20-24	30,950
PMTCT_STAT_DSD	By Number of new negative: 25-49	66,045
PMTCT_STAT_DSD	By Number of new negative: 50+	4,680
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Numerator): <10	2
PMTCT_STAT_DSD	By Age (Numerator): 10-14	508

PMTCT_STAT_DSD	By Age (Numerator): 15-19	2,642
PMTCT_STAT_DSD	By Age (Numerator): 20-24	33,567
PMTCT_STAT_DSD	By Age (Numerator): 25-49	69,080
PMTCT_STAT_DSD	By Age (Numerator): 50+	3,864
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	14,647
PP_PREV_DSD	Age/sex: 10-14 Male	1,000
PP_PREV_DSD	Age/sex: 15-19 Male	2,613
PP_PREV_DSD	Age/sex: 20-24 Male	2,300
PP_PREV_DSD	Age/sex: 25-49 Male	500
PP_PREV_DSD	Age/sex: 10-14 Female	1,000
PP_PREV_DSD	Age/sex: 15-19 Female	3,800
PP_PREV_DSD	Age/sex: 20-24 Female	3,234
PP_PREV_DSD	Age/sex: 25-49 Female	200
PP_PREV_DSD	Sum of Age/Sex disaggregates	14,647
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	342,224
HTC_TST_DSD	By Test Result: Positive	9,639
HTC_TST_DSD	Sum of Test Result disaggregates	9,639
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	1,012
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	1,003
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	138
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	93
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	3

HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	100
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	94
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	305
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	145
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	8
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	29
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	44
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	476
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	41
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	221
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1,908

HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	1,803
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	2,667
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	89
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	1,965
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	111
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	1,931
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	95
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	1,848
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	95
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	5,149
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	36
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	3,189
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	208
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	20

HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	209
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1, Negative	703
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	703
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	8
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	3,520
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	30
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	2,962
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	33
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	39,162
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	805
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	22,135
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	784
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Negative	1
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Positive	0

HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	4,124
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	57
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	91
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	62
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	63
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	61
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	219
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	90
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	50
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	4
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	85
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Positive	2
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	1,658
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	78
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	1,068
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	34
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Negative	0

HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	725
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	191
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	1,055
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	74
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	767
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	63
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	800
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	113
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	767
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	74
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	2,013
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	17

HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	1,002
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	68
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	68
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	38
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	538
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative	732
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	8
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative	934
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive	11
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	14,091
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	456
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	7,041
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	552
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Positive	0

HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_DSD	By Key Population: FSW, Negative	178
HTC_TST_DSD	By Key Population: FSW, Positive	26
HTC_TST_DSD	By Key Population: MSM, Negative	598
HTC_TST_DSD	By Key Population: MSM, Positive	26
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	705
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	66
HTC_TST_DSD	By Key Population: PWID, Negative	44
HTC_TST_DSD	By Key Population: PWID, Positive	17
HTC_TST_DSD	By Key Population: TG, Negative	33
HTC_TST_DSD	By Key Population: TG, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	2,331
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	26
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	1,231
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	4,265
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	43
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	6,239
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	255
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	25
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	80
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age,	0

	Negative	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: <15, Negative	3,908
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: <15, Positive	117
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative	35,771
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive	858
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	398
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	247
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	5,011
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	3,415
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	36
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	3,470
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	58
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	3,106
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male,	23

	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	9,406
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	72
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	6,303
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	689
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	325
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	398
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	203
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	1,803
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	18
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	3,678
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	92
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	4,597
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	92
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	69,926
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	1,625
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	34,735

HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	1,255
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Positive	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	5,323
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	5,639
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	66
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	525
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	146
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,064
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	66
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	546
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	146

TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,088
GEND_GBV_DSD	Number of people receiving post-GBV care	11,095
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	8,462
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	2,633
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	395
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	572
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	105
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	297
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	51
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	1,420
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	371
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	1,134
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	165
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	2,036
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	726
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	1,095
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	195
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	1,287
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	1,064
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	7
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	0

GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,621
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,627
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	44
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	811
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	40
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	725
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	45
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The	813

	number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	42
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	725
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	4,598
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	190
PMTCT_EID_DSD	Unknown, <= 2 months	244
PMTCT_EID_DSD	Unknown, 2 - 12 months	165
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	2,598
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	128
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	1,273
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	55,487
TX_CURR_DSD	Age/Sex: 15-19 Male	499
TX_CURR_DSD	Age/Sex: 15-19 Female	592
TX_CURR_DSD	Sum of age/sex disaggregates	1,091
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,526
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	10,567
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,751
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	20,891
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	3,277
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	31,458

TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	34,735
TX_CURR_DSD	Age/Sex: <1	9
TX_CURR_DSD	Age/Sex: <1-9	192
TX_CURR_DSD	Age/Sex: 10-14 Male	188
TX_CURR_DSD	Age/Sex: 10-14 Female	302
TX_CURR_DSD	Age/Sex: 20-24 Male	1,716
TX_CURR_DSD	Age/Sex: 25-49 Male	3,975
TX_CURR_DSD	Age/Sex: 50+ Male	375
TX_CURR_DSD	Age/Sex: 20-24 Female	3,679
TX_CURR_DSD	Age/Sex: 25-49 Female	8,630
TX_CURR_DSD	Age/Sex: 50+ Female	595
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	9,096
TX_NEW_DSD	By Age/Sex: <1	34
TX_NEW_DSD	By Age/Sex: 1-9	87
TX_NEW_DSD	By Age/Sex: 10-14 Male	81
TX_NEW_DSD	By Age/Sex: 15-19 Male	55
TX_NEW_DSD	By Age/Sex: 20-24 Male	149
TX_NEW_DSD	By Age/Sex: 25-49 Male	345
TX_NEW_DSD	By Age/Sex: 50+ Male	36
TX_NEW_DSD	By Age/Sex: 10-14 Female	91
TX_NEW_DSD	By Age/Sex: 15-19 Female	73
TX_NEW_DSD	By Age/Sex: 20-24 Female	327
TX_NEW_DSD	By Age/Sex: 25-49 Female	847
TX_NEW_DSD	By Age/Sex: 50+ Female	55
TX_NEW_DSD	Sum of Age/Sex disaggregates	2,059
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	223
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,929
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	399
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	4,379
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	6,930
TX_PVLS_DSD	Number of adults and pediatric patients on ART with	48,108

	suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	55,425
TX_PVLS_DSD	Numerator: Indication: Routine	48,108
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	384
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	1,754
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	15,120
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	1,840
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	29,388
TX_PVLS_DSD	Denominator: Indication: Routine	50,356
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	2,091
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	16,748
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,293
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	34,261
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	7,829
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	8,680
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	328

TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,159
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	453
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,888
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	356
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,373
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	507
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,444
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	644
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	56,074
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	13
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	15

TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	298
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	317
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	1,399
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	1,460
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	33,833
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	19,348
TX_TB_DSD	Denominator: By Screen Result: Negative	43,097
TX_TB_DSD	Denominator: By Screen Result: Positive	11,686
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	14,759
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	29
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	0
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	10,469

Implementing Mechanism Details

Mechanism ID: 17944	**Mechanism Name: Linkages**
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,931,219	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,931,219	
Funding Source	**Funding Amount**
GHP-State	3,931,219

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17944		
Mechanism Name:	Linkages		
Prime Partner Name:	FHI 360		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	91,638	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	3,839,581	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	70,648
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	9,895
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on	6,593

	evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	54,160
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	13,367
HTC_TST_DSD	By Test Result: Positive	380

HTC_TST_DSD	Sum of Test Result disaggregates	380
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing:	0

	50+, Female, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	471
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	9

	15-19, Female, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	229
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	2,294
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	68
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	918
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	31
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	4,182
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	121
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	1,030
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	26
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	46
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	33
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	0

	Unknown Age, Male, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Other: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Other: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Other: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Male,	0

	Positive	
HTC_TST_DSD	Service Delivery Point (Community) Other: 25-49, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Other: 25-49, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Other: 25-49, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Other: 25-49, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Other: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Other: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Other: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Other: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Other: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Other: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Other: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Other: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Other: 1-9, Positive	0
HTC_TST_DSD	By Key Population: FSW, Negative	9,887
HTC_TST_DSD	By Key Population: FSW, Positive	273
HTC_TST_DSD	By Key Population: MSM, Negative	3,100
HTC_TST_DSD	By Key Population: MSM, Positive	107

HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	0
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	0
HTC_TST_DSD	By Key Population: PWID, Negative	0
HTC_TST_DSD	By Key Population: PWID, Positive	0
HTC_TST_DSD	By Key Population: TG, Negative	0
HTC_TST_DSD	By Key Population: TG, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	0

HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Female, Positive	0

HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	194
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	92
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	950
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	27
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	370
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 25-49, Female, Negative	1,734
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 25-49, Female, Positive	52
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 25-49, Male, Negative	416
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 25-49, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	20
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	12

HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Positive	0
GEND_GBV_DSD	Number of people receiving post-GBV care	40,159
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	26,098
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	14,061
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	2,110
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	877

GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	449
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	325
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	226
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	2,541
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	1,301
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	1,047
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	728
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	6,980
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	3,569
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	1,321
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	918
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	279
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	143
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	15
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	10
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0

Implementing Mechanism Details

Mechanism ID: 17945	**Mechanism Name: mHealth**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: mHealth Kenya	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 850,000	**Total Mechanism Pipeline: N/A**

Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 850,000	
Funding Source	**Funding Amount**
GHP-State	850,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 17945 **Mechanism Name:** mHealth **Prime Partner Name:** mHealth Kenya			
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HVSI	850,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17947	**Mechanism Name: Implementation of Sustainable Laboratory Quality Systems**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Medical and Research Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,267,392	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,267,392	
Funding Source	**Funding Amount**
GHP-State	2,267,392

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**17947**		
Mechanism Name:	**Implementation of Sustainable Laboratory Quality Systems**		
Prime Partner Name:	**African Medical and Research Foundation**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HLAB	1,989,221	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HMBL	97,750	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HMIN	180,421	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17948	**Mechanism Name: Laboratory Networking**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement

Prime Partner Name: African Society for Laboratory Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 100,000	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 100,000	
Funding Source	**Funding Amount**
GHP-State	100,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**17948**		
Mechanism Name:	**Laboratory Networking**		
Prime Partner Name:	**African Society for Laboratory Medicine**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HLAB	100,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17950	**Mechanism Name: Implementation of Sustainable Laboratory Quality Systems**

Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 4,695,387	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 4,695,387	
Funding Source	**Funding Amount**
GHP-State	4,695,387

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**17950**		
Mechanism Name:	**Implementation of Sustainable Laboratory Quality Systems**		
Prime Partner Name:	**University of Maryland**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HLAB	3,307,505	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	OHSS	212,000	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HMBL	333,250	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**

Prevention	HMIN	442,632	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	400,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17951	**Mechanism Name: Implementation of Sustainable Laboratory Quality Systems**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,475,736	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,475,736	
Funding Source	**Funding Amount**
GHP-State	1,475,736

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17951		
Mechanism Name:	Implementation of Sustainable Laboratory Quality Systems		
Prime Partner Name:	FHI 360		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HLAB	1,170,552	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HMBL	127,500	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HMIN	177,684	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17954	**Mechanism Name: Implementation of Sustainable Laboratory Quality Systems**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Global Implementation Solutions	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,175,208	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,175,208	
Funding Source	**Funding Amount**
GHP-State	3,175,208

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	17954		
Mechanism Name:	Implementation of Sustainable Laboratory Quality Systems		
Prime Partner Name:	Global Implementation Solutions		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HLAB	2,384,445	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HMBL	161,500	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HMIN	629,263	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17956	**Mechanism Name: VMMC QA Support**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: JHPIEGO	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**

Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**17956**		
Mechanism Name:	**VMMC QA Support**		
Prime Partner Name:	**JHPIEGO**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	CIRC	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17958	**Mechanism Name: Afyainfo National Mechanism Follow on (HIGDA)**
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Palladium Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,850,000	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,850,000	
Funding Source	**Funding Amount**
GHP-State	2,850,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**17958**		
Mechanism Name:	**Afyainfo National Mechanism Follow on (HIGDA)**		
Prime Partner Name:	**Palladium Group**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HVSI	2,850,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17959	**Mechanism Name: Sustaining National HMIS Kenya**
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Nairobi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,500,000	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,500,000	
Funding Source	**Funding Amount**
GHP-State	1,500,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**17959**		
Mechanism Name:	**Sustaining National HMIS Kenya**		
Prime Partner Name:	**University of Nairobi**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HVSI	1,500,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17960	**Mechanism Name: Avenir Health**
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Council	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 300,000	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 300,000	
Funding Source	**Funding Amount**
GHP-State	300,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**17960**		
Mechanism Name:	**Avenir Health**		
Prime Partner Name:	**Population Council**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	CIRC	300,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17964	**Mechanism Name: Measure Evaluation IV**
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: University of North Carolina	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 200,000	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 200,000	
Funding Source	**Funding Amount**
GHP-State	200,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**17964**		
Mechanism Name:	**Measure Evaluation IV**		
Prime Partner Name:	**University of North Carolina**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	100,000	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HVSI	100,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18203	**Mechanism Name: EGPAF Timiza**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted

TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 18,162,015	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 18,162,015	
Funding Source	**Funding Amount**
GHP-State	18,162,015

Cross-Cutting Budget Attribution(s)

Gender: GBV	350,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	350,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Key Populations: FSW	120,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Key Populations: MSM and TG	30,000
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance

Motor Vehicles: Leased	180,000
Human Resources for Health	6,287,321
Motor Vehicles: Purchased	352,168

Budget Code Information

Mechanism ID:	**18203**		
Mechanism Name:	**EGPAF Timiza**		
Prime Partner Name:	**Elizabeth Glaser Pediatric AIDS Foundation**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	1,073,366	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	822,746	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HLAB	103,437	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	CIRC	1,147,793	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HMIN	20,000	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	4,177,373	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	371,050	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**

Prevention	MTCT	1,036,333	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	8,556,623	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	853,294	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	5,326
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	52,339
PMTCT_ART_DSD	New on ART	1,208
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	4,118
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	52,339
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	88
PMTCT_STAT_DSD	By Age (Denominator): <15-19	9,846
PMTCT_STAT_DSD	By Age (Denominator): 20-24	17,258
PMTCT_STAT_DSD	By Age (Denominator): 25-49	25,147
PMTCT_STAT_DSD	By Age (Denominator): 50+	0
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	0

PMTCT_STAT_DSD	By Number of known positives: 15-19	661
PMTCT_STAT_DSD	By Number of known positives: 20-24	1,193
PMTCT_STAT_DSD	By Number of known positives: 25-49	2,039
PMTCT_STAT_DSD	By Number of known positives: 50+	0
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	0
PMTCT_STAT_DSD	By Number of new positives: 15-19	193
PMTCT_STAT_DSD	By Number of new positives: 20-24	374
PMTCT_STAT_DSD	By Number of new positives: 25-49	865
PMTCT_STAT_DSD	By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	0
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	107
PMTCT_STAT_DSD	By Number of new negative: 15-19	9,043
PMTCT_STAT_DSD	By Number of new negative: 20-24	15,720
PMTCT_STAT_DSD	By Number of new negative: 25-49	22,144
PMTCT_STAT_DSD	By Number of new negative: 50+	0
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	89
PMTCT_STAT_DSD	By Age (Numerator): 15-19	9,846
PMTCT_STAT_DSD	By Age (Numerator): 20-24	17,258
PMTCT_STAT_DSD	By Age (Numerator): 25-49	25,146
PMTCT_STAT_DSD	By Age (Numerator): 50+	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	49,192
VMMC_CIRC_DSD	By Age: 0-60 days	1,003
VMMC_CIRC_DSD	By Age: 2 months - 9 years	0
VMMC_CIRC_DSD	By Age: 10-14	19,676
VMMC_CIRC_DSD	By Age: 15-19	4,920

VMMC_CIRC_DSD	By Age: 20-24	4,920
VMMC_CIRC_DSD	By Age: 25-29	9,838
VMMC_CIRC_DSD	By Age: 30-49	8,344
VMMC_CIRC_DSD	By Age: 50+	491
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	30,007
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	48,189
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	47,995
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	1,197
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	0
PrEP_NEW_DSD	Male 15-19	0
PrEP_NEW_DSD	Male 20-24	0
PrEP_NEW_DSD	Male 25-49	0
PrEP_NEW_DSD	Male 50+	0
PrEP_NEW_DSD	Female 15-19	0
PrEP_NEW_DSD	Female 20-24	0
PrEP_NEW_DSD	Female 25-49	0
PrEP_NEW_DSD	Female 50+	0
PrEP_NEW_DSD	FSW	0
PrEP_NEW_DSD	MSM	0
PrEP_NEW_DSD	TG	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	7,859
PP_PREV_DSD	Age/sex: 10-14 Male	119
PP_PREV_DSD	Age/sex: 15-19 Male	71
PP_PREV_DSD	Age/sex: 20-24 Male	73
PP_PREV_DSD	Age/sex: 25-49 Male	1,759
PP_PREV_DSD	Age/sex: 50+ Male	607
PP_PREV_DSD	Age/sex: 10-14 Female	133
PP_PREV_DSD	Age/sex: 15-19 Female	132

PP_PREV_DSD	Age/sex: 20-24 Female	405
PP_PREV_DSD	Age/sex: 25-49 Female	3,853
PP_PREV_DSD	Age/sex: 50+ Female	707
PP_PREV_DSD	Sum of Age/Sex disaggregates	7,859
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	2,197
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	197
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	143
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,857
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached	0

	with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,710,398
HTC_TST_DSD	By Test Result: Positive	30,427
HTC_TST_DSD	Sum of Test Result disaggregates	30,427
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	448
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	571
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	4,249
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	78
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	1,326
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	18

HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	9,359
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	189
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	2,252
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	15,707
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	298
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	9,129
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	153
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	2,252
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	90
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	2,366
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	44
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	226
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	0

HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	3,132
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	23,675
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	189
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	23,458
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	205
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	147,566
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	2,705
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	90,448
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	1,676
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	226,217
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	4,169
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	98,916
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	1,883
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	363,530
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	6,744
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	285,134
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	5,385

HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	34,948
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	701
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	38,527
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	700
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1, Negative	1,250
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	77,995
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	516
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	86
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	15
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	22
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	66

HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	144
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	138
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	52
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	168
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	43
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	181
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	67
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	330
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	91
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	99
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	59
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	121
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	59
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	1

HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	127
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	88
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: <1, Negative	954
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	19,287
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	399
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	4,898
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	77
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	4,999
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Negative	18,343
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	493
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	1,703
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	1,340
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female,	25,063

	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	437
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	14,324
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	330
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	7,909
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	119
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	3,299
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	12,792
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	207
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	9,604
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	166
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	1,224
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	69
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	1,285
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	69
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age,	0

	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	78
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	5,902
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	43
HTC_TST_DSD	By Key Population: FSW, Negative	1,582
HTC_TST_DSD	By Key Population: FSW, Positive	31
HTC_TST_DSD	By Key Population: MSM, Negative	213
HTC_TST_DSD	By Key Population: MSM, Positive	4
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	0
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	0
HTC_TST_DSD	By Key Population: PWID, Negative	0
HTC_TST_DSD	By Key Population: PWID, Positive	0
HTC_TST_DSD	By Key Population: TG, Negative	0
HTC_TST_DSD	By Key Population: TG, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	123
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	8,853
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	276
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	15,466

HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	482
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	22,240
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	670
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	41
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	34
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	5,720
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	121
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	4,794
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	96
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	5,459
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	113
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	5,965
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	123
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female,	4,616

	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	97
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	6,279
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	128
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	202
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	509
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT:	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	163
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	1
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,467
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,631
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	201
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented	1,322

	HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	154
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	790
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	205
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,425
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	167
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	834
GEND_GBV_DSD	Number of people receiving post-GBV care	45,241
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	33,342
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	11,897
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	4,761
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	356
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	486
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	392
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	541
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	1,959
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	1,584
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	3,821

GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	1,582
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	422
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	10
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	5,487
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	3,645
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	3,599
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	503
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	6,023
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	3,504
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	11,595
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	56
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	36
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	18,690
OVC_SERV_DSD	Age/Sex: 10-14 Male	2,868
OVC_SERV_DSD	Age/Sex: 15-17 Male	1,884
OVC_SERV_DSD	By: Age/sex: Male 18-24	1,795
OVC_SERV_DSD	By: Age/sex: Male 25+	0
OVC_SERV_DSD	Age/Sex: 10-14 Female	3,208
OVC_SERV_DSD	Age/Sex: 15-17 Female	2,091
OVC_SERV_DSD	By: Age/sex: 18-24 Female	1,440
OVC_SERV_DSD	By: Age/sex: 25+ Female	0

OVC_SERV_DSD	Sum of Age/Sex disaggregates	10,051
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	957
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	439
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	323
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14	837
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17	452
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24	351
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	2,028
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	937
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	688
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14	1,775
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17	960
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24	721
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	973

	and sex: Social Protection Female 10-14	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	447
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	329
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14	851
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17	460
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24	356
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	890
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	411
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	300
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14	778
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17	420
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24	323
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	174
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	78

	and sex: Other Services Female 15-17	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	57
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 10-14	152
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 15-17	82
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 18-24	77
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Male 25+	0
OVC_SERV_DSD	Age/Sex: <1	10
OVC_SERV_DSD	Age/Sex: 1-9	5,394
OVC_SERV_DSD	Program Completion: Active	17,365
OVC_SERV_DSD	Program Completion: Graduation	1,325
OVC_SERV_DSD	Program Completion: Transferred	0
OVC_SERV_DSD	Program Completion: Exited without graduation	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,025
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,032
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	108
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	525
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The	62

	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	330
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	107
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	529
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	63
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	332
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	5,325
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	249
PMTCT_EID_DSD	Unknown, <= 2 months	0
PMTCT_EID_DSD	Unknown, 2 - 12 months	0
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	3,402
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	44
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	1,630

TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	98,472
TX_CURR_DSD	Age/Sex: 15-19 Male	857
TX_CURR_DSD	Age/Sex: 15-19 Female	1,586
TX_CURR_DSD	Sum of age/sex disaggregates	2,443
TX_CURR_DSD	Age/Sex: <1	292
TX_CURR_DSD	Age/Sex: <1-9	3,716
TX_CURR_DSD	Age/Sex: 10-14 Male	1,362
TX_CURR_DSD	Age/Sex: 10-14 Female	1,518
TX_CURR_DSD	Age/Sex: 20-24 Male	872
TX_CURR_DSD	Age/Sex: 25-49 Male	21,102
TX_CURR_DSD	Age/Sex: 50+ Male	7,362
TX_CURR_DSD	Age/Sex: 20-24 Female	4,883
TX_CURR_DSD	Age/Sex: 25-49 Female	46,387
TX_CURR_DSD	Age/Sex: 50+ Female	8,511
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	28,435
TX_NEW_DSD	By Age/Sex: <1	220
TX_NEW_DSD	By Age/Sex: 1-9	482
TX_NEW_DSD	By Age/Sex: 10-14 Male	257
TX_NEW_DSD	By Age/Sex: 15-19 Male	254
TX_NEW_DSD	By Age/Sex: 20-24 Male	258
TX_NEW_DSD	By Age/Sex: 25-49 Male	6,290
TX_NEW_DSD	By Age/Sex: 50+ Male	2,172
TX_NEW_DSD	By Age/Sex: 10-14 Female	208
TX_NEW_DSD	By Age/Sex: 15-19 Female	474
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,454
TX_NEW_DSD	By Age/Sex: 25-49 Female	13,827
TX_NEW_DSD	By Age/Sex: 50+ Female	2,539
TX_NEW_DSD	Sum of Age/Sex disaggregates	27,733
TX_NEW_DSD	Pregnancy status	1,182
TX_NEW_DSD	Breastfeeding status	37

TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	87,614
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	98,081
TX_PVLS_DSD	Numerator: Indication: Routine	81,482
TX_PVLS_DSD	Numerator: Indication: Targeted	6,132
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	1,162
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	39
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	227
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	1,982
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	143
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	3,780
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	2,442
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	25,439
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	2,466
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	51,135
TX_PVLS_DSD	Denominator: Indication: Routine	91,219
TX_PVLS_DSD	Denominator: Indication: Targeted	6,865
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	1,181

TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	35
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	0
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	288
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	2,168
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	213
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	4,192
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	3,033
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	28,268
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	3,102
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	56,813
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0

TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	2
TX_PVLS_DSD	Unknown Age, Targeted, Male	2
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0

TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	27,013
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	28,468
TX_RET_DSD	Numerator by Status: Pregnant	1,204
TX_RET_DSD	Numerator by Status: Breastfeeding	41
TX_RET_DSD	Denominator by Status: Pregnant	1,204
TX_RET_DSD	Denominator by Status: Breastfeeding	42
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	550
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,519
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	547
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17,397
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	642
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,958

TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	627
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	18,241
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	25,437
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	28,255
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	604
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	556
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	18,166
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	8,929
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	28,255
TB_PREV_DSD	By Therapy type (Denominator): Alternative Regimen	0
TB_PREV_DSD	By Therapy type (Denominator): Continuous IPT	0
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	558
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	519
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	16,347
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	8,010
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	25,437
TB_PREV_DSD	By Therapy type (Numerator): Alternative Regimen	0
TB_PREV_DSD	By Therapy type (Numerator): Continuous IPT	0

TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	407
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	93,805
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	15
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	44
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	125
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	223
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	709
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	854
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	7,105
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	10,095
TX_TB_DSD	Denominator: By Screen Result: Negative	75,042
TX_TB_DSD	Denominator: By Screen Result: Positive	18,763
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	18,763
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	931
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	2,857
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	14,974

Implementing Mechanism Details

Mechanism ID: 18204	**Mechanism Name: UON CRISSP Plus**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Nairobi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 4,381,085	**Total Mechanism Pipeline: N/A**

Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 4,381,085	
Funding Source	**Funding Amount**
GHP-State	4,381,085

Cross-Cutting Budget Attribution(s)

Gender: GBV	150,000
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	150,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Key Populations: FSW	150,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Key Populations: MSM and TG	100,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Human Resources for Health	1,347,890

Budget Code Information

Mechanism ID:	18204		
Mechanism Name:	UON CRISSP Plus		
Prime Partner Name:	University of Nairobi		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	262,284	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	529,401	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	561,261	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	2,823,406	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	204,733	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1,401
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	47,751
PMTCT_ART_DSD	New on ART	490

PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	911
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	47,751
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	96
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	24
PMTCT_STAT_DSD	By Age (Denominator): <15-19	5,188
PMTCT_STAT_DSD	By Age (Denominator): 20-24	13,770
PMTCT_STAT_DSD	By Age (Denominator): 25-49	28,673
PMTCT_STAT_DSD	By Age (Denominator): 50+	0
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	8
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	0
PMTCT_STAT_DSD	By Number of known positives: 15-19	490
PMTCT_STAT_DSD	By Number of known positives: 20-24	1,340
PMTCT_STAT_DSD	By Number of known positives: 25-49	2,841
PMTCT_STAT_DSD	By Number of known positives: 50+	0
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	7
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	0
PMTCT_STAT_DSD	By Number of new positives: 15-19	239
PMTCT_STAT_DSD	By Number of new positives: 20-24	669
PMTCT_STAT_DSD	By Number of new positives: 25-49	1,407
PMTCT_STAT_DSD	By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	81
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	0
PMTCT_STAT_DSD	By Number of new negative: 15-19	4,442
PMTCT_STAT_DSD	By Number of new negative: 20-24	11,666
PMTCT_STAT_DSD	By Number of new negative: 25-49	24,561
PMTCT_STAT_DSD	By Number of new negative: 50+	0

PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	96
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	0
PMTCT_STAT_DSD	By Age (Numerator): 15-19	5,171
PMTCT_STAT_DSD	By Age (Numerator): 20-24	13,675
PMTCT_STAT_DSD	By Age (Numerator): 25-49	28,809
PMTCT_STAT_DSD	By Age (Numerator): 50+	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	255,882
HTC_TST_DSD	By Test Result: Positive	4,982
HTC_TST_DSD	Sum of Test Result disaggregates	4,982
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	939
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive	15
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	790
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive	14
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	8,066
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	170
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	4,934
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	82
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Negative	0

HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	9,149
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	171
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	6,817
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	122
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	93,234
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	1,714
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	61,427
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	1,067
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	1,898
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	88
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	101
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	1
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	68

HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Positive	1
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	1,091
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	17
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	705
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	9
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: <15, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: <15, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative	1
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15,	0

	Male, Negative	
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	47
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	26
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: <15, Negative	2,781
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: <15, Positive	67
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative	25,287
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive	558
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15,	1,256

	Female, Negative	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	20
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	904
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	13
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	13,299
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	237
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	8,561
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	149
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Positive	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,888
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,961
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	126
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	981
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number	86

	of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	693
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	132
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,017
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	88
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	723
GEND_GBV_DSD	Number of people receiving post-GBV care	5,324
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	3,264
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	2,058
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	965
GEND_GBV_TA	Number of people receiving post-GBV care	274
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	138
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	136
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	102
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	447
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB	447

	treatment during the reporting period	
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	36
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	217
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	26
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	168
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	36
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	217
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	26
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	168
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,401

PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	0
PMTCT_EID_DSD	Unknown, <= 2 months	164
PMTCT_EID_DSD	Unknown, 2 - 12 months	35
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	808
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	25
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	369
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	27,539
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	703
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	10,329
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,008
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	15,499
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,711
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	25,828
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	27,539
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,905
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	307
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,136
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	455
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,748
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	3,646
TX_NEW_DSD	Pregnancy status	37
TX_NEW_DSD	Breastfeeding status	196
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	23,396
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral	26,167

	load result documented in the patient medical record and /or laboratory records in the past 12 months.	
TX_PVLS_DSD	Numerator: Indication: Routine	18,965
TX_PVLS_DSD	Numerator: Indication: Targeted	3,316
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	197
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	975
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	34
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	187
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	320
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	996
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	648
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1,353
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	1,913
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	5,824
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	3,605
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	7,622
TX_PVLS_DSD	Denominator: Indication: Routine	21,020
TX_PVLS_DSD	Denominator: Indication: Targeted	3,912
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	219
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	1,100
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	42
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Targeted	204

TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	382
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	1,201
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	736
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1,593
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	2,183
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	6,417
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	4,100
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	8,319
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	233
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	111
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	502
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	387
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0

TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	64
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	12
TX_PVLS_DSD	Undocumented Test Indication	1,232
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	212
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	111
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	454
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	337
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	1
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	63
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	10
TX_PVLS_DSD	Undocumented Test Indication	1,115
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,719
TX_RET_DSD	Total number of adults and children who initiated ART in	3,731

	the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	
TX_RET_DSD	Numerator by Status: Pregnant	33
TX_RET_DSD	Numerator by Status: Breastfeeding	184
TX_RET_DSD	Denominator by Status: Pregnant	33
TX_RET_DSD	Denominator by Status: Breastfeeding	184
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	301
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,192
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	431
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,795
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	302
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,199
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	431
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total	1,799

	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	172
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	172
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	6
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	8
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	62
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	96
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	6
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	8
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	63
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	95
TX_TB_DSD	Denominator: By Screen Result: Negative	99
TX_TB_DSD	Denominator: By Screen Result: Positive	72
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	166
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	22
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	82
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	68

Implementing Mechanism Details

Mechanism ID: 18205	**Mechanism Name: UMB PACT Kamili**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland Baltimore	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No

Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 7,083,122	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 7,083,122	
Funding Source	**Funding Amount**
GHP-State	7,083,122

Cross-Cutting Budget Attribution(s)

Gender: GBV	17,500
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	140,000

Budget Code Information

Mechanism ID:	**18205**		
Mechanism Name:	**UMB PACT Kamili**		
Prime Partner Name:	**University of Maryland Baltimore**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	280,672	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	579,878	0

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	2,282,868	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	IDUP	420,913	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	405,383	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	3,021,348	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	92,060	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1,634
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	28,607
PMTCT_ART_DSD	New on ART	710
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	924
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	28,607
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	34

PMTCT_STAT_DSD	By Age (Denominator): <15-19	2,878
PMTCT_STAT_DSD	By Age (Denominator): 20-24	10,887
PMTCT_STAT_DSD	By Age (Denominator): 25-49	14,808
PMTCT_STAT_DSD	By Age (Denominator): 50+	0
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	0
PMTCT_STAT_DSD	By Number of known positives: 15-19	25
PMTCT_STAT_DSD	By Number of known positives: 20-24	165
PMTCT_STAT_DSD	By Number of known positives: 25-49	786
PMTCT_STAT_DSD	By Number of known positives: 50+	0
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	0
PMTCT_STAT_DSD	By Number of new positives: 15-19	40
PMTCT_STAT_DSD	By Number of new positives: 20-24	237
PMTCT_STAT_DSD	By Number of new positives: 25-49	381
PMTCT_STAT_DSD	By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	0
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	34
PMTCT_STAT_DSD	By Number of new negative: 15-19	2,812
PMTCT_STAT_DSD	By Number of new negative: 20-24	10,485
PMTCT_STAT_DSD	By Number of new negative: 25-49	13,642
PMTCT_STAT_DSD	By Number of new negative: 50+	0
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	34
PMTCT_STAT_DSD	By Age (Numerator): 15-19	2,878
PMTCT_STAT_DSD	By Age (Numerator): 20-24	10,887
PMTCT_STAT_DSD	By Age (Numerator): 25-49	14,808
PMTCT_STAT_DSD	By Age (Numerator): 50+	0

KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	2,301
KP_MAT_DSD	Sex: Male	2,018
KP_MAT_DSD	Sex: Female	283
KP_MAT_DSD	Sum of Sex disaggregates	2,301
KP_MAT_DSD	Unknown Sex	0
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	28,411
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,155
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	21,526
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,228
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	502

HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	247,272
HTC_TST_DSD	By Test Result: Positive	8,480
HTC_TST_DSD	Sum of Test Result disaggregates	8,480
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	60
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	97
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	263
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	438
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	55
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male,	1,382

	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	88
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	147
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	311
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	478
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	11,519
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	234
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	5,802
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	41,274
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24,	925

	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	12,507
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	239
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	78,364
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	3,072
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	38,129
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	1,435
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	2,360
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	118
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	2,807
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	164
HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	1,389
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	44
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	3,720
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male,	5

	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	29
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	33
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	52
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	65
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	162
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	48
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	225
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	49
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	28
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age,	0

	Female, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	37
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	182
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	284
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	101
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	84
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	34
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	47
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female,	19

	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	119
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	56
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	803
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	29
HTC_TST_DSD	By Key Population: FSW, Negative	20,237
HTC_TST_DSD	By Key Population: FSW, Positive	701
HTC_TST_DSD	By Key Population: MSM, Negative	703
HTC_TST_DSD	By Key Population: MSM, Positive	161
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	0
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	0
HTC_TST_DSD	By Key Population: PWID, Negative	2,995
HTC_TST_DSD	By Key Population: PWID, Positive	213
HTC_TST_DSD	By Key Population: TG, Negative	0
HTC_TST_DSD	By Key Population: TG, Positive	0

HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	34
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	2,812
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	65
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	10,485
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	402
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	13,642
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	1,167
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	227
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	254
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	438
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	242
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female,	1,395

	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	685
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	2,219
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	129
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	2,279
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	55
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	83
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	478
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,497
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,541
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	106
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of	1,354

	registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	56
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	981
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	110
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,373
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	56
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,002
GEND_GBV_DSD	Number of people receiving post-GBV care	25,080
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	17,218
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	7,862
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	7,625
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	687
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	315
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	170
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	79
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	1,378
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	628
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	346
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	158

GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	5,510
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	2,514
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	1,377
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	630
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	5,511
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	2,514
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	1,379
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	630
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	690
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	311
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	170
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	83
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	775
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	775
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	36
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	417
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	18
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	304

TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	36
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	417
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	18
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	304
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,634
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	17
PMTCT_EID_DSD	Unknown, <= 2 months	0
PMTCT_EID_DSD	Unknown, 2 - 12 months	0
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	1,520
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	15
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	82
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	25,844
TX_CURR_DSD	Age/Sex: 15-19 Male	101
TX_CURR_DSD	Age/Sex: 15-19 Female	378
TX_CURR_DSD	Sum of age/sex disaggregates	479
TX_CURR_DSD	Age/Sex: <1	56

TX_CURR_DSD	Age/Sex: <1-9	537
TX_CURR_DSD	Age/Sex: 10-14 Male	92
TX_CURR_DSD	Age/Sex: 10-14 Female	103
TX_CURR_DSD	Age/Sex: 20-24 Male	279
TX_CURR_DSD	Age/Sex: 25-49 Male	5,324
TX_CURR_DSD	Age/Sex: 50+ Male	1,217
TX_CURR_DSD	Age/Sex: 20-24 Female	1,942
TX_CURR_DSD	Age/Sex: 25-49 Female	14,437
TX_CURR_DSD	Age/Sex: 50+ Female	1,378
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,848
TX_NEW_DSD	By Age/Sex: <1	18
TX_NEW_DSD	By Age/Sex: 1-9	41
TX_NEW_DSD	By Age/Sex: 10-14 Male	16
TX_NEW_DSD	By Age/Sex: 15-19 Male	48
TX_NEW_DSD	By Age/Sex: 20-24 Male	140
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,269
TX_NEW_DSD	By Age/Sex: 50+ Male	84
TX_NEW_DSD	By Age/Sex: 10-14 Female	10
TX_NEW_DSD	By Age/Sex: 15-19 Female	132
TX_NEW_DSD	By Age/Sex: 20-24 Female	823
TX_NEW_DSD	By Age/Sex: 25-49 Female	3,079
TX_NEW_DSD	By Age/Sex: 50+ Female	188
TX_NEW_DSD	Sum of Age/Sex disaggregates	5,789
TX_NEW_DSD	Pregnancy status	50
TX_NEW_DSD	Breastfeeding status	4
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	23,035
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	25,788

TX_PVLS_DSD	Numerator: Indication: Routine	21,353
TX_PVLS_DSD	Numerator: Indication: Targeted	1,682
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	86
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	1,626
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	5
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	85
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	22
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	455
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	19
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1,186
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	269
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	5,744
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	277
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	15,063
TX_PVLS_DSD	Denominator: Indication: Routine	23,913
TX_PVLS_DSD	Denominator: Indication: Targeted	1,875
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	95
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	1,805
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	5
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Targeted	95
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	26

TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	503
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	25
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1,321
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	338
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	6,415
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	345
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	16,815
TX_PVLS_DSD	Undocumented Test Indication	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	5,763
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	5,848
TX_RET_DSD	Numerator by Status: Pregnant	50
TX_RET_DSD	Numerator by Status: Breastfeeding	4
TX_RET_DSD	Denominator by Status: Pregnant	50
TX_RET_DSD	Denominator by Status: Breastfeeding	4
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	44
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,494
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	37

TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,188
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	44
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,516
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	41
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,247
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	5,263
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	5,848
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	41
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	44

TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	4,248
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	1,515
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	5,848
TB_PREV_DSD	By Therapy type (Denominator): Continuous IPT	0
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	40
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	40
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	3,817
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,366
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	5,263
TB_PREV_DSD	By Therapy type (Numerator): Alternative Regimen	0
TB_PREV_DSD	By Therapy type (Numerator): Continuous IPT	0
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	310
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	25,844
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	63
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	63
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	132
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	52
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	401
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	389
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	18,136
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	6,918
TX_TB_DSD	Denominator: By Screen Result: Negative	20,676
TX_TB_DSD	Denominator: By Screen Result: Positive	5,168
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	5,168
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	257
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	772
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of	4,139

	Specimen Sent]: Gene Xpert MTB / R if Assay	

Implementing Mechanism Details

Mechanism ID: 18206	**Mechanism Name: KCCB KARP**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Kenya Conference of Catholic Bishops	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 11,141,713	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 11,141,713	
Funding Source	**Funding Amount**
GHP-State	11,141,713

Cross-Cutting Budget Attribution(s)

Gender: GBV	240,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	240,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	8,388,346

Budget Code Information

Mechanism ID:	18206		
Mechanism Name:	KCCB KARP		
Prime Partner Name:	Kenya Conference of Catholic Bishops		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	759,718	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	1,107,462	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	357,489	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	8,178,144	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	738,900	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18207	**Mechanism Name: Columbia STARS**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	

G2G: No	Managing Agency:

Total All Funding Sources: 3,242,218	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,242,218	
Funding Source	**Funding Amount**
GHP-State	3,242,218

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	2,873
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: GBV	2,873
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Education	95,705
Human Resources for Health	1,630,033

Budget Code Information

Mechanism ID:	**18207**		
Mechanism Name:	**Columbia STARS**		
Prime Partner Name:	**Columbia University**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**

Care	HVTB	202,545	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	CIRC	146,568	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	132,216	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	IDUP	101,393	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	59,733	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	2,180,336	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	419,427	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	411
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	2,462
PMTCT_ART_DSD	New on ART	145
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	266
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received	2,462

	their results)	
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	0
PMTCT_STAT_DSD	By Age (Denominator): <15-19	70
PMTCT_STAT_DSD	By Age (Denominator): 20-24	531
PMTCT_STAT_DSD	By Age (Denominator): 25-49	1,861
PMTCT_STAT_DSD	By Age (Denominator): 50+	0
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	0
PMTCT_STAT_DSD	By Number of known positives: 15-19	5
PMTCT_STAT_DSD	By Number of known positives: 20-24	59
PMTCT_STAT_DSD	By Number of known positives: 25-49	215
PMTCT_STAT_DSD	By Number of known positives: 50+	0
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	0
PMTCT_STAT_DSD	By Number of new positives: 15-19	25
PMTCT_STAT_DSD	By Number of new positives: 20-24	42
PMTCT_STAT_DSD	By Number of new positives: 25-49	86
PMTCT_STAT_DSD	By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	0
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	0
PMTCT_STAT_DSD	By Number of new negative: 15-19	39
PMTCT_STAT_DSD	By Number of new negative: 20-24	429
PMTCT_STAT_DSD	By Number of new negative: 25-49	1,562
PMTCT_STAT_DSD	By Number of new negative: 50+	0
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	0

PMTCT_STAT_DSD	By Age (Numerator): 15-19	70
PMTCT_STAT_DSD	By Age (Numerator): 20-24	531
PMTCT_STAT_DSD	By Age (Numerator): 25-49	1,861
PMTCT_STAT_DSD	By Age (Numerator): 50+	0
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	423
KP_MAT_DSD	Sex: Male	338
KP_MAT_DSD	Sex: Female	85
KP_MAT_DSD	Sum of Sex disaggregates	423
KP_MAT_DSD	Unknown Sex	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	2,500
VMMC_CIRC_DSD	By Age: 0-60 days	500
VMMC_CIRC_DSD	By Age: 2 months - 9 years	0
VMMC_CIRC_DSD	By Age: 10-14	1,000
VMMC_CIRC_DSD	By Age: 15-19	250
VMMC_CIRC_DSD	By Age: 20-24	250
VMMC_CIRC_DSD	By Age: 25-29	500
VMMC_CIRC_DSD	By Age: 30-49	0
VMMC_CIRC_DSD	By Age: 50+	0
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	1,500
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	2,000
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	2,346
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	154
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	0
PrEP_NEW_DSD	Male 15-19	0
PrEP_NEW_DSD	Male 20-24	0
PrEP_NEW_DSD	Male 25-49	0
PrEP_NEW_DSD	Male 50+	0

PrEP_NEW_DSD	Female 15-19	0
PrEP_NEW_DSD	Female 20-24	0
PrEP_NEW_DSD	Female 25-49	0
PrEP_NEW_DSD	Female 50+	0
PrEP_NEW_DSD	FSW	0
PrEP_NEW_DSD	MSM	0
PrEP_NEW_DSD	TG	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	43,914
HTC_TST_DSD	By Test Result: Positive	1,842
HTC_TST_DSD	Sum of Test Result disaggregates	1,842
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	188
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	304
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	570
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	254
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	1,556
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	60
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	596

HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	2,785
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	192
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	2,740
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	145
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	472
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	410
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	415
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	710
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	25

HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	909
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,293
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	40
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	576
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	3,530
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	105
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	1,866
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	6,328
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	340
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	6,235
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	233
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	687
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	545

HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	297
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	0

HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	26
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	46
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	45
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	1

HTC_TST_DSD	Service Delivery Point (Facility) VMMC: <1, Negative	495
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: <1, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	991
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	248
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	248
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Negative	496
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	16
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male,	0

	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	44
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	17
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	79
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	78
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	0

HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	1
HTC_TST_DSD	By Key Population: FSW, Negative	0
HTC_TST_DSD	By Key Population: FSW, Positive	0
HTC_TST_DSD	By Key Population: MSM, Negative	0
HTC_TST_DSD	By Key Population: MSM, Positive	0
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	0
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	0
HTC_TST_DSD	By Key Population: PWID, Negative	0
HTC_TST_DSD	By Key Population: PWID, Positive	0
HTC_TST_DSD	By Key Population: TG, Negative	0
HTC_TST_DSD	By Key Population: TG, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	287
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	988
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	38
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	1,029
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	108
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age,	0

	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	65
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	105
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	197
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	88
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	537
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	205
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	961
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	66
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	945
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male,	50

	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	163
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	141
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT:	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	143
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	11
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	141
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	144
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	45
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	7
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with	86

	documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	46
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	7
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	88
GEND_GBV_DSD	Number of people receiving post-GBV care	2,956
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	2,152
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	804
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	322
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	492
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	184
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	24
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	9
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	397
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	148
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	56
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	21
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	484
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	181
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	24
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	9
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	326
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	122

GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	64
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	24
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	268
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	101
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	16
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	6
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	76
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	76
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	24
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	4

	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	46
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	2
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	24
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	4
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	46
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	411
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	7
PMTCT_EID_DSD	Unknown, <= 2 months	0
PMTCT_EID_DSD	Unknown, 2 - 12 months	0
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	358
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	6
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	40
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	8,301

TX_CURR_DSD	Age/Sex: 15-19 Male	113
TX_CURR_DSD	Age/Sex: 15-19 Female	153
TX_CURR_DSD	Sum of age/sex disaggregates	266
TX_CURR_DSD	Age/Sex: <1	11
TX_CURR_DSD	Age/Sex: <1-9	331
TX_CURR_DSD	Age/Sex: 10-14 Male	116
TX_CURR_DSD	Age/Sex: 10-14 Female	103
TX_CURR_DSD	Age/Sex: 20-24 Male	71
TX_CURR_DSD	Age/Sex: 25-49 Male	1,725
TX_CURR_DSD	Age/Sex: 50+ Male	736
TX_CURR_DSD	Age/Sex: 20-24 Female	310
TX_CURR_DSD	Age/Sex: 25-49 Female	3,900
TX_CURR_DSD	Age/Sex: 50+ Female	732
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,953
TX_NEW_DSD	By Age/Sex: <1	1
TX_NEW_DSD	By Age/Sex: 1-9	31
TX_NEW_DSD	By Age/Sex: 10-14 Male	16
TX_NEW_DSD	By Age/Sex: 15-19 Male	64
TX_NEW_DSD	By Age/Sex: 20-24 Male	127
TX_NEW_DSD	By Age/Sex: 25-49 Male	191
TX_NEW_DSD	By Age/Sex: 50+ Male	255
TX_NEW_DSD	By Age/Sex: 10-14 Female	31
TX_NEW_DSD	By Age/Sex: 15-19 Female	124
TX_NEW_DSD	By Age/Sex: 20-24 Female	247
TX_NEW_DSD	By Age/Sex: 25-49 Female	371
TX_NEW_DSD	By Age/Sex: 50+ Female	495
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,921
TX_NEW_DSD	Pregnancy status	118
TX_NEW_DSD	Breastfeeding status	13
TX_NEW_DSD	FSW	0
TX_NEW_DSD	MSM	0

TX_NEW_DSD	People in prisons and other enclosed settings	0
TX_NEW_DSD	TG	0
TX_NEW_DSD	By Key populations: People who inject drugs (PWID)	0
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	7,406
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	8,290
TX_PVLS_DSD	Numerator: Indication: Routine	6,887
TX_PVLS_DSD	Numerator: Indication: Targeted	519
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	21
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	28
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	2
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	2
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	229
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	31
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	259
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	186
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	2,091
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	224
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	4,386

TX_PVLS_DSD	Denominator: Indication: Routine	7,710
TX_PVLS_DSD	Denominator: Indication: Targeted	580
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	23
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	31
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	2
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Targeted	2
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	254
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	39
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	287
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	233
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	2,323
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	280
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	4,874
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0

TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0

TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,855
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,024
TX_RET_DSD	Numerator by Status: Pregnant	6
TX_RET_DSD	Numerator by Status: Breastfeeding	4
TX_RET_DSD	Denominator by Status: Pregnant	9
TX_RET_DSD	Denominator by Status: Breastfeeding	6
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	26
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	605
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	50
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,174
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	178
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the	0

	12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	346
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,500
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,758
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	1,953
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	53
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	26
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	1,237
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	637
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	1,953
TB_PREV_DSD	By Therapy type (Denominator): Alternative Regimen	0
TB_PREV_DSD	By Therapy type (Denominator): Continuous IPT	0
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	47
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	24
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	1,113
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	574

TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	1,758
TB_PREV_DSD	By Therapy type (Numerator): Alternative Regimen	0
TB_PREV_DSD	By Therapy type (Numerator): Continuous IPT	0
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	31
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	8,301
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	1
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	1
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	19
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	10
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	78
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	39
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	1,018
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	525
TX_TB_DSD	Denominator: By Screen Result: Negative	6,641
TX_TB_DSD	Denominator: By Screen Result: Positive	1,660
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	1,660
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	83
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	1,328
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	249

Implementing Mechanism Details

Mechanism ID: 18208	**Mechanism Name: IRDO Tuungane 3**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Impact Research and Development Organization	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No

Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 10,783,836	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 10,783,836	
Funding Source	**Funding Amount**
GHP-State	10,783,836

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	230,050
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: FSW	730,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Gender: GBV	320,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	100,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Education	130,000
Human Resources for Health	420,000

Condom programming	105,000
Renovation	27,000
Economic Strengthening	250,000

Budget Code Information

Mechanism ID:	**18208**		
Mechanism Name:	**IRDO Tuungane 3**		
Prime Partner Name:	**Impact Research and Development Organization**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	1,165,101	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	CIRC	731,223	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	3,135,680	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	5,751,832	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	13,402
VMMC_CIRC_DSD	By Age: 10-14	5,362
VMMC_CIRC_DSD	By Age: 15-19	1,340
VMMC_CIRC_DSD	By Age: 20-24	1,340

VMMC_CIRC_DSD	By Age: 25-29	2,680
VMMC_CIRC_DSD	By Age: 30-49	2,546
VMMC_CIRC_DSD	By Age: 50+	134
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	8,176
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	13,402
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	12,402
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	1,000
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	1,012
PrEP_NEW_DSD	Female 15-19	336
PrEP_NEW_DSD	Female 20-24	676
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	69,516
PP_PREV_DSD	Age/sex: 10-14 Male	1,924
PP_PREV_DSD	Age/sex: 15-19 Male	8,482
PP_PREV_DSD	Age/sex: 20-24 Male	6,581
PP_PREV_DSD	Age/sex: 25-49 Male	14,905
PP_PREV_DSD	Age/sex: 50+ Male	2,443
PP_PREV_DSD	Age/sex: 10-14 Female	1,721
PP_PREV_DSD	Age/sex: 15-19 Female	9,593
PP_PREV_DSD	Age/sex: 20-24 Female	8,476
PP_PREV_DSD	Age/sex: 25-49 Female	11,729
PP_PREV_DSD	Age/sex: 50+ Female	3,662
PP_PREV_DSD	Sum of Age/Sex disaggregates	69,516
PP_PREV_TA	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	40,741
PP_PREV_TA	Age/sex: 15-19 Female	24,034
PP_PREV_TA	Age/sex: 20-24 Female	16,707
PP_PREV_TA	Sum of Age/Sex disaggregates	40,741
KP_PREV_DSD	Number of key populations reached with individual	3,926

	and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	628
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,150
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	136
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	12
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	317,760
HTC_TST_DSD	By Test Result: Positive	5,880
HTC_TST_DSD	Sum of Test Result disaggregates	5,880
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative	4,822
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive	70
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Male, Negative	4,655
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing:	67

	10-14, Male, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Negative	27,673
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Positive	458
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Male, Negative	26,109
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Male, Positive	259
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Negative	14,029
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Positive	399
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Male, Negative	9,581
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Male, Positive	165
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Female, Negative	28,371
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Female, Positive	828
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Male, Negative	21,105
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Male, Positive	532
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 50+, Female, Negative	17,624
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 50+, Female, Positive	306
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 50+, Male, Negative	10,442
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 50+, Male, Positive	250
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing:	11,863

	1-9, Negative	
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 1-9, Positive	233
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	1,721
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	1,910
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	9,500
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	93
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	8,461
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	21
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	8,258
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	218
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	6,531
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	50
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	11,454
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	275
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	14,481
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing:	424

	25-49, Male, Positive	
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	3,623
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	39
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	2,391
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	52
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,817
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	45
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	1,443
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	2,209
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	178
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	2,256
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	3,495
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	228
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49,	1,329

	Male, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	37
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	637
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	479
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	23,919
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	113
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	16,353
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	356
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	5,336
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	26
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	1,325
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	1,325
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Negative	5,187
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	125
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	9
HTC_TST_DSD	By Key Population: FSW, Negative	2,739
HTC_TST_DSD	By Key Population: FSW, Positive	411
HTC_TST_DSD	By Key Population: MSM, Negative	601
HTC_TST_DSD	By Key Population: MSM, Positive	27

HTC_TST_DSD	By Key Population: PWID, Negative	144
HTC_TST_DSD	By Key Population: PWID, Positive	26
GEND_GBV_DSD	Number of people receiving post-GBV care	13,473
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	11,045
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	2,428
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	2,363
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	1,462
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	133
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	173
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	36
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	3,301
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	1,063
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	209
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	44
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	3,079
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	533
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	209
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	44
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	2,240
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	496
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	76
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	17
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	266
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	61
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	31
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	0
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	22,239
OVC_SERV_DSD	Age/Sex: 15-17 Female	22,239
OVC_SERV_DSD	Sum of Age/Sex disaggregates	22,239

OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	13,832
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	2,519
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17	11,480
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24	69
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	4,328
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	3,936
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	22,958
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	16,663
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	24,020
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	16,721
OVC_SERV_DSD	Program Completion: Active	22,239
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	33
TX_CURR_DSD	Age/Sex: 15-19 Female	5
TX_CURR_DSD	Sum of age/sex disaggregates	5
TX_CURR_DSD	Age/Sex: 20-24 Male	2
TX_CURR_DSD	Age/Sex: 25-49 Male	2
TX_CURR_DSD	Age/Sex: 20-24 Female	9
TX_CURR_DSD	Age/Sex: 25-49 Female	13
TX_CURR_DSD	Age/Sex: 50+ Female	2
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	35
TX_NEW_DSD	By Age/Sex: 20-24 Male	2

TX_NEW_DSD	By Age/Sex: 25-49 Male	2
TX_NEW_DSD	By Age/Sex: 15-19 Female	6
TX_NEW_DSD	By Age/Sex: 20-24 Female	10
TX_NEW_DSD	By Age/Sex: 25-49 Female	13
TX_NEW_DSD	By Age/Sex: 50+ Female	2
TX_NEW_DSD	Sum of Age/Sex disaggregates	35
TX_NEW_DSD	FSW	31
TX_NEW_DSD	MSM	2
TX_NEW_DSD	By Key populations: People who inject drugs (PWID)	2

Implementing Mechanism Details

Mechanism ID: 18209	**Mechanism Name: LVCT Daraja**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Liverpool VCT and Care	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 5,626,931	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 5,626,931	
Funding Source	**Funding Amount**
GHP-State	5,626,931

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	25,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance

Key Populations: FSW	25,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	50,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	1,250,000

Budget Code Information

Mechanism ID:	**18209**		
Mechanism Name:	**LVCT Daraja**		
Prime Partner Name:	**Liverpool VCT and Care**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	702,340	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	PDCS	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	224,128	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**

Prevention	HVOP	4,548,014	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	IDUP	152,449	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	0
PMTCT_ART_DSD	New on ART	0
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	0
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	636
KP_MAT_DSD	Sex: Male	445
KP_MAT_DSD	Sex: Female	191
KP_MAT_DSD	Sum of Sex disaggregates	636
KP_MAT_DSD	Unknown Sex	0
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	437
PrEP_NEW_DSD	Female 15-19	111
PrEP_NEW_DSD	Female 20-24	291
PrEP_NEW_DSD	Female 25-49	35
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	64,130
PP_PREV_DSD	Age/sex: 10-14 Male	6,313

PP_PREV_DSD	Age/sex: 15-19 Male	6,313
PP_PREV_DSD	Age/sex: 20-24 Male	6,313
PP_PREV_DSD	Age/sex: 25-49 Male	6,313
PP_PREV_DSD	Age/sex: 50+ Male	0
PP_PREV_DSD	Age/sex: 10-14 Female	8,146
PP_PREV_DSD	Age/sex: 15-19 Female	12,647
PP_PREV_DSD	Age/sex: 20-24 Female	13,872
PP_PREV_DSD	Age/sex: 25-49 Female	4,213
PP_PREV_DSD	Age/sex: 50+ Female	0
PP_PREV_DSD	Sum of Age/Sex disaggregates	64,130
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	14,571
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	340
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	3,558
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	10

KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	9,947
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	501
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	215
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	33,136
HTC_TST_DSD	By Test Result: Positive	1,094
HTC_TST_DSD	Sum of Test Result disaggregates	1,094
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	56
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	56
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	708

HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	62
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	532
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	46
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	1,457
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	133
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	857
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	80
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	1,117
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	110
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	816
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	78
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	29
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	29
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: Unknown Age, Female, Positive	0

HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: <1, Negative	29
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	31
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	48
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	33
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	214
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	52
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	221

HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	56
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	508
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	130
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	472
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	117
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	20
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	4
HTC_TST_DSD	By Key Population: FSW, Negative	4,534
HTC_TST_DSD	By Key Population: FSW, Positive	111
HTC_TST_DSD	By Key Population: MSM, Negative	2,346
HTC_TST_DSD	By Key Population: MSM, Positive	74

HTC_TST_DSD	By Key Population: PWID, Negative	63
HTC_TST_DSD	By Key Population: PWID, Positive	2
HTC_TST_DSD	By Key Population: TG, Negative	8
HTC_TST_DSD	By Key Population: TG, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Negative	15
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Negative	24
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Negative	30
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 20-24, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Negative	54
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Female, Positive	18
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Negative	54

HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 25-49, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 50+, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) Index Mod: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	264
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	264
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	0

HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	3,125
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	2,346
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	6,183
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	77
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	3,638
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	85
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	4,510
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	190
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	3,230
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	177
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	98
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	94
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age,	0

	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) VCT:	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	101
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	118
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Negative	18
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Negative	13
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Negative	36
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Negative	21
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 20-24, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 25-49, Female, Negative	27

HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 25-49, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 25-49, Male, Negative	20
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 25-49, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: <1, Negative	1
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Negative	2
HTC_TST_DSD	Service Delivery Point (Community) VCT Mod: 1-9, Positive	0
GEND_GBV_DSD	Number of people receiving post-GBV care	15,786
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	11,843
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	3,943

GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1,578
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	1,698
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	321
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	1,416
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	624
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	68
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	31
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	3,448
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	1,585
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	344
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	126
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	4,545
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	1,091
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	219
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	105
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	89
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	52
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	16
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	8
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	0

GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	13,406
OVC_SERV_DSD	Age/Sex: 10-14 Female	2,893
OVC_SERV_DSD	Age/Sex: 15-17 Female	4,765
OVC_SERV_DSD	By: Age/sex: 18-24 Female	4,905
OVC_SERV_DSD	By: Age/sex: 25+ Female	843
OVC_SERV_DSD	Sum of Age/Sex disaggregates	7,658
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	401
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	2,927
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	1,126
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+	53
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	3,003
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14	0
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	532
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	1,513
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 25+	127
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14	49
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	592
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	2,193
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+	172

OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	3,216
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	5,334
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	5,632
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 25+	843
OVC_SERV_DSD	Age/Sex: <1	0
OVC_SERV_DSD	Age/Sex: 1-9	0
OVC_SERV_DSD	Program Completion: Active	13,060
OVC_SERV_DSD	Program Completion: Graduation	0
OVC_SERV_DSD	Program Completion: Transferred	135
OVC_SERV_DSD	Program Completion: Exited without graduation	211
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	5,044
TX_CURR_DSD	Age/Sex: 15-19 Male	160
TX_CURR_DSD	Age/Sex: 15-19 Female	254
TX_CURR_DSD	Sum of age/sex disaggregates	414
TX_CURR_DSD	Age/Sex: <1	0
TX_CURR_DSD	Age/Sex: <1-9	26
TX_CURR_DSD	Age/Sex: 10-14 Male	30
TX_CURR_DSD	Age/Sex: 10-14 Female	42
TX_CURR_DSD	Age/Sex: 20-24 Male	366
TX_CURR_DSD	Age/Sex: 25-49 Male	1,333
TX_CURR_DSD	Age/Sex: 50+ Male	211
TX_CURR_DSD	Age/Sex: 20-24 Female	510
TX_CURR_DSD	Age/Sex: 25-49 Female	2,004
TX_CURR_DSD	Age/Sex: 50+ Female	108
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,140
TX_NEW_DSD	By Age/Sex: <1	0
TX_NEW_DSD	By Age/Sex: 1-9	0

TX_NEW_DSD	By Age/Sex: 10-14 Male	11
TX_NEW_DSD	By Age/Sex: 15-19 Male	43
TX_NEW_DSD	By Age/Sex: 20-24 Male	110
TX_NEW_DSD	By Age/Sex: 25-49 Male	138
TX_NEW_DSD	By Age/Sex: 50+ Male	26
TX_NEW_DSD	By Age/Sex: 10-14 Female	19
TX_NEW_DSD	By Age/Sex: 15-19 Female	92
TX_NEW_DSD	By Age/Sex: 20-24 Female	283
TX_NEW_DSD	By Age/Sex: 25-49 Female	375
TX_NEW_DSD	By Age/Sex: 50+ Female	43
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,140
TX_NEW_DSD	Pregnancy status	0
TX_NEW_DSD	Breastfeeding status	0
TX_NEW_DSD	FSW	230
TX_NEW_DSD	MSM	83
TX_NEW_DSD	People in prisons and other enclosed settings	0
TX_NEW_DSD	TG	0
TX_NEW_DSD	By Key populations: People who inject drugs (PWID)	55
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	4,539
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	5,044
TX_PVLS_DSD	Numerator: Indication: Routine	4,221
TX_PVLS_DSD	Numerator: Indication: Targeted	318
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	0

TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	2
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	132
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	4
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	180
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	25
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,731
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	57
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	2,408
TX_PVLS_DSD	Denominator: Indication: Routine	4,691
TX_PVLS_DSD	Denominator: Indication: Targeted	353
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	0
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	0
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	0
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	2
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	146
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	5
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	200
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	28

TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,923
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	62
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	2,678
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0

TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,083
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,140
TX_RET_DSD	Numerator by Status: Pregnant	0
TX_RET_DSD	Numerator by Status: Breastfeeding	0
TX_RET_DSD	Denominator by Status: Pregnant	0
TX_RET_DSD	Denominator by Status: Breastfeeding	0
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	11

TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	301
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	19
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	752
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	11
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	317
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	793
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,026
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period	1,140

	and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	19
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	11
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	793
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	317
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	1,140
TB_PREV_DSD	By Therapy type (Denominator): Alternative Regimen	0
TB_PREV_DSD	By Therapy type (Denominator): Continuous IPT	0
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	10
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	7
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	711
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	298
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	1,026
TB_PREV_DSD	By Therapy type (Numerator): Alternative Regimen	0
TB_PREV_DSD	By Therapy type (Numerator): Continuous IPT	0

Implementing Mechanism Details

Mechanism ID: 18213	**Mechanism Name: Partnership with MOH on HIV/AIDS and TB Programs**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health (MOH)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 4,516,289	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 4,516,289	
Funding Source	**Funding Amount**

GHP-State	4,516,289

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	50,000
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Capacity building
Key Populations: MSM and TG	100,000
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Collection and use of strategic information
Focus Area:	Monitoring and evaluation of MSM/TG programs
Key Populations: FSW	120,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Collection and use of strategic information on SWs and clients
Focus Area:	Monitoring and evaluation of SW programs
Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	50,000
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Human Resources for Health	1,200,000

Budget Code Information

Mechanism ID:	**18213**		
Mechanism Name:	**Partnership with MOH on HIV/AIDS and TB Programs**		
Prime Partner Name:	**Ministry of Health (MOH)**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	470,588	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HLAB	99,000	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HVSI	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	OHSS	320,000	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HMIN	50,000	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	300,000	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	582,353	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	IDUP	300,000	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	1,514,706	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**

Treatment	HTXS	414,936	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	464,706	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_TA	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	101
PMTCT_ART_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,140
PMTCT_ART_TA	New on ART	34
PMTCT_ART_TA	Already on ART at beginning of current pregnancy	67
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	1,140
PMTCT_STAT_TA	By Age (Denominator): 10-14	5
PMTCT_STAT_TA	By Age (Denominator): 15-19	123
PMTCT_STAT_TA	By Age (Denominator): 20-24	377
PMTCT_STAT_TA	By Age (Denominator): 25-49	635
PMTCT_STAT_TA	By known positives: 10-14	0
PMTCT_STAT_TA	By known positives: 15-19	42
PMTCT_STAT_TA	By known positives: 20-24	17
PMTCT_STAT_TA	By known positives: 25-49	40
PMTCT_STAT_TA	By new positives: 10-14	0
PMTCT_STAT_TA	By new positives: 15-19	1
PMTCT_STAT_TA	By new positives: 20-24	2
PMTCT_STAT_TA	By new positives: 25-49	7

PMTCT_STAT_TA	By new negatives: 10-14	5
PMTCT_STAT_TA	By new negatives: 15-19	87
PMTCT_STAT_TA	By new negatives: 20-24	358
PMTCT_STAT_TA	By new negatives: 25-49	580
PMTCT_STAT_TA	By Age (Numerator): 10-14	5
PMTCT_STAT_TA	By Age (Numerator): : 15-19	123
PMTCT_STAT_TA	By Age (Numerator): 20-24	377
PMTCT_STAT_TA	By Age (Numerator): 25-49	635
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	11,942
HTC_TST_TA	By Test Result: Positive	518
HTC_TST_TA	Sum of Test Result disaggregates	518
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Negative	213
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Female, Positive	8
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Negative	204
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: <15, Male, Positive	32
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Negative	5,654
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Female, Positive	244
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Negative	3,912
HTC_TST_TA	Service Delivery Point Agg Age (Facility) Other PITC: 15+, Male, Positive	535
HTC_TST_TA	Service Delivery Point Agg Age (Facility) ANC: <15, Negative	6
HTC_TST_TA	Service Delivery Point Agg Age (Facility) ANC: <15, Positive	0

HTC_TST_TA	Service Delivery Point Agg Age (Facility) ANC: 15+, Negative	1,026
HTC_TST_TA	Service Delivery Point Agg Age (Facility) ANC: 15+, Positive	108
TB_STAT_TA	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,015
TB_STAT_TA	Total number of registered new and relapsed TB cases, during the reporting period.	1,360
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	39
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	53
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	532
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	736
TB_STAT_TA	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	41
TB_STAT_TA	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	549
TB_STAT_TA	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	27
TB_STAT_TA	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	398
GEND_GBV_TA	Number of people receiving post-GBV care	278
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	226

GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	52
GEND_GBV_TA	By PEP service provision (related to sexual violence services provided)	21
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	143
TB_ART_TA	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	36
TB_ART_TA	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	72

	TB treatment during the reporting period)	
TB_ART_TA	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	2
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	66
TB_ART_TA	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	1
TB_ART_TA	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	18
TB_ART_TA	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	0
TB_ART_TA	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	17
PMTCT_EID_TA	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	101
PMTCT_EID_TA	Number of infants with a positive virological test result within 2 months of birth	1
PMTCT_EID_TA	Number of infants with a negative virological test result within 2 months of birth	78
PMTCT_EID_TA	Number of infants with a positive virological test result between 2 and 12 months of birth	1
PMTCT_EID_TA	Number of infants with a negative virological test result between 2 and 12 months of birth	21

TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	1,342
TX_CURR_TA	Aggregated Age/Sex: <15 Male	56
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	390
TX_CURR_TA	Aggregated Age/Sex: <15 Female	61
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	835
TX_CURR_TA	Sum of Aggregated Age/Sex <15	117
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	1,225
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	1,342
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)	353
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Male	3
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Male	111
TX_NEW_TA	Aggregated Grouping by Age/Sex: <15 Female	5
TX_NEW_TA	Aggregated Grouping by Age/Sex: 15+ Female	233
TX_NEW_TA	Sum of Aggregated Age/Sex disaggregates	352
TX_NEW_TA	Pregnancy status	17
TX_NEW_TA	Breastfeeding status	2
TX_PVLS_TA	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	1,187
TX_PVLS_TA	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,328
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	41
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	4
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	37
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	2

TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	705
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	52
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	320
TX_PVLS_TA	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	26
TX_PVLS_TA	Numerator: Indication: Routine	1,103
TX_PVLS_TA	Numerator: Indication: Targeted	84
TX_PVLS_TA	Numerator: Preg/BF by Indication: Breastfeeding Routine	20
TX_PVLS_TA	Numerator: Preg/BF by Indication: Breastfeeding Targeted	4
TX_PVLS_TA	Numerator: Preg/BF by Indication: Pregnant Routine	10
TX_PVLS_TA	Numerator: Preg/BF by Indication: Pregnant Targeted	2
TX_PVLS_TA	Denominator: Indication: Routine	1,234
TX_PVLS_TA	Denominator: Indication: Targeted	94
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	49
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	4
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	45
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	3
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	785
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	60
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	355
TX_PVLS_TA	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	27

TX_PVLS_TA	Denominator: Preg/BF by Indication: Breastfeeding Routine	23
TX_PVLS_TA	Denominator: Preg/BF by Indication: Breastfeeding Targeted	5
TX_PVLS_TA	Denominator: Preg/BF by Indication: Pregnant Routine	11
TX_PVLS_TA	Denominator: Preg/BF by Indication: Pregnant Targeted	2
TX_RET_TA	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	336
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	336
TX_RET_TA	Numerator by Status: Pregnant	17
TX_RET_TA	Numerator by Status: Breastfeeding	10
TX_RET_TA	Denominator by Status: Pregnant	17
TX_RET_TA	Denominator by Status: Breastfeeding	10
TX_RET_TA	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	104
TX_RET_TA	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	7
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	222
TX_RET_TA	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3
TX_RET_TA	Aggregated Age/Sex: 15+ Male (Denominator: Total	104

	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_TA	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7
TX_RET_TA	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	222
TB_PREV_TA	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	318
TB_PREV_TA	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	353
TB_PREV_TA	By Age/Sex (Denominator): <15, Female	4
TB_PREV_TA	By Age/Sex (Denominator): <15, Male	4
TB_PREV_TA	By Age/Sex (Denominator): 15+, Female	68
TB_PREV_TA	By Age/Sex (Denominator): 15+, Male	32
TB_PREV_TA	By Age/Sex (Numerator): <15, Female	4
TB_PREV_TA	By Age/Sex (Numerator): <15, Male	3
TB_PREV_TA	By Age/Sex (Numerator): 15+, Female	61
TB_PREV_TA	By Age/Sex (Numerator): 15+, Male	29
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	1

TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	1
TX_TB_TA	Number of ART patients who were started on TB treatment during the reporting period.	58
TX_TB_TA	Number of ART patients who were screened for TB at least once during the reporting period	56

Implementing Mechanism Details

Mechanism ID: 18214	**Mechanism Name: Health Information Systems Innovations**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Palladium Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 4,495,000	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 4,495,000	
Funding Source	**Funding Amount**
GHP-State	4,495,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**18214**
Mechanism Name:	**Health Information Systems Innovations**
Prime Partner Name:	**Palladium Group**

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	3,900,000	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	OHSS	595,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18215	**Mechanism Name: Coptic Hospitals**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Coptic Hospital	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,200,517	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,200,517	
Funding Source	**Funding Amount**
GHP-State	3,200,517

Cross-Cutting Budget Attribution(s)

Gender: GBV	80,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care

Sub Area:	Implementation
Sub Area:	Capacity building
Motor Vehicles: Purchased	200,000
Human Resources for Health	1,600,000

Budget Code Information

Mechanism ID:	**18215**		
Mechanism Name:	**Coptic Hospitals**		
Prime Partner Name:	**Coptic Hospital**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	199,023	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	144,881	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	41,514	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	2,442,419	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	372,680	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission	345

	(MTCT) during pregnancy	
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	999
PMTCT_ART_DSD	New on ART	135
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	210
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	999
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	0
PMTCT_STAT_DSD	By Age (Denominator): <15-19	12
PMTCT_STAT_DSD	By Age (Denominator): 20-24	181
PMTCT_STAT_DSD	By Age (Denominator): 25-49	806
PMTCT_STAT_DSD	By Age (Denominator): 50+	0
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	0
PMTCT_STAT_DSD	By Number of known positives: 15-19	2
PMTCT_STAT_DSD	By Number of known positives: 20-24	13
PMTCT_STAT_DSD	By Number of known positives: 25-49	180
PMTCT_STAT_DSD	By Number of known positives: 50+	0
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	0
PMTCT_STAT_DSD	By Number of new positives: 15-19	0
PMTCT_STAT_DSD	By Number of new positives: 20-24	52
PMTCT_STAT_DSD	By Number of new positives: 25-49	116
PMTCT_STAT_DSD	By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	0
PMTCT_STAT_DSD	By Number of new negative: <10	0

PMTCT_STAT_DSD	By Number of new negative: 10-14	0
PMTCT_STAT_DSD	By Number of new negative: 15-19	10
PMTCT_STAT_DSD	By Number of new negative: 20-24	116
PMTCT_STAT_DSD	By Number of new negative: 25-49	510
PMTCT_STAT_DSD	By Number of new negative: 50+	0
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	0
PMTCT_STAT_DSD	By Age (Numerator): 15-19	12
PMTCT_STAT_DSD	By Age (Numerator): 20-24	181
PMTCT_STAT_DSD	By Age (Numerator): 25-49	806
PMTCT_STAT_DSD	By Age (Numerator): 50+	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	31,198
HTC_TST_DSD	By Test Result: Positive	925
HTC_TST_DSD	Sum of Test Result disaggregates	925
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	33
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	127
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	94
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	0

HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	195
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	162
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	822
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	572
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	142
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	131
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	17
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	0

HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	95
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	294
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	243
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,114
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	828
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	1,714
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	54
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	1,444
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	7,176
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	267
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	5,003
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	148

HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	1,247
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	47
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,145
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	54
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1, Negative	155
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	830
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	34

HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	21
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	49
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	41
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	205
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	143
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	36
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	31
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0

HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	21
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female,	82

	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	59
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	122
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	102
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	513
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	357
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	88
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	80
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age,	0

	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	58
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	0
HTC_TST_DSD	By Key Population: FSW, Negative	0
HTC_TST_DSD	By Key Population: FSW, Positive	0
HTC_TST_DSD	By Key Population: MSM, Negative	0
HTC_TST_DSD	By Key Population: MSM, Positive	0
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	0
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	0
HTC_TST_DSD	By Key Population: PWID, Negative	0
HTC_TST_DSD	By Key Population: PWID, Positive	0
HTC_TST_DSD	By Key Population: TG, Negative	0
HTC_TST_DSD	By Key Population: TG, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	63
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	52
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	238

HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	178
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	367
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	309
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	1,538
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	56
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	1,072
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	31
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	267
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	244
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT:	0

HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	35
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	178
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	2
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	238
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	250
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	108
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	122
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	4
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	113
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	4
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	129

GEND_GBV_DSD	Number of people receiving post-GBV care	4,579
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	3,168
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,411
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	564
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	56
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	62
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	45
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	13
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	270
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	125
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	218
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	38
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	170
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	210
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	148
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	185
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	610
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	315
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	291
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	90
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	1,100
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	267
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	130
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	46
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	120
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	60
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	10
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	0

GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	161
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	161
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	72
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	4
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	81
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	4
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	72

TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	4
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	81
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	345
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	4
PMTCT_EID_DSD	Unknown, <= 2 months	0
PMTCT_EID_DSD	Unknown, 2 - 12 months	0
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	308
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	5
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	28
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	16,495
TX_CURR_DSD	Age/Sex: 15-19 Male	210
TX_CURR_DSD	Age/Sex: 15-19 Female	195
TX_CURR_DSD	Sum of age/sex disaggregates	405
TX_CURR_DSD	Age/Sex: <1	17
TX_CURR_DSD	Age/Sex: <1-9	225
TX_CURR_DSD	Age/Sex: 10-14 Male	188
TX_CURR_DSD	Age/Sex: 10-14 Female	171
TX_CURR_DSD	Age/Sex: 20-24 Male	123
TX_CURR_DSD	Age/Sex: 25-49 Male	3,228
TX_CURR_DSD	Age/Sex: 50+ Male	1,895
TX_CURR_DSD	Age/Sex: 20-24 Female	264

TX_CURR_DSD	Age/Sex: 25-49 Female	7,857
TX_CURR_DSD	Age/Sex: 50+ Female	2,122
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	3,530
TX_NEW_DSD	By Age/Sex: <1	5
TX_NEW_DSD	By Age/Sex: 1-9	24
TX_NEW_DSD	By Age/Sex: 10-14 Male	23
TX_NEW_DSD	By Age/Sex: 15-19 Male	46
TX_NEW_DSD	By Age/Sex: 20-24 Male	28
TX_NEW_DSD	By Age/Sex: 25-49 Male	703
TX_NEW_DSD	By Age/Sex: 50+ Male	410
TX_NEW_DSD	By Age/Sex: 10-14 Female	21
TX_NEW_DSD	By Age/Sex: 15-19 Female	42
TX_NEW_DSD	By Age/Sex: 20-24 Female	58
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,714
TX_NEW_DSD	By Age/Sex: 50+ Female	456
TX_NEW_DSD	Sum of Age/Sex disaggregates	3,501
TX_NEW_DSD	Pregnancy status	135
TX_NEW_DSD	Breastfeeding status	15
TX_NEW_DSD	FSW	0
TX_NEW_DSD	MSM	0
TX_NEW_DSD	People in prisons and other enclosed settings	0
TX_NEW_DSD	TG	0
TX_NEW_DSD	By Key populations: People who inject drugs (PWID)	0
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	14,772
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	16,478
TX_PVLS_DSD	Numerator: Indication: Routine	13,737
TX_PVLS_DSD	Numerator: Indication: Targeted	1,035

TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	290
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	33
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	21
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	3
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	17
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	344
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	16
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	658
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	228
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	4,566
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	206
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	8,737
TX_PVLS_DSD	Denominator: Indication: Routine	15,324
TX_PVLS_DSD	Denominator: Indication: Targeted	1,154
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	322
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	36
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	23
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Targeted	3
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	22
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	382

TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	19
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	731
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	286
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	5,074
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	256
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	9,708
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0

TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,354
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,530
TX_RET_DSD	Numerator by Status: Pregnant	128

TX_RET_DSD	Numerator by Status: Breastfeeding	14
TX_RET_DSD	Denominator by Status: Pregnant	135
TX_RET_DSD	Denominator by Status: Breastfeeding	15
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	38
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,127
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	32
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,157
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	38
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,187
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	35
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,270

TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	64
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	16,495
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	3
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	3
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	31
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	27
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	43
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	41
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	2,100
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	1,115
TX_TB_DSD	Denominator: By Screen Result: Negative	13,196
TX_TB_DSD	Denominator: By Screen Result: Positive	3,299
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	3,299
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	165
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	495
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	2,639

Implementing Mechanism Details

Mechanism ID: 18216	**Mechanism Name: UMB PACE Kamilisha**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland Baltimore	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 600,000	**Total Mechanism Pipeline: N/A**

Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 600,000	
Funding Source	**Funding Amount**
GHP-State	600,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**18216**		
Mechanism Name:	**UMB PACE Kamilisha**		
Prime Partner Name:	**University of Maryland Baltimore**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	51,000	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	549,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18217	**Mechanism Name: Ngima for Sure**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: County Government of Siaya	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	

G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 1,927,704	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,927,704	
Funding Source	**Funding Amount**
GHP-State	1,927,704

Cross-Cutting Budget Attribution(s)

Gender: GBV	5,200
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	5,200
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Motor Vehicles: Purchased	100,000
Human Resources for Health	1,600,000

Budget Code Information

Mechanism ID:	18217		
Mechanism Name:	Ngima for Sure		
Prime Partner Name:	County Government of Siaya		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	122,644	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	326,909	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	76,617	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	1,320,225	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	81,309	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	485
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	3,391
PMTCT_ART_DSD	New on ART	210
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	275
PMTCT_STAT_DSD	Number of pregnant women with known HIV status	3,391

	(includes women who were tested for HIV and received their results)	
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	74
PMTCT_STAT_DSD	By Age (Denominator): <15-19	589
PMTCT_STAT_DSD	By Age (Denominator): 20-24	918
PMTCT_STAT_DSD	By Age (Denominator): 25-49	1,793
PMTCT_STAT_DSD	By Age (Denominator): 50+	29
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	6
PMTCT_STAT_DSD	By Number of known positives: 15-19	55
PMTCT_STAT_DSD	By Number of known positives: 20-24	120
PMTCT_STAT_DSD	By Number of known positives: 25-49	165
PMTCT_STAT_DSD	By Number of known positives: 50+	7
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	5
PMTCT_STAT_DSD	By Number of new positives: 15-19	23
PMTCT_STAT_DSD	By Number of new positives: 20-24	38
PMTCT_STAT_DSD	By Number of new positives: 25-49	70
PMTCT_STAT_DSD	By Number of new positives: 50+	4
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	0
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	63
PMTCT_STAT_DSD	By Number of new negative: 15-19	509
PMTCT_STAT_DSD	By Number of new negative: 20-24	760
PMTCT_STAT_DSD	By Number of new negative: 25-49	1,548
PMTCT_STAT_DSD	By Number of new negative: 50+	18
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0

PMTCT_STAT_DSD	By Age (Numerator): 10-14	74
PMTCT_STAT_DSD	By Age (Numerator): 15-19	547
PMTCT_STAT_DSD	By Age (Numerator): 20-24	892
PMTCT_STAT_DSD	By Age (Numerator): 25-49	1,849
PMTCT_STAT_DSD	By Age (Numerator): 50+	29
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	58,563
HTC_TST_DSD	By Test Result: Positive	1,195
HTC_TST_DSD	Sum of Test Result disaggregates	1,195
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	0

HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	0

HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	372
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	270
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	400
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	372
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	22

HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	573
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	479
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	19
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	740
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	494
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	126
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	81
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1, Negative	64
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	2

HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	79
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	72
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	5

HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	2

HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	12
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0

HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	94
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	504
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	68
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	807
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	136
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	1,242
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	190
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	18
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Positive	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	60
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	60
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	14

TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	17
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	10
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	19
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	14
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	17
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	10
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	19
GEND_GBV_DSD	Number of people receiving post-GBV care	1,290
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	946
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	344
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	138
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	4
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	85
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	42
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	57

GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	27
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	154
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	56
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	91
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	25
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	189
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	62
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	97
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	27
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	142
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	49
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	69
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	23
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	47
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	18
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	15
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	8
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	43
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	43
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during	7

	TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	12
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	9
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	15
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	7
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	12
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	9
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	15
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	445
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	9
PMTCT_EID_DSD	Unknown, <= 2 months	0
PMTCT_EID_DSD	Unknown, 2 - 12 months	0

PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	130
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	12
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	294
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	3,594
TX_CURR_DSD	Age/Sex: 15-19 Male	119
TX_CURR_DSD	Age/Sex: 15-19 Female	179
TX_CURR_DSD	Sum of age/sex disaggregates	298
TX_CURR_DSD	Age/Sex: <1	9
TX_CURR_DSD	Age/Sex: <1-9	123
TX_CURR_DSD	Age/Sex: 10-14 Male	75
TX_CURR_DSD	Age/Sex: 10-14 Female	113
TX_CURR_DSD	Age/Sex: 20-24 Male	314
TX_CURR_DSD	Age/Sex: 25-49 Male	902
TX_CURR_DSD	Age/Sex: 50+ Male	83
TX_CURR_DSD	Age/Sex: 20-24 Female	423
TX_CURR_DSD	Age/Sex: 25-49 Female	1,115
TX_CURR_DSD	Age/Sex: 50+ Female	139
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,167
TX_NEW_DSD	By Age/Sex: <1	4
TX_NEW_DSD	By Age/Sex: 1-9	16
TX_NEW_DSD	By Age/Sex: 10-14 Male	10
TX_NEW_DSD	By Age/Sex: 15-19 Male	105
TX_NEW_DSD	By Age/Sex: 20-24 Male	113
TX_NEW_DSD	By Age/Sex: 25-49 Male	207
TX_NEW_DSD	By Age/Sex: 50+ Male	67
TX_NEW_DSD	By Age/Sex: 10-14 Female	17
TX_NEW_DSD	By Age/Sex: 15-19 Female	127

TX_NEW_DSD	By Age/Sex: 20-24 Female	139
TX_NEW_DSD	By Age/Sex: 25-49 Female	269
TX_NEW_DSD	By Age/Sex: 50+ Female	93
TX_NEW_DSD	Sum of Age/Sex disaggregates	1,147
TX_NEW_DSD	Pregnancy status	21
TX_NEW_DSD	Breastfeeding status	13
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	3,227
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	3,667
TX_PVLS_DSD	Numerator: Indication: Routine	2,942
TX_PVLS_DSD	Numerator: Indication: Targeted	285
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	28
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	14
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	27
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	14
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	9
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	107
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	10
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	159
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	112
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,090
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15	153

	Female Routine	
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	1,587
TX_PVLS_DSD	Denominator: Indication: Routine	3,298
TX_PVLS_DSD	Denominator: Indication: Targeted	369
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	28
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	14
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	27
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Targeted	14
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	39
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	124
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	51
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	155
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	131
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,438
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	149
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	1,580
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0

TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0

TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,108
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,166
TX_RET_DSD	Numerator by Status: Pregnant	31
TX_RET_DSD	Numerator by Status: Breastfeeding	15
TX_RET_DSD	Denominator by Status: Pregnant	31
TX_RET_DSD	Denominator by Status: Breastfeeding	15
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	17
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	493
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	29
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	569
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped	18

	ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	480
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	27
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	641
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	17
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	3,400
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	4
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	2
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	6
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	5
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	94
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	69
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	300
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	218
TX_TB_DSD	Denominator: By Screen Result: Negative	2,719
TX_TB_DSD	Denominator: By Screen Result: Positive	681
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	681
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of	31

	Specimen Sent]: Other (No Xpert)	
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	102
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	548

Implementing Mechanism Details

Mechanism ID: 18223	**Mechanism Name: Kemri Non-Research**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,500,000	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,500,000	
Funding Source	**Funding Amount**
GHP-State	1,500,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	49,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Gender: Gender Equality	49,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Gender: GBV	49,000
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Gender: Gender Equality	49,000
Focus Area:	Equity in HIV prevention, care, treatment and support

Human Resources for Health	525,570

Budget Code Information

Mechanism ID:	18223		
Mechanism Name:	Kemri Non-Research		
Prime Partner Name:	University of Maryland		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	0	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HVSI	150,000	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	1,350,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18260	**Mechanism Name: International AIDS Education and Training Center (I-TECH)**
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 650,000	**Total Mechanism Pipeline: N/A**

Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 650,000	
Funding Source	**Funding Amount**
GHP-State	650,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**18260**		
Mechanism Name:	**International AIDS Education and Training Center (I-TECH)**		
Prime Partner Name:	**University of Washington**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HVSI	350,000	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	300,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18261	**Mechanism Name: Quality Improvement Capacity for Impact Project (QICIP)**
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University Mailman School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No

Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 300,000	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 300,000	
Funding Source	**Funding Amount**
GHP-State	300,000

Cross-Cutting Budget Attribution(s)

Human Resources for Health	150,000

Budget Code Information

Mechanism ID:	**18261**		
Mechanism Name:	**Quality Improvement Capacity for Impact Project (QICIP)**		
Prime Partner Name:	**Columbia University Mailman School of Public Health**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HVSI	50,000	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	250,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18262	**Mechanism Name: Strengthening Public Health Capacity and SI Systems**

Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: UNAIDS - Joint United Nations Programme on HIV/AIDS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 200,000	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 200,000	
Funding Source	**Funding Amount**
GHP-State	200,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**18262**		
Mechanism Name:	**Strengthening Public Health Capacity and SI Systems**		
Prime Partner Name:	**UNAIDS - Joint United Nations Programme on HIV/AIDS**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HVSI	200,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18281	**Mechanism Name: Kenya Supply Chain System**

	Strengthening
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Chemonics. Inc	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 895,000	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 895,000	
Funding Source	**Funding Amount**
GHP-State	895,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	**18281**		
Mechanism Name:	**Kenya Supply Chain System Strengthening**		
Prime Partner Name:	**Chemonics. Inc**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	OHSS	895,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18283	**TBD: Yes**
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18284	**TBD: Yes**
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18285	**Mechanism Name: Coordinating Comprehensive Care for Children**
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Catholic Relief Services	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,600,000	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 1,600,000	
Funding Source	**Funding Amount**
GHP-State	1,600,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18285		
Mechanism Name:	Coordinating Comprehensive Care for Children		
Prime Partner Name:	Catholic Relief Services		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	1,600,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18317	**Mechanism Name: General Nursing Capacity Building Program**
Funding Agency: HHS/HRSA	Procurement Type: Cooperative Agreement
Prime Partner Name: Columbia University Mailman School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 0	
Funding Source	**Funding Amount**
GHP-State	0

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18317		
Mechanism Name:	General Nursing Capacity Building Program		
Prime Partner Name:	Columbia University Mailman School of Public Health		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18318	**Mechanism Name: County Measurement Learning & Accountability Project (CMLAP)**
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Palladium Group	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,850,000	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,850,000	
Funding Source	**Funding Amount**
GHP-State	3,850,000

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID:	18318		
Mechanism Name:	County Measurement Learning & Accountability Project (CMLAP)		
Prime Partner Name:	Palladium Group		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	1,000,000	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HVSI	2,850,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18490	**TBD: Yes**
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18491	**TBD: Yes**
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18492	**TBD: Yes**
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18493	**TBD: Yes**
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18494	**TBD: Yes**
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18495	**TBD: Yes**
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18496	**TBD: Yes**
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18497	**TBD: Yes**
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18498	**TBD: Yes**
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18499	**TBD: Yes**
REDACTED	

Implementing Mechanism Details

Mechanism ID: 18504	**Mechanism Name: UMB Timiza**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Maryland Baltimore	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 11,467,637	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 11,467,637	
Funding Source	**Funding Amount**
GHP-State	11,467,637

Cross-Cutting Budget Attribution(s)

Key Populations: FSW	1,539,567
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Key Populations: MSM and TG	81,030
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Gender: GBV	10,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care

Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	891,387

Budget Code Information

Mechanism ID:	18504		
Mechanism Name:	UMB Timiza		
Prime Partner Name:	University of Maryland Baltimore		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	628,264	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	CIRC	1,054,087	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	1,352,838	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	40,926	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	849,142	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	6,763,080	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	779,300	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	4,100
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	51,562
PMTCT_ART_DSD	New on ART	1,154
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,946
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	51,562
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	460
PMTCT_STAT_DSD	By Age (Denominator): <15-19	13,154
PMTCT_STAT_DSD	By Age (Denominator): 20-24	31,028
PMTCT_STAT_DSD	By Age (Denominator): 25-49	12,650
PMTCT_STAT_DSD	By Age (Denominator): 50+	47
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	0
PMTCT_STAT_DSD	By Number of known positives: 15-19	125
PMTCT_STAT_DSD	By Number of known positives: 20-24	1,210
PMTCT_STAT_DSD	By Number of known positives: 25-49	1,427
PMTCT_STAT_DSD	By Number of known positives: 50+	0
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	5
PMTCT_STAT_DSD	By Number of new positives: 15-19	85
PMTCT_STAT_DSD	By Number of new positives: 20-24	838

PMTCT_STAT_DSD	By Number of new positives: 25-49	536
PMTCT_STAT_DSD	By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	0
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	400
PMTCT_STAT_DSD	By Number of new negative: 15-19	11,570
PMTCT_STAT_DSD	By Number of new negative: 20-24	25,804
PMTCT_STAT_DSD	By Number of new negative: 25-49	9,521
PMTCT_STAT_DSD	By Number of new negative: 50+	41
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	405
PMTCT_STAT_DSD	By Age (Numerator): 15-19	11,848
PMTCT_STAT_DSD	By Age (Numerator): 20-24	27,889
PMTCT_STAT_DSD	By Age (Numerator): 25-49	11,379
PMTCT_STAT_DSD	By Age (Numerator): 50+	41
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	19,520
VMMC_CIRC_DSD	By Age: 0-60 days	1,000
VMMC_CIRC_DSD	By Age: 2 months - 9 years	0
VMMC_CIRC_DSD	By Age: 10-14	7,808
VMMC_CIRC_DSD	By Age: 15-19	1,952
VMMC_CIRC_DSD	By Age: 20-24	1,952
VMMC_CIRC_DSD	By Age: 25-29	3,904
VMMC_CIRC_DSD	By Age: 30-49	2,709
VMMC_CIRC_DSD	By Age: 50+	195
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	11,907
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	18,520
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	19,070
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	450
KP_PREV_DSD	Number of key populations reached with individual	818

	and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	8
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	100
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	710
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	537,956
HTC_TST_DSD	By Test Result: Positive	10,266
HTC_TST_DSD	Sum of Test Result disaggregates	10,266
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	940
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive	3
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	906
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive	3
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	5,012
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	29

HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	2,816
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	43
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	34,906
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	188
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	32,947
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	173
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	218,449
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	5,575
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	144,190
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	2,263
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Negative	0

HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	5,866
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	18
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	272
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	2
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	252

HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	1,131
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	86
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	763
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	54
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: <15, Negative	8,397
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: <15, Positive	11
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Negative	11,044
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Positive	271
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female,	1

	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	2
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative	1,063
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	8
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative	644
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	2,383
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	35
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	1,343
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	137
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_DSD	By Key Population: FSW, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	641
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: <15,	400

	Negative	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: <15, Positive	5
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative	49,572
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive	1,448
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	80
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	75
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	254
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	154
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Negative	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,379
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,396
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	50
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,258
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number	64

	of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,004
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	51
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,277
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	64
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,000
GEND_GBV_DSD	Number of people receiving post-GBV care	27,371
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	19,899
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	7,472
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	2,990
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	362
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	946
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	955
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	18

TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	347
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	12
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	569
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	18
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	357
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	13
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	567
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	4,101
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	44
PMTCT_EID_DSD	Unknown, <= 2 months	0
PMTCT_EID_DSD	Unknown, 2 - 12 months	0
PMTCT_EID_DSD	Number of infants with a negative virological test result	2,666

	within 2 months of birth	
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	79
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	1,312
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	75,421
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	2,447
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	20,939
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	2,693
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	49,342
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	5,140
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	70,281
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	75,421
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	10,259
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	215
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	3,787
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	368
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	5,889
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	10,259
TX_NEW_DSD	Pregnancy status	1,191
TX_NEW_DSD	Breastfeeding status	162
TX_NEW_DSD	By Key populations: People who inject drugs (PWID)	0
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	66,880
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	74,676
TX_PVLS_DSD	Numerator: Indication: Routine	62,369
TX_PVLS_DSD	Numerator: Indication: Targeted	4,504

TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	424
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	636
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	61
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	1,005
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	186
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	3,259
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	1,670
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	16,238
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	2,081
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	42,016
TX_PVLS_DSD	Denominator: Indication: Routine	69,023
TX_PVLS_DSD	Denominator: Indication: Targeted	5,493
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	549
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	511
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	0
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	184
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	1,349

TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	396
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	3,554
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	2,263
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	18,033
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,561
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	46,187
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	4
TX_PVLS_DSD	Unknown Age, Targeted, Male	5
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0

TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	7
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	9,746
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	11,289
TX_RET_DSD	Numerator by Status: Pregnant	979

TX_RET_DSD	Numerator by Status: Breastfeeding	261
TX_RET_DSD	Denominator by Status: Pregnant	763
TX_RET_DSD	Denominator by Status: Breastfeeding	196
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	284
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,554
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	346
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,562
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	287
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,573
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	371
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	6,883

TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	379
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	379
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	16
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	7
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	213
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	143
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	112
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	11
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	117
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	131
TX_TB_DSD	Denominator: By Screen Result: Negative	271
TX_TB_DSD	Denominator: By Screen Result: Positive	100
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	100
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	0
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	5
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	95

Implementing Mechanism Details

Mechanism ID: 18505	**Mechanism Name: CHS Shinda**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Center for Health Solutions (CHS)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 15,251,051	**Total Mechanism Pipeline: N/A**

Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 15,251,051	
Funding Source	**Funding Amount**
GHP-State	15,251,051

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	81,030
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Gender: GBV	5,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Key Populations: FSW	1,425,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Human Resources for Health	810,352
Motor Vehicles: Purchased	70,200

Budget Code Information

Mechanism ID:	**18505**

Mechanism Name:	CHS Shinda		
Prime Partner Name:	Center for Health Solutions (CHS)		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	801,195	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	CIRC	1,211,718	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	3,192,180	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	689,552	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	8,624,625	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	731,781	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	4,368
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	30,523
PMTCT_ART_DSD	New on ART	1,156
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	3,212
PMTCT_STAT_DSD	Number of pregnant women with known HIV status	30,523

	(includes women who were tested for HIV and received their results)	
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	115
PMTCT_STAT_DSD	By Age (Denominator): <15-19	3,735
PMTCT_STAT_DSD	By Age (Denominator): 20-24	9,512
PMTCT_STAT_DSD	By Age (Denominator): 25-49	17,148
PMTCT_STAT_DSD	By Age (Denominator): 50+	13
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	0
PMTCT_STAT_DSD	By Number of known positives: 15-19	89
PMTCT_STAT_DSD	By Number of known positives: 20-24	659
PMTCT_STAT_DSD	By Number of known positives: 25-49	2,464
PMTCT_STAT_DSD	By Number of known positives: 50+	0
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	0
PMTCT_STAT_DSD	By Number of new positives: 15-19	128
PMTCT_STAT_DSD	By Number of new positives: 20-24	516
PMTCT_STAT_DSD	By Number of new positives: 25-49	742
PMTCT_STAT_DSD	By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	0
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	115
PMTCT_STAT_DSD	By Number of new negative: 15-19	3,511
PMTCT_STAT_DSD	By Number of new negative: 20-24	8,340
PMTCT_STAT_DSD	By Number of new negative: 25-49	13,946
PMTCT_STAT_DSD	By Number of new negative: 50+	13
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0

PMTCT_STAT_DSD	By Age (Numerator): 10-14	115
PMTCT_STAT_DSD	By Age (Numerator): 15-19	3,735
PMTCT_STAT_DSD	By Age (Numerator): 20-24	9,512
PMTCT_STAT_DSD	By Age (Numerator): 25-49	17,147
PMTCT_STAT_DSD	By Age (Numerator): 50+	14
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	50,217
VMMC_CIRC_DSD	By Age: 0-60 days	1,000
VMMC_CIRC_DSD	By Age: 2 months - 9 years	0
VMMC_CIRC_DSD	By Age: 10-14	20,087
VMMC_CIRC_DSD	By Age: 15-19	5,022
VMMC_CIRC_DSD	By Age: 20-24	5,022
VMMC_CIRC_DSD	By Age: 25-29	10,043
VMMC_CIRC_DSD	By Age: 30-49	8,541
VMMC_CIRC_DSD	By Age: 50+	502
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	30,633
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	49,217
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	48,017
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	2,200
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,177,280
HTC_TST_DSD	By Test Result: Positive	35,623
HTC_TST_DSD	Sum of Test Result disaggregates	35,623
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	201
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	176
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	0

HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	512
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	221
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	745
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	229
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	1,342
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	91
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	674
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	446
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	360
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	0

HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	1,063
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	72,854
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	138
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	47,063
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	69
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	110,076
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	1,431
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	64,169
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	344
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	137,444
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	4,915
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	57,192
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	1,372

HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	193,002
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	10,207
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	102,674
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	7,924
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	47,678
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	1,096
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	32,354
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	1,319
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1, Negative	610
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	183,508
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	422
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	0

HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	136
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	76
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	24
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	1

HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	20,674
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	4,971
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	258
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	5,006
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	177
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Negative	18,561
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	56
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	501
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	954
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	749
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female,	511

	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	357
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	1,120
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	224
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	809
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	42
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	1,799
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	323
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	1,524
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	331
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	297
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	583
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age,	0

	Female, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	30
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	2,653
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	116
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	3,501
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	232
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	8,321
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	1,198
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	13,974
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	3,168
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Positive	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,475
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,487

TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	36
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	733
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	21
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	685
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	36
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	739
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	21
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	691
GEND_GBV_DSD	Number of people receiving post-GBV care	36,722
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	26,693
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	10,029
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	4,011
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	891
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	337
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	594
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	224

GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	484
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	175
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	425
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	157
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	475
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	177
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	274
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	103
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	1,946
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	732
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	635
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	241
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	11,510
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	4,319
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	5,523
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	2,081
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	2,416
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	909
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	1,520
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	574
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	916
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	916

TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	14
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	461
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	15
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	426
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	14
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	461
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	15
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	426
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	4,368
PMTCT_EID_DSD	Number of infants with a positive virological test result	140

	within 2 months of birth	
PMTCT_EID_DSD	Unknown, <= 2 months	0
PMTCT_EID_DSD	Unknown, 2 - 12 months	0
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	3,672
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	83
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	473
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	103,477
TX_CURR_DSD	Age/Sex: 15-19 Male	1,089
TX_CURR_DSD	Age/Sex: 15-19 Female	1,879
TX_CURR_DSD	Sum of age/sex disaggregates	2,968
TX_CURR_DSD	Age/Sex: <1	240
TX_CURR_DSD	Age/Sex: <1-9	3,991
TX_CURR_DSD	Age/Sex: 10-14 Male	1,144
TX_CURR_DSD	Age/Sex: 10-14 Female	1,290
TX_CURR_DSD	Age/Sex: 20-24 Male	2,536
TX_CURR_DSD	Age/Sex: 25-49 Male	22,008
TX_CURR_DSD	Age/Sex: 50+ Male	6,049
TX_CURR_DSD	Age/Sex: 20-24 Female	7,728
TX_CURR_DSD	Age/Sex: 25-49 Female	45,875
TX_CURR_DSD	Age/Sex: 50+ Female	9,648
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	32,382
TX_NEW_DSD	By Age/Sex: <1	94
TX_NEW_DSD	By Age/Sex: 1-9	572
TX_NEW_DSD	By Age/Sex: 10-14 Male	78
TX_NEW_DSD	By Age/Sex: 15-19 Male	334
TX_NEW_DSD	By Age/Sex: 20-24 Male	1,344
TX_NEW_DSD	By Age/Sex: 25-49 Male	8,563

TX_NEW_DSD	By Age/Sex: 50+ Male	1,046
TX_NEW_DSD	By Age/Sex: 10-14 Female	154
TX_NEW_DSD	By Age/Sex: 15-19 Female	1,160
TX_NEW_DSD	By Age/Sex: 20-24 Female	5,487
TX_NEW_DSD	By Age/Sex: 25-49 Female	12,309
TX_NEW_DSD	By Age/Sex: 50+ Female	1,241
TX_NEW_DSD	Sum of Age/Sex disaggregates	31,716
TX_NEW_DSD	Pregnancy status	1,040
TX_NEW_DSD	Breastfeeding status	116
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	89,658
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	100,318
TX_PVLS_DSD	Numerator: Indication: Routine	83,382
TX_PVLS_DSD	Numerator: Indication: Targeted	6,276
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	148
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	1,942
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	204
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	3,982
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male	1,993

	Routine	
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	25,751
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	2,681
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	52,957
TX_PVLS_DSD	Denominator: Indication: Routine	93,295
TX_PVLS_DSD	Denominator: Indication: Targeted	7,023
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	0
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	0
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	0
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	185
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	2,147
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	255
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	4,436
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	2,492
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	28,608
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	3,350
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	58,845
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0

TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0

TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	30,763
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	30,763
TX_RET_DSD	Numerator by Status: Pregnant	0
TX_RET_DSD	Numerator by Status: Breastfeeding	0
TX_RET_DSD	Denominator by Status: Pregnant	0
TX_RET_DSD	Denominator by Status: Breastfeeding	0
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	344
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	10,705
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	509
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	19,205
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total	344

	number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	10,705
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	509
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	19,205
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	29,144
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	32,382
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	542
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	342
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	20,196
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	11,302
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	32,382
TB_PREV_DSD	By Therapy type (Denominator): Alternative Regimen	0

TB_PREV_DSD	By Therapy type (Denominator): Continuous IPT	0
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	518
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	340
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	18,157
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	10,129
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	29,144
TB_PREV_DSD	By Therapy type (Numerator): Alternative Regimen	0
TB_PREV_DSD	By Therapy type (Numerator): Continuous IPT	0
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	366
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	103,477
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	1
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	1
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	176
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	188
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	3,829
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	2,841
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	65,135
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	31,672
TX_TB_DSD	Denominator: By Screen Result: Negative	82,783
TX_TB_DSD	Denominator: By Screen Result: Positive	20,694
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	20,695
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	1,031
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	3,103
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	16,562

Implementing Mechanism Details

Mechanism ID: 18506	**Mechanism Name: UCSF Clinical Kisumu**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of California at San Francisco	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 10,584,812	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 10,584,812	
Funding Source	**Funding Amount**
GHP-State	10,584,812

Cross-Cutting Budget Attribution(s)

Gender: GBV	224,425
Focus Area:	GBV Prevention
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	224,425
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: GBV	224,425
Focus Area:	GBV Prevention
Sub Area:	Implementation

Budget Code Information

Mechanism ID:	18506		
Mechanism Name:	UCSF Clinical Kisumu		
Prime Partner Name:	University of California at San Francisco		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	587,854	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	CIRC	1,062,344	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	1,494,548	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	498,633	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	6,328,077	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	613,356	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	3,235
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	21,682

PMTCT_ART_DSD	New on ART	1,027
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	2,208
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	21,682
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	94
PMTCT_STAT_DSD	By Age (Denominator): <15-19	3,631
PMTCT_STAT_DSD	By Age (Denominator): 20-24	8,205
PMTCT_STAT_DSD	By Age (Denominator): 25-49	9,752
PMTCT_STAT_DSD	By Age (Denominator): 50+	0
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	0
PMTCT_STAT_DSD	By Number of known positives: 15-19	81
PMTCT_STAT_DSD	By Number of known positives: 20-24	649
PMTCT_STAT_DSD	By Number of known positives: 25-49	1,472
PMTCT_STAT_DSD	By Number of known positives: 50+	0
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	8
PMTCT_STAT_DSD	By Number of new positives: 15-19	175
PMTCT_STAT_DSD	By Number of new positives: 20-24	551
PMTCT_STAT_DSD	By Number of new positives: 25-49	468
PMTCT_STAT_DSD	By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	0
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	86
PMTCT_STAT_DSD	By Number of new negative: 15-19	3,375
PMTCT_STAT_DSD	By Number of new negative: 20-24	7,005
PMTCT_STAT_DSD	By Number of new negative: 25-49	7,812

PMTCT_STAT_DSD	By Number of new negative: 50+	0
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	94
PMTCT_STAT_DSD	By Age (Numerator): 15-19	3,631
PMTCT_STAT_DSD	By Age (Numerator): 20-24	8,205
PMTCT_STAT_DSD	By Age (Numerator): 25-49	9,752
PMTCT_STAT_DSD	By Age (Numerator): 50+	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	40,040
VMMC_CIRC_DSD	By Age: 0-60 days	500
VMMC_CIRC_DSD	By Age: 2 months - 9 years	0
VMMC_CIRC_DSD	By Age: 10-14	16,016
VMMC_CIRC_DSD	By Age: 15-19	4,004
VMMC_CIRC_DSD	By Age: 20-24	4,004
VMMC_CIRC_DSD	By Age: 25-29	8,008
VMMC_CIRC_DSD	By Age: 30-49	7,108
VMMC_CIRC_DSD	By Age: 50+	400
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	24,424
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	39,540
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	38,033
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	2,007
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	551,417
HTC_TST_DSD	By Test Result: Positive	20,007
HTC_TST_DSD	Sum of Test Result disaggregates	20,007
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male,	0

	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male,	0

	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	9,408
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	93
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	8,385
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	77
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	63,857
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	1,075
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	43,445
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	133
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	73,680
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	2,404
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24,	40,918

	Male, Negative	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	666
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	103,049
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	5,733
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	74,307
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	4,510
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	22,484
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	426
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	16,302
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	696
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	17,658
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	389
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	0

HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female,	0

	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: <1, Negative	495
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: <1, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	15,855
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	161
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	3,963
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	41
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	3,965
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Negative	14,964
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	152
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	398
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: Unknown Age, Negative	0

HTC_TST_DSD	Service Delivery Point (Facility) VMMC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	0

HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	86
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	3,375
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	256
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	7,005
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	1,200
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	7,811

HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	1,941
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female,	0

	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT:	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,143
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,183
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	65
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	508
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number	62

	of registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	508
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	68
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	521
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	67
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	527
GEND_GBV_DSD	Number of people receiving post-GBV care	24,036
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	17,489
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	6,547
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	2,619
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	671
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	247
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	289
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	107
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	272
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	101
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	113
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	37
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	331
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	124
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	147

GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	50
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	1,943
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	731
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	823
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	314
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	7,777
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	2,921
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	3,334
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	1,245
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	1,254
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	467
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	535
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	203
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	657
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	657
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	28
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	291

TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	28
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	310
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	28
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	291
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	28
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	310
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3,235
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	138
PMTCT_EID_DSD	Unknown, <= 2 months	0
PMTCT_EID_DSD	Unknown, 2 - 12 months	0
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	2,622
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	30
PMTCT_EID_DSD	Number of infants with a negative virological test result	445

	between 2 and 12 months of birth	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	67,583
TX_CURR_DSD	Age/Sex: 15-19 Male	720
TX_CURR_DSD	Age/Sex: 15-19 Female	1,257
TX_CURR_DSD	Sum of age/sex disaggregates	1,977
TX_CURR_DSD	Age/Sex: <1	132
TX_CURR_DSD	Age/Sex: <1-9	2,415
TX_CURR_DSD	Age/Sex: 10-14 Male	903
TX_CURR_DSD	Age/Sex: 10-14 Female	1,028
TX_CURR_DSD	Age/Sex: 20-24 Male	2,211
TX_CURR_DSD	Age/Sex: 25-49 Male	13,756
TX_CURR_DSD	Age/Sex: 50+ Male	3,821
TX_CURR_DSD	Age/Sex: 20-24 Female	7,164
TX_CURR_DSD	Age/Sex: 25-49 Female	29,384
TX_CURR_DSD	Age/Sex: 50+ Female	4,792
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	15,896
TX_NEW_DSD	By Age/Sex: <1	100
TX_NEW_DSD	By Age/Sex: 1-9	330
TX_NEW_DSD	By Age/Sex: 10-14 Male	126
TX_NEW_DSD	By Age/Sex: 15-19 Male	106
TX_NEW_DSD	By Age/Sex: 20-24 Male	452
TX_NEW_DSD	By Age/Sex: 25-49 Male	4,265
TX_NEW_DSD	By Age/Sex: 50+ Male	765
TX_NEW_DSD	By Age/Sex: 10-14 Female	70
TX_NEW_DSD	By Age/Sex: 15-19 Female	999
TX_NEW_DSD	By Age/Sex: 20-24 Female	2,414
TX_NEW_DSD	By Age/Sex: 25-49 Female	5,884
TX_NEW_DSD	By Age/Sex: 50+ Female	385
TX_NEW_DSD	Sum of Age/Sex disaggregates	15,466
TX_NEW_DSD	Pregnancy status	1,558

TX_NEW_DSD	Breastfeeding status	365
TX_NEW_DSD	FSW	0
TX_NEW_DSD	MSM	0
TX_NEW_DSD	People in prisons and other enclosed settings	0
TX_NEW_DSD	TG	0
TX_NEW_DSD	By Key populations: People who inject drugs (PWID)	0
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	60,261
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	67,446
TX_PVLS_DSD	Numerator: Indication: Routine	56,040
TX_PVLS_DSD	Numerator: Indication: Targeted	4,221
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	287
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	497
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	101
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	1,350
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	164
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	2,606
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	1,475
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	17,450
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15	1,795

	Female Routine	
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	35,320
TX_PVLS_DSD	Denominator: Indication: Routine	62,725
TX_PVLS_DSD	Denominator: Indication: Targeted	4,721
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	287
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	532
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	23
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	172
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	1,512
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	140
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	2,898
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,938
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	19,419
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,162
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	39,205
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0

TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0

TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	15,101
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	15,896
TX_RET_DSD	Numerator by Status: Pregnant	1,276
TX_RET_DSD	Numerator by Status: Breastfeeding	286
TX_RET_DSD	Denominator by Status: Pregnant	1,557
TX_RET_DSD	Denominator by Status: Breastfeeding	365
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	323
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	5,321
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	270
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9,187
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped	348

	ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	5,590
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	295
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,663
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	14,306
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	15,896
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	296
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	346
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	9,657
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	5,597
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	15,896
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	261
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	309
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	8,696

TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	5,040
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	14,306
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	263
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	67,582
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	10
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	9
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	134
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	110
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	2,157
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	2,175
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	42,690
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	20,560
TX_TB_DSD	Denominator: By Screen Result: Negative	54,065
TX_TB_DSD	Denominator: By Screen Result: Positive	13,517
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	13,517
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	679
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	2,030
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	10,808

Implementing Mechanism Details

Mechanism ID: 18507	**Mechanism Name: CHS Tegemeza Plus**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Center for Health Solutions (CHS)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	

G2G: No	Managing Agency:

Total All Funding Sources: 4,014,012	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 4,014,012	
Funding Source	**Funding Amount**
GHP-State	4,014,012

Cross-Cutting Budget Attribution(s)

Gender: GBV	128,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Motor Vehicles: Purchased	65,200

Budget Code Information

Mechanism ID:	**18507**		
Mechanism Name:	**CHS Tegemeza Plus**		
Prime Partner Name:	**Center for Health Solutions (CHS)**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	169,516	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	1,440,424	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**

Prevention	MTCT	375,870	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	1,824,790	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	203,412	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	846
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	33,529
PMTCT_ART_DSD	New on ART	312
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	534
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	33,529
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	11
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	31
PMTCT_STAT_DSD	By Age (Denominator): <15-19	3,481
PMTCT_STAT_DSD	By Age (Denominator): 20-24	10,841
PMTCT_STAT_DSD	By Age (Denominator): 25-49	19,162
PMTCT_STAT_DSD	By Age (Denominator): 50+	12
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	2
PMTCT_STAT_DSD	By Number of known positives: <10	0

PMTCT_STAT_DSD	By Number of known positives: 10-14	2
PMTCT_STAT_DSD	By Number of known positives: 15-19	16
PMTCT_STAT_DSD	By Number of known positives: 20-24	104
PMTCT_STAT_DSD	By Number of known positives: 25-49	433
PMTCT_STAT_DSD	By Number of known positives: 50+	0
PMTCT_STAT_DSD	By Number of new positives: 15-19	16
PMTCT_STAT_DSD	By Number of new positives: 20-24	102
PMTCT_STAT_DSD	By Number of new positives: 25-49	230
PMTCT_STAT_DSD	By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	77
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	29
PMTCT_STAT_DSD	By Number of new negative: 15-19	3,451
PMTCT_STAT_DSD	By Number of new negative: 20-24	10,668
PMTCT_STAT_DSD	By Number of new negative: 25-49	18,479
PMTCT_STAT_DSD	By Number of new negative: 50+	14
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	12
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	31
PMTCT_STAT_DSD	By Age (Numerator): 15-19	3,482
PMTCT_STAT_DSD	By Age (Numerator): 20-24	10,836
PMTCT_STAT_DSD	By Age (Numerator): 25-49	19,151
PMTCT_STAT_DSD	By Age (Numerator): 50+	14
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	522,696
HTC_TST_DSD	By Test Result: Positive	6,087
HTC_TST_DSD	Sum of Test Result disaggregates	6,087
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	9,687
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	103

HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	4,845
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	48
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	305,197
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	3,307
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	164,711
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	1,782
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative	32,111
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive	929
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,207
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,262
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	69
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,378
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	73
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	687
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during	68

	the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,405
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	86
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	703
GEND_GBV_DSD	Number of people receiving post-GBV care	5,468
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	4,575
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	893
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	357
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	614
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	614
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	6
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	338
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	11
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The	259

	number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	6
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	337
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	11
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	260
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	846
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	6
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	588
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	6
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	246
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	26,822
TX_CURR_DSD	Age/Sex: 15-19 Male	739
TX_CURR_DSD	Age/Sex: 15-19 Female	523
TX_CURR_DSD	Sum of age/sex disaggregates	1,262

TX_CURR_DSD	Age/Sex: <1	41
TX_CURR_DSD	Age/Sex: <1-9	592
TX_CURR_DSD	Age/Sex: 10-14 Male	487
TX_CURR_DSD	Age/Sex: 10-14 Female	517
TX_CURR_DSD	Age/Sex: 20-24 Male	429
TX_CURR_DSD	Age/Sex: 25-49 Male	4,360
TX_CURR_DSD	Age/Sex: 50+ Male	2,522
TX_CURR_DSD	Age/Sex: 20-24 Female	695
TX_CURR_DSD	Age/Sex: 25-49 Female	12,009
TX_CURR_DSD	Age/Sex: 50+ Female	3,908
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	5,728
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	94
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,649
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	85
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,900
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	5,728
TX_NEW_DSD	Pregnancy status	20
TX_NEW_DSD	Breastfeeding status	7
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	23,962
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	26,815
TX_PVLS_DSD	Numerator: Indication: Routine	22,284
TX_PVLS_DSD	Numerator: Indication: Targeted	1,678
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	39
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	496
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15	36

	Female Targeted	
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1,106
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	611
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	6,312
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	613
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	14,749
TX_PVLS_DSD	Denominator: Indication: Routine	24,942
TX_PVLS_DSD	Denominator: Indication: Targeted	1,884
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	52
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	534
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	62
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1,229
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	759
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	7,276
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	759
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	16,118
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,900
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	5,442

	stopped ART, and those lost to follow-up	
TX_RET_DSD	Numerator by Status: Pregnant	553
TX_RET_DSD	Numerator by Status: Breastfeeding	12
TX_RET_DSD	Denominator by Status: Pregnant	616
TX_RET_DSD	Denominator by Status: Breastfeeding	12
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	76
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,496
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	78
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,250
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	84
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,660
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	86
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	3,612

	including those who have died, those who have stopped ART, and those lost to follow-up)	
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	5,232
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	5,746
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	108
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	70
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	3,618
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	1,950
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	5,746
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	103
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	70
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	3,285
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,780
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	6,232
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	347
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	26,824
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	6
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	1
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	173
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	167
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	972
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	940
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	16,484

TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	8,428
TX_TB_DSD	Denominator: By Screen Result: Negative	21,451
TX_TB_DSD	Denominator: By Screen Result: Positive	5,362
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	5,362
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	255
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	823
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	4,284

Implementing Mechanism Details

Mechanism ID: 18508	**Mechanism Name: CHS Naishi**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Center for Health Solutions (CHS)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 10,669,097	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 10,669,097	
Funding Source	**Funding Amount**
GHP-State	10,669,097

Cross-Cutting Budget Attribution(s)

Gender: GBV	158,000
Focus Area:	GBV Prevention
Sub Area:	Implementation

Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building

Budget Code Information

Mechanism ID:	**18508**		
Mechanism Name:	**CHS Naishi**		
Prime Partner Name:	**Center for Health Solutions (CHS)**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	578,384	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	2,275,400	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	893,651	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	6,226,133	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	695,529	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission	2,440

	(MTCT) during pregnancy	
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	69,934
PMTCT_ART_DSD	New on ART	1,151
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,289
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	69,934
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	110
PMTCT_STAT_DSD	By Age (Denominator): <15-19	8,458
PMTCT_STAT_DSD	By Age (Denominator): 20-24	25,114
PMTCT_STAT_DSD	By Age (Denominator): 25-49	36,246
PMTCT_STAT_DSD	By Age (Denominator): 50+	6
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	0
PMTCT_STAT_DSD	By Number of known positives: 15-19	37
PMTCT_STAT_DSD	By Number of known positives: 20-24	268
PMTCT_STAT_DSD	By Number of known positives: 25-49	989
PMTCT_STAT_DSD	By Number of known positives: 50+	12
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	0
PMTCT_STAT_DSD	By Number of new positives: 15-19	45
PMTCT_STAT_DSD	By Number of new positives: 20-24	365
PMTCT_STAT_DSD	By Number of new positives: 25-49	683
PMTCT_STAT_DSD	By Number of new positives: 50+	2
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	0
PMTCT_STAT_DSD	By Number of new negative: <10	0

PMTCT_STAT_DSD	By Number of new negative: 10-14	103
PMTCT_STAT_DSD	By Number of new negative: 15-19	8,205
PMTCT_STAT_DSD	By Number of new negative: 20-24	24,056
PMTCT_STAT_DSD	By Number of new negative: 25-49	34,384
PMTCT_STAT_DSD	By Number of new negative: 50+	785
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	111
PMTCT_STAT_DSD	By Age (Numerator): 15-19	8,457
PMTCT_STAT_DSD	By Age (Numerator): 20-24	25,116
PMTCT_STAT_DSD	By Age (Numerator): 25-49	36,241
PMTCT_STAT_DSD	By Age (Numerator): 50+	9
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	846,057
HTC_TST_DSD	By Test Result: Positive	14,264
HTC_TST_DSD	Sum of Test Result disaggregates	14,264
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	382
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	281
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	1,750
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	907
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	2

HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	2,912
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	988
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	6,980
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	139
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	3,108
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	85
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	1,636
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	1,053
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	0

HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	588
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	12,704
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	87
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	9,557
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	65
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	61,734
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	324
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	31,883
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	102
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	100,838
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	1,012
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	34,070
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	240
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	242,336
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	5,483
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	107,252
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	3,154

HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	55,970
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	1,076
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	35,881
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	630
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	20,261
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	164
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	27,279
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	200
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	92
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	40
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	354

HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	175
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	591
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	202
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	1,296
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	148
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	611
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	77
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	319
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	192
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0

HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	125
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	0

HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	0
HTC_TST_DSD	By Key Population: FSW, Negative	0
HTC_TST_DSD	By Key Population: FSW, Positive	0
HTC_TST_DSD	By Key Population: MSM, Negative	0
HTC_TST_DSD	By Key Population: MSM, Positive	0
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	0
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	0
HTC_TST_DSD	By Key Population: PWID, Negative	0

HTC_TST_DSD	By Key Population: PWID, Positive	0
HTC_TST_DSD	By Key Population: TG, Negative	0
HTC_TST_DSD	By Key Population: TG, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	109
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	8,348
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	45
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	24,456
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	382
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	34,524
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	692
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	23
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	0

HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT:	0

HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	5,052
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	5,138
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	185
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3,249
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	113
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,505
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	196
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3,301
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	115
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,526

GEND_GBV_DSD	Number of people receiving post-GBV care	15,695
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	12,381
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	3,314
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1,312
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	328
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	72
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	310
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	68
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	331
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	76
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	183
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	39
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	255
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	56
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	182
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	37
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	357
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	84
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	108
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	22
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	5,722
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	1,524
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	1,680
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	451
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	1,909
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	510
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	976
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	249
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	0

GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,378
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,378
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	60
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	893
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	28
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	397
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	60
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	893

TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	28
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	397
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,440
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	38
PMTCT_EID_DSD	Unknown, <= 2 months	0
PMTCT_EID_DSD	Unknown, 2 - 12 months	0
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	1,801
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	55
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	546
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	66,205
TX_CURR_DSD	Age/Sex: 15-19 Male	1,021
TX_CURR_DSD	Age/Sex: 15-19 Female	1,429
TX_CURR_DSD	Sum of age/sex disaggregates	2,450
TX_CURR_DSD	Age/Sex: <1	39
TX_CURR_DSD	Age/Sex: <1-9	2,637
TX_CURR_DSD	Age/Sex: 10-14 Male	1,277
TX_CURR_DSD	Age/Sex: 10-14 Female	1,402
TX_CURR_DSD	Age/Sex: 20-24 Male	627
TX_CURR_DSD	Age/Sex: 25-49 Male	9,141
TX_CURR_DSD	Age/Sex: 50+ Male	5,380
TX_CURR_DSD	Age/Sex: 20-24 Female	1,901

TX_CURR_DSD	Age/Sex: 25-49 Female	30,830
TX_CURR_DSD	Age/Sex: 50+ Female	10,521
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	14,592
TX_NEW_DSD	By Age/Sex: <1	54
TX_NEW_DSD	By Age/Sex: 1-9	433
TX_NEW_DSD	By Age/Sex: 10-14 Male	71
TX_NEW_DSD	By Age/Sex: 15-19 Male	115
TX_NEW_DSD	By Age/Sex: 20-24 Male	344
TX_NEW_DSD	By Age/Sex: 25-49 Male	3,025
TX_NEW_DSD	By Age/Sex: 50+ Male	858
TX_NEW_DSD	By Age/Sex: 10-14 Female	79
TX_NEW_DSD	By Age/Sex: 15-19 Female	355
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,346
TX_NEW_DSD	By Age/Sex: 25-49 Female	6,657
TX_NEW_DSD	By Age/Sex: 50+ Female	1,255
TX_NEW_DSD	Sum of Age/Sex disaggregates	14,105
TX_NEW_DSD	Pregnancy status	898
TX_NEW_DSD	Breastfeeding status	91
TX_NEW_DSD	FSW	0
TX_NEW_DSD	MSM	0
TX_NEW_DSD	People in prisons and other enclosed settings	0
TX_NEW_DSD	TG	0
TX_NEW_DSD	By Key populations: People who inject drugs (PWID)	0
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	59,053
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	66,205
TX_PVLS_DSD	Numerator: Indication: Routine	54,912
TX_PVLS_DSD	Numerator: Indication: Targeted	4,141

TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	2,537
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	93
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	1,237
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	93
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	133
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	1,029
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	144
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	2,835
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	1,914
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	13,463
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	1,997
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	37,537
TX_PVLS_DSD	Denominator: Indication: Routine	61,552
TX_PVLS_DSD	Denominator: Indication: Targeted	4,653
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	1,201
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	148
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	913
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Targeted	101
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	179
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	1,135

TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	188
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	3,150
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	2,428
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	15,312
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	2,563
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	41,250
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0

TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	14,010
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	14,777
TX_RET_DSD	Numerator by Status: Pregnant	919

TX_RET_DSD	Numerator by Status: Breastfeeding	98
TX_RET_DSD	Denominator by Status: Pregnant	914
TX_RET_DSD	Denominator by Status: Breastfeeding	98
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	747
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,316
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	775
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	9,172
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	777
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,478
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	812
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,710

TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	12,600
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	14,651
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	352
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	371
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	9,680
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	4,242
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	14,651
TB_PREV_DSD	By Therapy type (Denominator): Alternative Regimen	0
TB_PREV_DSD	By Therapy type (Denominator): Continuous IPT	0
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	297
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	257
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	8,328
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	3,718
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	12,600
TB_PREV_DSD	By Therapy type (Numerator): Alternative Regimen	0
TB_PREV_DSD	By Therapy type (Numerator): Continuous IPT	0
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	551
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	66,205
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	1
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	10
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	177
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	363
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	2,767

TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	2,620
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	44,646
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	16,172
TX_TB_DSD	Denominator: By Screen Result: Negative	52,959
TX_TB_DSD	Denominator: By Screen Result: Positive	13,246
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	13,241
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	0
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	0
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	13,241

Implementing Mechanism Details

Mechanism ID: 18509	**Mechanism Name: AMREF Nairobi Kitui**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Medical and Research Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,468,513	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 2,468,513	
Funding Source	**Funding Amount**
GHP-State	2,468,513

Cross-Cutting Budget Attribution(s)

Gender: GBV	6,760

Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	279,737

Budget Code Information

Mechanism ID:	**18509**		
Mechanism Name:	**AMREF Nairobi Kitui**		
Prime Partner Name:	**African Medical and Research Foundation**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	179,103	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	182,608	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	140,220	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	1,927,990	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	38,592	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	666
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	10,335
PMTCT_ART_DSD	New on ART	274
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	392
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	10,335
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	0
PMTCT_STAT_DSD	By Age (Denominator): <15-19	972
PMTCT_STAT_DSD	By Age (Denominator): 20-24	4,113
PMTCT_STAT_DSD	By Age (Denominator): 25-49	5,250
PMTCT_STAT_DSD	By Age (Denominator): 50+	0
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	0
PMTCT_STAT_DSD	By Number of known positives: 15-19	27
PMTCT_STAT_DSD	By Number of known positives: 20-24	59
PMTCT_STAT_DSD	By Number of known positives: 25-49	306
PMTCT_STAT_DSD	By Number of known positives: 50+	0
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	0
PMTCT_STAT_DSD	By Number of new positives: 15-19	9
PMTCT_STAT_DSD	By Number of new positives: 20-24	89
PMTCT_STAT_DSD	By Number of new positives: 25-49	176
PMTCT_STAT_DSD	By Number of new positives: 50+	0

PMTCT_STAT_DSD	By Number of new negative: Unknown Age	0
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	0
PMTCT_STAT_DSD	By Number of new negative: 15-19	936
PMTCT_STAT_DSD	By Number of new negative: 20-24	3,965
PMTCT_STAT_DSD	By Number of new negative: 25-49	4,768
PMTCT_STAT_DSD	By Number of new negative: 50+	0
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	0
PMTCT_STAT_DSD	By Age (Numerator): 15-19	972
PMTCT_STAT_DSD	By Age (Numerator): 20-24	4,113
PMTCT_STAT_DSD	By Age (Numerator): 25-49	5,250
PMTCT_STAT_DSD	By Age (Numerator): 50+	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	79,982
HTC_TST_DSD	By Test Result: Positive	1,741
HTC_TST_DSD	Sum of Test Result disaggregates	1,741
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	638
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	686
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	8,046
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	2,712

HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	8,015
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	62
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	4,259
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	16,048
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	433
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	9,517
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	192
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	1,140
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,063
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0

HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	2,590
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	49
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	3,004
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	22
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	20
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	26
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	172

HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	121
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	100
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	64
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	12
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	657
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	457
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	686

HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	456
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	207
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	143
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	247
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	237
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	64
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	92
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0

HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	2,215
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	28
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	738
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	3,120
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	72
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	3,766
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	173
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	193
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male,	139

	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	668
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	476
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	1,215
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	468
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	1,640
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	47
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	1,155
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	21
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	170
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	138
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	9

HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT:	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	179
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	14
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	679
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	679
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	22
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	258
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	28
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	371
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	22
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	258
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total	28

	number of registered new and relapsed TB cases, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	371
GEND_GBV_DSD	Number of people receiving post-GBV care	3,934
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	2,756
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,178
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	454
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	475
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	207
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	39
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	16
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	441
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	212
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	39
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	18
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	550
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	262
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	18
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	10
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	325
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	162
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	26
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	14
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	475
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	238
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	45
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	23
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	21

GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	11
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	6
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	5
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	277
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	277
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	17
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	90
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	17
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	153
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment	10

	during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	90
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	17
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	160
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	666
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	8
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	444
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	22
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	192
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	15,269
TX_CURR_DSD	Age/Sex: 15-19 Male	135
TX_CURR_DSD	Age/Sex: 15-19 Female	218
TX_CURR_DSD	Sum of age/sex disaggregates	353
TX_CURR_DSD	Age/Sex: <1	5
TX_CURR_DSD	Age/Sex: <1-9	290
TX_CURR_DSD	Age/Sex: 10-14 Male	52
TX_CURR_DSD	Age/Sex: 10-14 Female	93
TX_CURR_DSD	Age/Sex: 20-24 Male	372
TX_CURR_DSD	Age/Sex: 25-49 Male	3,969

TX_CURR_DSD	Age/Sex: 50+ Male	717
TX_CURR_DSD	Age/Sex: 20-24 Female	684
TX_CURR_DSD	Age/Sex: 25-49 Female	7,388
TX_CURR_DSD	Age/Sex: 50+ Female	1,336
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,696
TX_NEW_DSD	By Age/Sex: <1	0
TX_NEW_DSD	By Age/Sex: 1-9	43
TX_NEW_DSD	By Age/Sex: 10-14 Male	5
TX_NEW_DSD	By Age/Sex: 15-19 Male	17
TX_NEW_DSD	By Age/Sex: 20-24 Male	65
TX_NEW_DSD	By Age/Sex: 25-49 Male	711
TX_NEW_DSD	By Age/Sex: 50+ Male	129
TX_NEW_DSD	By Age/Sex: 10-14 Female	16
TX_NEW_DSD	By Age/Sex: 15-19 Female	36
TX_NEW_DSD	By Age/Sex: 20-24 Female	119
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,317
TX_NEW_DSD	By Age/Sex: 50+ Female	238
TX_NEW_DSD	Sum of Age/Sex disaggregates	2,653
TX_NEW_DSD	Pregnancy status	249
TX_NEW_DSD	Breastfeeding status	25
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	10,356
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	11,553
TX_PVLS_DSD	Numerator: Indication: Routine	9,527
TX_PVLS_DSD	Numerator: Indication: Targeted	829
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	168
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	17

TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	386
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	44
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	16
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	273
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	29
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	501
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	172
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	3,255
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	312
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	5,788
TX_PVLS_DSD	Denominator: Indication: Routine	10,624
TX_PVLS_DSD	Denominator: Indication: Targeted	929
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	184
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	20
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	433
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Targeted	1,652
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	17
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	320
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	30
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+	562

	Female Targeted	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	193
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	3,638
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	347
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	6,446
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0

TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,665
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	12,890
TX_RET_DSD	Numerator by Status: Pregnant	554
TX_RET_DSD	Numerator by Status: Breastfeeding	61
TX_RET_DSD	Denominator by Status: Pregnant	618
TX_RET_DSD	Denominator by Status: Breastfeeding	71
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	26
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of	910

	adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	49
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,680
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	142
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,367
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	279
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	8,102
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	2,426
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period	2,696

	but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	42
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	23
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	1,711
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	920
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	2,696
TB_PREV_DSD	By Therapy type (Denominator): Alternative Regimen	0
TB_PREV_DSD	By Therapy type (Denominator): Continuous IPT	0
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	38
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	21
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	1,541
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	826
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	2,426
TB_PREV_DSD	By Therapy type (Numerator): Alternative Regimen	0
TB_PREV_DSD	By Therapy type (Numerator): Continuous IPT	0
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	112
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	15,191
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	6
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	4
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	64
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	38
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	346
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	184
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	9,528
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	5,133
TX_TB_DSD	Denominator: By Screen Result: Negative	12,153
TX_TB_DSD	Denominator: By Screen Result: Positive	3,038
TX_TB_DSD	Denominator: Number of ART patients who had a	607

	specimen sent for bacteriologic diagnosis of active TB disease	
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	30
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	93
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	485

Implementing Mechanism Details

Mechanism ID: 18511	**Mechanism Name: CHAK CHAP Uzima**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Christian Health Association of Kenya	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 8,009,304	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 8,009,304	
Funding Source	**Funding Amount**
GHP-State	8,009,304

Cross-Cutting Budget Attribution(s)

Gender: GBV	194,651
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Post GBV Care
Sub Area:	Implementation
Sub Area:	Capacity building

Human Resources for Health	1,557,207

Budget Code Information

Mechanism ID:	18511		
Mechanism Name:	CHAK CHAP Uzima		
Prime Partner Name:	Christian Health Association of Kenya		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	207,674	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	505,567	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	868,680	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	491,215	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	5,442,281	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	493,887	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission	1,807

	(MTCT) during pregnancy	
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	44,108
PMTCT_ART_DSD	New on ART	766
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	1,041
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	44,108
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	11
PMTCT_STAT_DSD	By Age (Denominator): <15-19	1,677
PMTCT_STAT_DSD	By Age (Denominator): 20-24	12,648
PMTCT_STAT_DSD	By Age (Denominator): 25-49	29,772
PMTCT_STAT_DSD	By Age (Denominator): 50+	0
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	0
PMTCT_STAT_DSD	By Number of known positives: 15-19	9
PMTCT_STAT_DSD	By Number of known positives: 20-24	210
PMTCT_STAT_DSD	By Number of known positives: 25-49	822
PMTCT_STAT_DSD	By Number of known positives: 50+	0
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	0
PMTCT_STAT_DSD	By Number of new positives: 15-19	15
PMTCT_STAT_DSD	By Number of new positives: 20-24	194
PMTCT_STAT_DSD	By Number of new positives: 25-49	619
PMTCT_STAT_DSD	By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	0
PMTCT_STAT_DSD	By Number of new negative: <10	0

PMTCT_STAT_DSD	By Number of new negative: 10-14	10
PMTCT_STAT_DSD	By Number of new negative: 15-19	1,655
PMTCT_STAT_DSD	By Number of new negative: 20-24	12,241
PMTCT_STAT_DSD	By Number of new negative: 25-49	28,387
PMTCT_STAT_DSD	By Number of new negative: 50+	0
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	10
PMTCT_STAT_DSD	By Age (Numerator): 15-19	1,677
PMTCT_STAT_DSD	By Age (Numerator): 20-24	12,650
PMTCT_STAT_DSD	By Age (Numerator): 25-49	29,771
PMTCT_STAT_DSD	By Age (Numerator): 50+	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	357,751
HTC_TST_DSD	By Test Result: Positive	7,841
HTC_TST_DSD	Sum of Test Result disaggregates	7,841
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	21
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	28
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	38
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	77
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	34
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	307

HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	139
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	140
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	145
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	124
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	1
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	1,625
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive	13
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	2,486
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive	13
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	14,049
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	185
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	9,176
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	110

HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	697
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	698
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,102
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	35
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	840
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	1,803
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	239
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	937
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	132
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	7,177

HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	461
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	4,465
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	240
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	2,046
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,844
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1, Negative	33
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	2,537
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	4
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	15,196
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	129
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	15,965
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	114
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	108,311
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	1,966
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	65,582
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC:	973

	15+, Male, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	4,409
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	4
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male,	8

	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	3
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	9
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Negative	35
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	1
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	47
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Positive	2
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	409
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	72
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	318
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	51
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	143
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	3

HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	101
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	77
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	54
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	75
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	55
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	108
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	92
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	27
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	14

HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	260
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	4
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative	1,908
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	15
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative	1,749
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive	10
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	3,864
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	108
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	2,350
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Positive	64
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	15
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	105
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	5

HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	940
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	61
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	2,335
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	245
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: <15, Negative	2
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: <15, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative	36,416
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive	1,214
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	296
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	207
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	473
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	27
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	338
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	1,292

HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	90
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	833
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	56
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	281
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	239
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	5
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	23
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	62
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	18,844
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	633
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	12,481
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	327
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Positive	0

HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Positive	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	2,396
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	2,512
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	180
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	789
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	108
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1,319
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	184
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	807
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	113
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1,375
GEND_GBV_DSD	Number of people receiving post-GBV care	14,771
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	11,594

GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	3,157
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1,292
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	423
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	154
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	58
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	22
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	423
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	154
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	59
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	22
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	506
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	186
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	68
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	25
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	506
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	186
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	68
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	25
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	210
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	78
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	28
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	12
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	41
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	14
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	5
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	2
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	3,965
OVC_SERV_DSD	Age/Sex: 10-14 Male	665
OVC_SERV_DSD	Age/Sex: 15-17 Male	371
OVC_SERV_DSD	By: Age/sex: Male 18-24	214

OVC_SERV_DSD	By: Age/sex: Male 25+	0
OVC_SERV_DSD	Age/Sex: 10-14 Female	675
OVC_SERV_DSD	Age/Sex: 15-17 Female	406
OVC_SERV_DSD	By: Age/sex: 18-24 Female	188
OVC_SERV_DSD	By: Age/sex: 25+ Female	0
OVC_SERV_DSD	Sum of Age/Sex disaggregates	2,117
OVC_SERV_DSD	Age/Sex: <1	8
OVC_SERV_DSD	Age/Sex: 1-9	1,437
OVC_SERV_DSD	Program Completion: Active	3,568
OVC_SERV_DSD	Program Completion: Graduation	199
OVC_SERV_DSD	Program Completion: Transferred	123
OVC_SERV_DSD	Program Completion: Exited without graduation	75
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	1,116
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	1,134
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	86
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	336
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	44
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	650

TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	90
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	342
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	48
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	654
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,737
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	1
PMTCT_EID_DSD	Unknown, <= 2 months	2
PMTCT_EID_DSD	Unknown, 2 - 12 months	0
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	1,331
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	3
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	400
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	58,280
TX_CURR_DSD	Age/Sex: 15-19 Male	468
TX_CURR_DSD	Age/Sex: 15-19 Female	608
TX_CURR_DSD	Sum of age/sex disaggregates	1,076
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,726

TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	13,682
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,755
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	31,909
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	3,481
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	45,591
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	49,072
TX_CURR_DSD	Age/Sex: <1	11
TX_CURR_DSD	Age/Sex: <1-9	46
TX_CURR_DSD	Age/Sex: 10-14 Male	169
TX_CURR_DSD	Age/Sex: 10-14 Female	134
TX_CURR_DSD	Age/Sex: 20-24 Male	1,306
TX_CURR_DSD	Age/Sex: 25-49 Male	1,503
TX_CURR_DSD	Age/Sex: 50+ Male	120
TX_CURR_DSD	Age/Sex: 20-24 Female	1,418
TX_CURR_DSD	Age/Sex: 25-49 Female	2,787
TX_CURR_DSD	Age/Sex: 50+ Female	637
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	10,272
TX_NEW_DSD	By Age/Sex: <1	9
TX_NEW_DSD	By Age/Sex: 1-9	6
TX_NEW_DSD	By Age/Sex: 10-14 Male	14
TX_NEW_DSD	By Age/Sex: 15-19 Male	52
TX_NEW_DSD	By Age/Sex: 20-24 Male	133
TX_NEW_DSD	By Age/Sex: 25-49 Male	313
TX_NEW_DSD	By Age/Sex: 50+ Male	4
TX_NEW_DSD	By Age/Sex: 10-14 Female	14
TX_NEW_DSD	By Age/Sex: 15-19 Female	64
TX_NEW_DSD	By Age/Sex: 20-24 Female	371
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,073
TX_NEW_DSD	By Age/Sex: 50+ Female	20
TX_NEW_DSD	Sum of Age/Sex disaggregates	2,058
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	260

TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,345
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	277
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	5,317
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	8,199
TX_NEW_DSD	Pregnancy status	622
TX_NEW_DSD	Breastfeeding status	101
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	52,061
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	58,267
TX_PVLS_DSD	Numerator: Indication: Routine	48,413
TX_PVLS_DSD	Numerator: Indication: Targeted	3,648
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	618
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	69
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	38
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	3
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	112
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	1,059
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	135
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	2,342
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	1,417
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	14,023
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15	1,461

	Female Routine	
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	31,482
TX_PVLS_DSD	Denominator: Indication: Routine	54,191
TX_PVLS_DSD	Denominator: Indication: Targeted	4,076
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	623
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	69
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	38
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Targeted	3
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	161
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	1,171
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	137
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	2,607
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,776
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	15,572
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,827
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	35,016
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	9,593
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have	11,427

	stopped ART, and those lost to follow-up	
TX_RET_DSD	Numerator by Status: Pregnant	661
TX_RET_DSD	Numerator by Status: Breastfeeding	73
TX_RET_DSD	Denominator by Status: Pregnant	661
TX_RET_DSD	Denominator by Status: Breastfeeding	73
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	299
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,818
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	298
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	6,177
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	348
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,329
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	354
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period,	7,396

	including those who have died, those who have stopped ART, and those lost to follow-up)	
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	9,819
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	10,023
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	287
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	271
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	6,478
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	2,987
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	7,270
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	284
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	268
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	6,342
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	2,924
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	6,660
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	413
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	50,750
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	10
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	30
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	248
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	125
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	1,917
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	1,962
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	32,060

TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	14,811
TX_TB_DSD	Denominator: By Screen Result: Negative	40,999
TX_TB_DSD	Denominator: By Screen Result: Positive	9,747
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	9,743
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	486
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	1,453
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	7,803

Implementing Mechanism Details

Mechanism ID: 18512	**Mechanism Name: UON COE Niche**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Nairobi	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 3,269,141	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 3,269,141	
Funding Source	**Funding Amount**
GHP-State	3,269,141

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	100,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation

Sub Area:	Capacity building
Gender: GBV	150,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Key Populations: FSW	50,000
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Key Populations: MSM and TG	50,000
Human Resources for Health	1,230,000

Budget Code Information

Mechanism ID:	**18512**		
Mechanism Name:	**UON COE Niche**		
Prime Partner Name:	**University of Nairobi**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	175,371	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Governance and Systems	HLAB	187,000	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	810,530	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	95,487	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**

Treatment	HTXS	1,887,823	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	112,930	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	431
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,125
PMTCT_ART_DSD	New on ART	109
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	322
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,125
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	0
PMTCT_STAT_DSD	By Age (Denominator): <15-19	99
PMTCT_STAT_DSD	By Age (Denominator): 20-24	935
PMTCT_STAT_DSD	By Age (Denominator): 25-49	5,090
PMTCT_STAT_DSD	By Age (Denominator): 50+	1
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	0
PMTCT_STAT_DSD	By Number of known positives: 15-19	1
PMTCT_STAT_DSD	By Number of known positives: 20-24	16

PMTCT_STAT_DSD	By Number of known positives: 25-49	223
PMTCT_STAT_DSD	By Number of known positives: 50+	0
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	0
PMTCT_STAT_DSD	By Number of new positives: 15-19	0
PMTCT_STAT_DSD	By Number of new positives: 20-24	23
PMTCT_STAT_DSD	By Number of new positives: 25-49	191
PMTCT_STAT_DSD	By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	0
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	0
PMTCT_STAT_DSD	By Number of new negative: 15-19	91
PMTCT_STAT_DSD	By Number of new negative: 20-24	857
PMTCT_STAT_DSD	By Number of new negative: 25-49	4,722
PMTCT_STAT_DSD	By Number of new negative: 50+	1
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	0
PMTCT_STAT_DSD	By Age (Numerator): 15-19	99
PMTCT_STAT_DSD	By Age (Numerator): 20-24	935
PMTCT_STAT_DSD	By Age (Numerator): 25-49	5,090
PMTCT_STAT_DSD	By Age (Numerator): 50+	1
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	112,648
HTC_TST_DSD	By Test Result: Positive	3,292
HTC_TST_DSD	Sum of Test Result disaggregates	3,292
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative	49
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive	1

HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative	60
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative	352
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative	273
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative	2,069
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive	58
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative	516
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Negative	7,105
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Female, Positive	395
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Negative	3,016
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 25-49, Male, Positive	168
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Negative	1,541
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Female, Positive	117
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Negative	1,699

HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 50+, Male, Positive	95
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Negative	290
HTC_TST_DSD	Service Delivery Point (Facility) Inpatient: 1-9, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	195
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	127
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	498
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	187
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	1,922
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	65

HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	547
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	44
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	9,274
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	410
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	4,257
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	279
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	1,039
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	73
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	1,015
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	94
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1, Negative	8
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	851
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	12

HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	400
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	21
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	34
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	103
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	67
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	127
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	109
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	1,031
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	22
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	674
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	15

HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	655
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	491
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	43
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	9
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	2
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	0

HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	11
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	28
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	6
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	14
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	10
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	0

HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	35
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	91
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	857
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	23
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	4,722
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	191
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	1
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	558
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	1,206
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	3,816
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	34
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male,	2,708

	Negative	
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	51
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	13,208
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	155
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	9,636
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	16,553
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	473
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	12,300
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	269
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	1,910
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	41
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	816
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	33
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT:	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	5

HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	200
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	1
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	90
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	91
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	4
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	32
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	53
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	4
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	33
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	53
GEND_GBV_DSD	Number of people receiving post-GBV care	4,331
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	3,024

GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,307
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	523
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	354
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	132
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	70
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	31
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	369
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	160
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	77
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	35
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	362
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	176
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	35
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	16
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	755
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	327
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	31
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	13
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	842
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	366
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	27
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	9
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	91
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	40
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	11
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	2
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional	0

	Violence	
GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	66
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	66
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	26
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	0
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	39
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	26
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment	0

	during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	39
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	431
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	7
PMTCT_EID_DSD	Unknown, <= 2 months	0
PMTCT_EID_DSD	Unknown, 2 - 12 months	0
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	393
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	11
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	20
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	15,789
TX_CURR_DSD	Age/Sex: 15-19 Male	242
TX_CURR_DSD	Age/Sex: 15-19 Female	230
TX_CURR_DSD	Sum of age/sex disaggregates	472
TX_CURR_DSD	Age/Sex: <1	24
TX_CURR_DSD	Age/Sex: <1-9	430
TX_CURR_DSD	Age/Sex: 10-14 Male	230
TX_CURR_DSD	Age/Sex: 10-14 Female	236
TX_CURR_DSD	Age/Sex: 20-24 Male	137
TX_CURR_DSD	Age/Sex: 25-49 Male	3,411
TX_CURR_DSD	Age/Sex: 50+ Male	1,451
TX_CURR_DSD	Age/Sex: 20-24 Female	232
TX_CURR_DSD	Age/Sex: 25-49 Female	7,558
TX_CURR_DSD	Age/Sex: 50+ Female	1,607
TX_NEW_DSD	Number of adults and children newly enrolled on	4,273

	antiretroviral therapy (ART)	
TX_NEW_DSD	By Age/Sex: <1	9
TX_NEW_DSD	By Age/Sex: 1-9	26
TX_NEW_DSD	By Age/Sex: 10-14 Male	34
TX_NEW_DSD	By Age/Sex: 15-19 Male	85
TX_NEW_DSD	By Age/Sex: 20-24 Male	102
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,278
TX_NEW_DSD	By Age/Sex: 50+ Male	241
TX_NEW_DSD	By Age/Sex: 10-14 Female	43
TX_NEW_DSD	By Age/Sex: 15-19 Female	136
TX_NEW_DSD	By Age/Sex: 20-24 Female	256
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,688
TX_NEW_DSD	By Age/Sex: 50+ Female	375
TX_NEW_DSD	Sum of Age/Sex disaggregates	4,238
TX_NEW_DSD	Pregnancy status	161
TX_NEW_DSD	Breastfeeding status	7
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	17,097
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	19,106
TX_PVLS_DSD	Numerator: Indication: Routine	15,900
TX_PVLS_DSD	Numerator: Indication: Targeted	1,197
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	380
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	335
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	28
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	26
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	27

TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	525
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	28
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	617
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	359
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	5,969
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	377
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	9,195
TX_PVLS_DSD	Denominator: Indication: Routine	17,769
TX_PVLS_DSD	Denominator: Indication: Targeted	1,337
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	422
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	372
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	32
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Targeted	28
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	34
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	583
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	35
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	685
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	449
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	6,632

TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	472
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	10,216
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	4,059
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,273
TX_RET_DSD	Numerator by Status: Pregnant	161
TX_RET_DSD	Numerator by Status: Breastfeeding	7
TX_RET_DSD	Denominator by Status: Pregnant	161
TX_RET_DSD	Denominator by Status: Breastfeeding	7
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	50
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,619
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	58
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,332
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	53
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped	1,704

	ART, and those lost to follow-up)	
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	61
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,455
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	3,846
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	4,273
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	61
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	53
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	2,454
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	1,705
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	4,273
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	56
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	48
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	2,209
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,533
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	3,846
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	26
TX_TB_DSD	Number of ART patients who were screened for TB at	15,789

	least once during the reporting period	
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	1
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	16
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	9
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	93
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	92
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	1,925
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	1,048
TX_TB_DSD	Denominator: By Screen Result: Negative	12,631
TX_TB_DSD	Denominator: By Screen Result: Positive	3,158
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	3,158
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	159
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	473
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	2,526

Implementing Mechanism Details

Mechanism ID: 18513	**Mechanism Name: LVCT Steps**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Liverpool VCT and Care	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 5,128,258	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 5,128,258	

Funding Source	Funding Amount
GHP-State	5,128,258

Cross-Cutting Budget Attribution(s)

Key Populations: MSM and TG	493,709
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: FSW	987,417
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Gender: Gender Equality	246,854
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: GBV	197,483
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	2,468,543
Motor Vehicles: Purchased	200,000

Budget Code Information

Mechanism ID:	**18513**

Mechanism Name:	LVCT Steps		
Prime Partner Name:	Liverpool VCT and Care		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	658,647	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	59,500	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	794,819	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	2,974,792	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	640,500	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	593
PrEP_NEW_DSD	Female 15-19	308
PrEP_NEW_DSD	Female 20-24	285
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	40,490
PP_PREV_DSD	Age/sex: 15-19 Male	489
PP_PREV_DSD	Age/sex: 20-24 Male	1,558
PP_PREV_DSD	Age/sex: 25-49 Male	7,102
PP_PREV_DSD	Age/sex: 50+ Male	645

PP_PREV_DSD	Age/sex: 15-19 Female	13,120
PP_PREV_DSD	Age/sex: 20-24 Female	12,710
PP_PREV_DSD	Age/sex: 25-49 Female	4,441
PP_PREV_DSD	Age/sex: 50+ Female	425
PP_PREV_DSD	Sum of Age/Sex disaggregates	40,490
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	9,573
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	24
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	1,269
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	7,693
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	111
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	476
HTC_TST_DSD	Number of individuals who received T&C services for	164,119

	HIV and received their test results during the past 12 months	
HTC_TST_DSD	By Test Result: Positive	1,841
HTC_TST_DSD	Sum of Test Result disaggregates	1,841
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Negative	3,209
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Male, Negative	1,375
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 10-14, Male, Positive	14
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Negative	7,958
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Female, Positive	69
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Male, Negative	5,029
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 15-19, Male, Positive	67
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Negative	23,701
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Female, Positive	251
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Male, Negative	18,083
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 20-24, Male, Positive	212
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Female, Negative	30,273
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Female, Positive	354
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Male, Negative	31,130

HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 25-49, Male, Positive	347
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 50+, Female, Negative	1,045
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 50+, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 50+, Male, Negative	1,253
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 50+, Male, Positive	16
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 1-9, Negative	3,239
HTC_TST_DSD	Service Delivery Point (Community) Homebased testing: 1-9, Positive	22
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Negative	54
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Female, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Negative	30
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 10-14, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Negative	134
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Negative	89
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 15-19, Male, Positive	2
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Negative	483
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Female, Positive	12

HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Negative	371
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 20-24, Male, Positive	10
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Negative	657
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Female, Positive	10
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Negative	738
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 25-49, Male, Positive	12
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Negative	21
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Negative	30
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 50+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Negative	84
HTC_TST_DSD	Service Delivery Point (Community) Mobile Testing: 1-9, Positive	2
HTC_TST_DSD	By Key Population: FSW, Negative	4,112
HTC_TST_DSD	By Key Population: FSW, Positive	379
HTC_TST_DSD	By Key Population: MSM, Negative	820
HTC_TST_DSD	By Key Population: MSM, Positive	40
HTC_TST_DSD	By Key Population: PWID, Negative	572
HTC_TST_DSD	By Key Population: PWID, Positive	4
HTC_TST_DSD	By Key Population: TG, Negative	1,288
HTC_TST_DSD	By Key Population: TG, Positive	10
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	1,044

HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	570
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	1,659
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	964
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	17
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	5,597
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	67
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	4,569
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	54
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	8,322
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	93
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	8,701
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	96
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	295
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	2

HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	365
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	3
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	1,247
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	5
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	4,352
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	6
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	6
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	3
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	3
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	1
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total	1

	number of registered new and relapsed TB cases, during the reporting period)	
GEND_GBV_DSD	Number of people receiving post-GBV care	14,472
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	11,046
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	3,425
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	685
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	3,766
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	1,003
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	192
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	79
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	4,186
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	1,207
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	349
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	129
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	1,868
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	749
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	594
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	222
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	69
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	27
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	20
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	7
GEND_GBV_TA	Number of people receiving post-GBV care	1,451
GEND_GBV_TA	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	907
GEND_GBV_TA	By type of service: Sexual Violence (Post-Rape Care)	544
GEND_GBV_TA	15-19, Female, Physical and/or Emotional Violence	180
GEND_GBV_TA	20-24, Female, Physical and/or Emotional Violence	270
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	12,571

OVC_SERV_DSD	Age/Sex: 15-17 Female	8,422
OVC_SERV_DSD	By: Age/sex: 18-24 Female	4,149
OVC_SERV_DSD	Sum of Age/Sex disaggregates	8,422
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	2,526
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	1,245
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	565
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	1,321
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	472
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	2,043
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 15-17	5,029
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	7,542
OVC_SERV_DSD	Program Completion: Active	12,571
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 15-17	3,657
OVC_SERV_TA	Required only for DREAMS countries: By Service Area, age and sex: Other Service Areas Female 18-24	5,486
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	6
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	6
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1

TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	3
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	3
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	1
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	1
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	4,091
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	83
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,676
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	110
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	2,222
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	193

TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	3,898
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	4,091
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	1,135
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	12
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	475
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	16
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	632
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	1,135
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	4,595
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	5,124
TX_PVLS_DSD	Numerator: Indication: Routine	4,270
TX_PVLS_DSD	Numerator: Indication: Targeted	325
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	5
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	128
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	6
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	186
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	58
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,678
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	86
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	2,448

TX_PVLS_DSD	Denominator: Indication: Routine	4,765
TX_PVLS_DSD	Denominator: Indication: Targeted	359
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	6
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	148
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	8
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	197
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	78
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	1,972
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	102
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	2,613
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	1,078
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,129
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	19
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	415
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	27
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number	617

	of adults and children who are still alive and on treatment at 12 months after initiating ART)	
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	13
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	466
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	18
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	632
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	1,021
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	1,135
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	331
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	214
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	296

TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	294
TB_PREV_DSD	By Therapy type (Denominator): 6-12 Month IPT	909
TB_PREV_DSD	By Therapy type (Denominator): Continuous IPT	226
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	230
TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	178
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	342
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	271
TB_PREV_DSD	By Therapy type (Numerator): 6-12 Month IPT	818
TB_PREV_DSD	By Therapy type (Numerator): Continuous IPT	203
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	2
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	2
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	1
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	1
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	1
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	1
TX_TB_DSD	Denominator: By Screen Result: Positive	2
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	2
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	2

Implementing Mechanism Details

Mechanism ID: 18514	**Mechanism Name: HWWK Nairobi Eastern**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Hope Worldwide	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 4,531,005	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 4,531,005	
Funding Source	**Funding Amount**
GHP-State	4,531,005

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	574,523
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Key Populations: MSM and TG	43,600
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Gender: GBV	21,900
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Key Populations: FSW	287,369
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Human Resources for Health	1,705,373
Motor Vehicles: Purchased	125,000

Budget Code Information

Mechanism ID:	18514		
Mechanism Name:	HWWK Nairobi Eastern		
Prime Partner Name:	Hope Worldwide		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	366,678	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	11,957	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	294,235	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	3,597,486	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	IDUP	130,637	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	128,714	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	1,298	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	0

PMTCT_STAT_DSD	By Number of new negative: Unknown Age	0
PMTCT_STAT_DSD	By Number of new negative: 25-49	0
PMTCT_STAT_DSD	By Age (Numerator): 25-49	0
KP_MAT_DSD	Number of people who inject drugs (PWID) on medication assisted therapy (MAT) for at least 6 months	0
KP_MAT_DSD	Sex: Male	0
KP_MAT_DSD	Sex: Female	0
KP_MAT_DSD	Sum of Sex disaggregates	0
KP_MAT_DSD	Unknown Sex	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0
PrEP_NEW_DSD	Number of individuals who have been newly enrolled on oral antiretroviral pre-exposure prophylaxis (PrEP) in the reporting period to prevent HIV infection	228
PrEP_NEW_DSD	Female 15-19	45
PrEP_NEW_DSD	Female 20-24	183
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	26,017
PP_PREV_DSD	Age/sex: 10-14 Male	0
PP_PREV_DSD	Age/sex: 15-19 Male	0
PP_PREV_DSD	Age/sex: 20-24 Male	0
PP_PREV_DSD	Age/sex: 25-49 Male	0
PP_PREV_DSD	Age/sex: 50+ Male	0
PP_PREV_DSD	Age/sex: 10-14 Female	13,225
PP_PREV_DSD	Age/sex: 15-19 Female	12,792
PP_PREV_DSD	Age/sex: 20-24 Female	0
PP_PREV_DSD	Age/sex: 25-49 Female	0
PP_PREV_DSD	Age/sex: 50+ Female	0
PP_PREV_DSD	Sum of Age/Sex disaggregates	26,017
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions	33,538

	that are based on evidence and/or meet the minimum standards required	
KP_PREV_DSD	By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	4,034
KP_PREV_DSD	By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Transgender who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Transgender who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	28,527
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	970
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence	7

	and/or meet the minimum standards required)	
KP_PREV_DSD	By key population type: People in prisons and enclosed settings (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	57,847
HTC_TST_DSD	By Test Result: Positive	1,146
HTC_TST_DSD	Sum of Test Result disaggregates	1,146
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile Testing: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age(Community) Mobile	0

	Testing: Unknown Age, Male, Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1,438
HTC_TST_DSD	Service Delivery Point (Community) Other: 10-14, Female, Positive	4
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Negative	2,478
HTC_TST_DSD	Service Delivery Point (Community) Other: 15-19, Female, Positive	94
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Negative	2,089
HTC_TST_DSD	Service Delivery Point (Community) Other: 20-24, Female, Positive	174
HTC_TST_DSD	By Key Population: FSW, Negative	22,730
HTC_TST_DSD	By Key Population: FSW, Positive	416
HTC_TST_DSD	By Key Population: MSM, Negative	3,127
HTC_TST_DSD	By Key Population: MSM, Positive	52
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	0
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	0
HTC_TST_DSD	By Key Population: PWID, Negative	573
HTC_TST_DSD	By Key Population: PWID, Positive	0
HTC_TST_DSD	By Key Population: TG, Negative	0
HTC_TST_DSD	By Key Population: TG, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: <15, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: <15, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive	0

HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	7,293
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	43
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	1,834
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	39,417
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	793
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	2,136
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	50
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Positive	0
GEND_GBV_DSD	Number of people receiving post-GBV care	24,812
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	18,088
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	6,723
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	2,742

GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	597
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	101
GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	1,786
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	277
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	3,925
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	1,581
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	3,350
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	2,000
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	6,999
OVC_SERV_DSD	Age/Sex: 10-14 Female	1,821
OVC_SERV_DSD	Age/Sex: 15-17 Female	3,080
OVC_SERV_DSD	By: Age/sex: 18-24 Female	2,098
OVC_SERV_DSD	Sum of Age/Sex disaggregates	4,901
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14	528
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17	1,522
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24	65
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14	960
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17	648
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24	432
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17	863
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24	1,673
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 10-14	1,821
OVC_SERV_DSD	Required only for DREAMS countries - By service, age	3,080

	and sex: Other Services Female 15-17	
OVC_SERV_DSD	Required only for DREAMS countries - By service, age and sex: Other Services Female 18-24	2,098
OVC_SERV_DSD	Program Completion: Active	6,999
OVC_SERV_DSD	Program Completion: Transferred	0
OVC_SERV_DSD	Program Completion: Exited without graduation	0
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,013
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	0
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	0
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	0
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	1,013
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	0
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,013
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	1,013
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	227
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	0
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	1
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	88
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	90
TX_NEW_DSD	Pregnancy status	0
TX_NEW_DSD	Breastfeeding status	0
TX_NEW_DSD	FSW	226
TX_NEW_DSD	MSM	1
TX_NEW_DSD	People in prisons and other enclosed settings	0
TX_NEW_DSD	TG	0
TX_NEW_DSD	By Key populations: People who inject drugs (PWID)	0
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	911

TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	1,013
TX_PVLS_DSD	Numerator: Indication: Routine	911
TX_PVLS_DSD	Numerator: Indication: Targeted	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	0
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	0
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	9
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	902
TX_PVLS_DSD	Denominator: Indication: Routine	1,013
TX_PVLS_DSD	Denominator: Indication: Targeted	0
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	0
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	0
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	0
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding	0

	Targeted	
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	0
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	109
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	904
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0

TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	199

TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	244
TX_RET_DSD	Numerator by Status: Pregnant	0
TX_RET_DSD	Numerator by Status: Breastfeeding	0
TX_RET_DSD	Denominator by Status: Pregnant	0
TX_RET_DSD	Denominator by Status: Breastfeeding	0
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	199
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0

TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	244
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	0
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	0
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	0
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	0
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	0

Implementing Mechanism Details

Mechanism ID: 18515	**Mechanism Name: Faith-Based Sites in the Eastern Slums of Nairobi**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Eastern Deanery AIDS Relief Program	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 6,389,279	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 6,389,279	
Funding Source	**Funding Amount**
GHP-State	6,389,279

Cross-Cutting Budget Attribution(s)

Gender: GBV	89,149
Focus Area:	Post GBV Care
Sub Area:	Implementation

Sub Area:	Capacity building
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Key Populations: MSM and TG	33,627
Focus Area:	Training of health workers and community outreach workers
Focus Area:	Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance
Key Populations: FSW	78,520
Focus Area:	Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention
Focus Area:	Training of health workers and community outreach workers
Human Resources for Health	3,300,000

Budget Code Information

Mechanism ID:	**18515**		
Mechanism Name:	**Faith-Based Sites in the Eastern Slums of Nairobi**		
Prime Partner Name:	**Eastern Deanery AIDS Relief Program**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	311,804	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	CIRC	1,179,684	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVCT	995,209	0

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	91,323	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	272,899	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	3,356,479	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	181,881	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	1,763
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	12,405
PMTCT_ART_DSD	New on ART	785
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	978
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	12,405
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	0
PMTCT_STAT_DSD	By Age (Denominator): <15-19	1,948
PMTCT_STAT_DSD	By Age (Denominator): 20-24	4,407
PMTCT_STAT_DSD	By Age (Denominator): 25-49	6,050

PMTCT_STAT_DSD	By Age (Denominator): 50+	0
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	0
PMTCT_STAT_DSD	By Number of known positives: 15-19	28
PMTCT_STAT_DSD	By Number of known positives: 20-24	146
PMTCT_STAT_DSD	By Number of known positives: 25-49	804
PMTCT_STAT_DSD	By Number of known positives: 50+	0
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	0
PMTCT_STAT_DSD	By Number of new positives: 15-19	86
PMTCT_STAT_DSD	By Number of new positives: 20-24	277
PMTCT_STAT_DSD	By Number of new positives: 25-49	515
PMTCT_STAT_DSD	By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	0
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	0
PMTCT_STAT_DSD	By Number of new negative: 15-19	1,834
PMTCT_STAT_DSD	By Number of new negative: 20-24	3,984
PMTCT_STAT_DSD	By Number of new negative: 25-49	4,731
PMTCT_STAT_DSD	By Number of new negative: 50+	0
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	0
PMTCT_STAT_DSD	By Age (Numerator): 15-19	1,948
PMTCT_STAT_DSD	By Age (Numerator): 20-24	4,407
PMTCT_STAT_DSD	By Age (Numerator): 25-49	6,050
PMTCT_STAT_DSD	By Age (Numerator): 50+	0
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	23,119

VMMC_CIRC_DSD	By Age: 0-60 days	0
VMMC_CIRC_DSD	By Age: 2 months - 9 years	0
VMMC_CIRC_DSD	By Age: 10-14	9,833
VMMC_CIRC_DSD	By Age: 15-19	2,348
VMMC_CIRC_DSD	By Age: 20-24	2,191
VMMC_CIRC_DSD	By Age: 25-29	4,371
VMMC_CIRC_DSD	By Age: 30-49	4,160
VMMC_CIRC_DSD	By Age: 50+	216
VMMC_CIRC_DSD	Sum of age disaggregates (Prior to FY15)	14,588
VMMC_CIRC_DSD	Sum of age disaggregates (FY15-Current)	23,119
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	21,713
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	1,406
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	205,027
HTC_TST_DSD	By Test Result: Positive	6,595
HTC_TST_DSD	Sum of Test Result disaggregates	6,595
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative	1,046
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative	579
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative	1,572
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive	9
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative	966
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive	4

HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative	3,487
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive	45
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative	1,336
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive	15
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Negative	7,478
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Female, Positive	243
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Negative	3,306
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 25-49, Male, Positive	217
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Negative	721
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Female, Positive	32
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Negative	397
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 50+, Male, Positive	25
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility)Other PITC: <1, Negative	86
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: <1, Positive	9

HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Negative	2,399
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: 1-9, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	6,823
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Negative	47
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Female, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Negative	41
HTC_TST_DSD	Service Delivery Point (Facility) TB: 10-14, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Negative	19
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Female, Positive	24
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Negative	17
HTC_TST_DSD	Service Delivery Point (Facility) TB: 15-19, Male, Positive	8
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Negative	65
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Female, Positive	57
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Negative	93
HTC_TST_DSD	Service Delivery Point (Facility) TB: 20-24, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Negative	166
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Female, Positive	204

HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Negative	469
HTC_TST_DSD	Service Delivery Point (Facility) TB: 25-49, Male, Positive	229
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Negative	34
HTC_TST_DSD	Service Delivery Point (Facility) TB: 50+, Male, Positive	30
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) TB: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	8,738
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	2,186
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	2,186
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Negative	8,520

HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	216
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Negative	649
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Female, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Negative	631
HTC_TST_DSD	Service Delivery Point (Facility) Index: 10-14, Male, Positive	1
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Negative	462
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Female, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Negative	229
HTC_TST_DSD	Service Delivery Point (Facility) Index: 15-19, Male, Positive	6
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Negative	264
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Female, Positive	16
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Negative	131
HTC_TST_DSD	Service Delivery Point (Facility) Index: 20-24, Male, Positive	7
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female, Negative	678
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Female,	79

	Positive	
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Negative	705
HTC_TST_DSD	Service Delivery Point (Facility) Index: 25-49, Male, Positive	69
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Negative	87
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Female, Positive	14
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Negative	91
HTC_TST_DSD	Service Delivery Point (Facility) Index: 50+, Male, Positive	11
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Negative	107
HTC_TST_DSD	Service Delivery Point (Facility) Index: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Negative	3,391
HTC_TST_DSD	Service Delivery Point (Facility) Index: 1-9, Positive	2
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 10-14, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Negative	1,834
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 15-19, Positive	114
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 1-9, Positive	0

HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Negative	3,984
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 20-24, Positive	423
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Negative	4,731
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 25-49, Positive	1,319
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: 50+, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) ANC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Negative	2,106
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Female, Positive	12
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Negative	3,051
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 10-14, Male, Positive	13
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Negative	8,367
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Female, Positive	56
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Negative	4,567
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 15-19, Male, Positive	29
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Negative	17,917
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Female, Positive	243
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Negative	9,233
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 20-24, Male, Positive	87

HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Negative	40,228
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Female, Positive	1,312
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Negative	31,026
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 25-49, Male, Positive	1,171
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Negative	2,439
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Female, Positive	176
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Negative	3,015
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 50+, Male, Positive	125
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT:	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VCT: <1, Positive	39
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Negative	5,516
HTC_TST_DSD	Service Delivery Point (Facility) VCT: 1-9, Positive	53
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	1,551
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	1,556
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	54
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of	887

	registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	60
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	550
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	59
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	873
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	81
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	543
GEND_GBV_DSD	Number of people receiving post-GBV care	9,006
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	6,244
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	2,762
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1,105
GEND_GBV_DSD	<10, Female, Physical and/or Emotional Violence	1,405
GEND_GBV_DSD	<10, Female, Sexual Violence (Post-Rape Care)	498
GEND_GBV_DSD	<10, Male, Physical and/or Emotional Violence	275
GEND_GBV_DSD	<10, Male, Sexual Violence (Post-Rape Care)	111
GEND_GBV_DSD	10-14, Female, Physical and/or Emotional Violence	841
GEND_GBV_DSD	10-14, Female, Sexual Violence (Post-Rape Care)	250
GEND_GBV_DSD	10-14, Male, Physical and/or Emotional Violence	88
GEND_GBV_DSD	10-14, Male, Sexual Violence (Post-Rape Care)	82

GEND_GBV_DSD	15-19, Female, Physical and/or Emotional Violence	786
GEND_GBV_DSD	15-19, Female, Sexual Violence (Post-Rape Care)	164
GEND_GBV_DSD	15-19, Male, Physical and/or Emotional Violence	80
GEND_GBV_DSD	15-19, Male, Sexual Violence (Post-Rape Care)	7
GEND_GBV_DSD	20-24, Female, Physical and/or Emotional Violence	1,740
GEND_GBV_DSD	20-24, Female, Sexual Violence (Post-Rape Care)	311
GEND_GBV_DSD	20-24, Male, Physical and/or Emotional Violence	110
GEND_GBV_DSD	20-24, Male, Sexual Violence (Post-Rape Care)	13
GEND_GBV_DSD	25-49, Female, Physical and/or Emotional Violence	786
GEND_GBV_DSD	25-49, Female, Sexual Violence (Post-Rape Care)	1,233
GEND_GBV_DSD	25-49, Male, Physical and/or Emotional Violence	68
GEND_GBV_DSD	25-49, Male, Sexual Violence (Post-Rape Care)	63
GEND_GBV_DSD	50+, Female, Physical and/or Emotional Violence	56
GEND_GBV_DSD	50+, Female, Sexual Violence (Post-Rape Care)	26
GEND_GBV_DSD	50+, Male, Physical and/or Emotional Violence	3
GEND_GBV_DSD	50+, Male, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Female, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Female, Sexual Violence (Post-Rape Care)	0
GEND_GBV_DSD	Unknown Age, Male, Physical and/or Emotional Violence	0
GEND_GBV_DSD	Unknown Age, Male, Sexual Violence (Post-Rape Care)	0
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	598
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	598
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	13

TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	273
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	13
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	299
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	13
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	273
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	13
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	299
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	1,763
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	19
PMTCT_EID_DSD	Unknown, <= 2 months	0
PMTCT_EID_DSD	Unknown, 2 - 12 months	0
PMTCT_EID_DSD	Number of infants with a negative virological test result	1,394

	within 2 months of birth	
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	29
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	321
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	29,497
TX_CURR_DSD	Age/Sex: 15-19 Male	214
TX_CURR_DSD	Age/Sex: 15-19 Female	298
TX_CURR_DSD	Sum of age/sex disaggregates	512
TX_CURR_DSD	Age/Sex: <1	48
TX_CURR_DSD	Age/Sex: <1-9	734
TX_CURR_DSD	Age/Sex: 10-14 Male	347
TX_CURR_DSD	Age/Sex: 10-14 Female	368
TX_CURR_DSD	Age/Sex: 20-24 Male	198
TX_CURR_DSD	Age/Sex: 25-49 Male	6,842
TX_CURR_DSD	Age/Sex: 50+ Male	1,911
TX_CURR_DSD	Age/Sex: 20-24 Female	1,031
TX_CURR_DSD	Age/Sex: 25-49 Female	15,144
TX_CURR_DSD	Age/Sex: 50+ Female	2,362
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	6,595
TX_NEW_DSD	By Age/Sex: <1	48
TX_NEW_DSD	By Age/Sex: 1-9	67
TX_NEW_DSD	By Age/Sex: 10-14 Male	27
TX_NEW_DSD	By Age/Sex: 15-19 Male	47
TX_NEW_DSD	By Age/Sex: 20-24 Male	115
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,686
TX_NEW_DSD	By Age/Sex: 50+ Male	191
TX_NEW_DSD	By Age/Sex: 10-14 Female	26
TX_NEW_DSD	By Age/Sex: 15-19 Female	209
TX_NEW_DSD	By Age/Sex: 20-24 Female	784

TX_NEW_DSD	By Age/Sex: 25-49 Female	3,157
TX_NEW_DSD	By Age/Sex: 50+ Female	238
TX_NEW_DSD	Sum of Age/Sex disaggregates	6,480
TX_NEW_DSD	Pregnancy status	707
TX_NEW_DSD	Breastfeeding status	79
TX_NEW_DSD	FSW	0
TX_NEW_DSD	MSM	0
TX_NEW_DSD	People in prisons and other enclosed settings	0
TX_NEW_DSD	TG	0
TX_NEW_DSD	By Key populations: People who inject drugs (PWID)	0
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	26,360
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	29,450
TX_PVLS_DSD	Numerator: Indication: Routine	24,515
TX_PVLS_DSD	Numerator: Indication: Targeted	1,845
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	861
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	130
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	68
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	10
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	40
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	580
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	41
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1,184

TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	534
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	7,670
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	545
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	15,766
TX_PVLS_DSD	Denominator: Indication: Routine	27,389
TX_PVLS_DSD	Denominator: Indication: Targeted	2,061
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	955
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	142
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	73
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Targeted	10
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	51
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	643
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	50
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	1,317
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	668
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	8,522
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	681
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	17,518
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0

TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0

TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	6,265
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	6,595
TX_RET_DSD	Numerator by Status: Pregnant	672
TX_RET_DSD	Numerator by Status: Breastfeeding	75
TX_RET_DSD	Denominator by Status: Pregnant	707
TX_RET_DSD	Denominator by Status: Breastfeeding	79
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	78
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,937
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	81
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	4,169

TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	82
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,039
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	86
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	4,388
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	5,936
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	6,595
TB_PREV_DSD	By Age/Sex (Denominator): <15, Female	86
TB_PREV_DSD	By Age/Sex (Denominator): <15, Male	82
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Female	4,388
TB_PREV_DSD	By Age/Sex (Denominator): 15+, Male	2,039
TB_PREV_DSD	By Age/Sex (Numerator): <15, Female	75

TB_PREV_DSD	By Age/Sex (Numerator): <15, Male	72
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Female	3,952
TB_PREV_DSD	By Age/Sex (Numerator): 15+, Male	1,837
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	239
TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	29,497
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	10
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	10
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	86
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	133
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Female	755
TX_TB_DSD	Denominator: By Aggregated Age/Sex: <15, Male	742
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Female	18,835
TX_TB_DSD	Denominator: By Aggregated Age/Sex:15+, Male	9,165
TX_TB_DSD	Denominator: By Screen Result: Negative	23,597
TX_TB_DSD	Denominator: By Screen Result: Positive	5,900
TX_TB_DSD	Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease	5,900
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Other (No Xpert)	294
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only	886
TX_TB_DSD	Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay	4,720

Implementing Mechanism Details

Mechanism ID: 18516	**Mechanism Name: Bomu Hospital Affiliated Sites**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Mkomani Society Clinic	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No

Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 4,151,888	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 4,151,888	
Funding Source	**Funding Amount**
GHP-State	4,151,888

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	89,193
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	2,070,379
Motor Vehicles: Purchased	60,000

Budget Code Information

Mechanism ID:	**18516**		
Mechanism Name:	**Bomu Hospital Affiliated Sites**		
Prime Partner Name:	**Mkomani Society Clinic**		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HKID	213,227	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	253,765	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**

Prevention	HVCT	252,386	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	HVOP	267,226	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Prevention	MTCT	139,167	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	2,731,701	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	PDTX	294,416	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2018
PMTCT_ART_DSD	Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy	846
PMTCT_ART_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,523
PMTCT_ART_DSD	New on ART	406
PMTCT_ART_DSD	Already on ART at beginning of current pregnancy	440
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,523
PMTCT_STAT_DSD	By Age (Denominator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Denominator): <10	0
PMTCT_STAT_DSD	By Age (Denominator): 10-14	0
PMTCT_STAT_DSD	By Age (Denominator): <15-19	58
PMTCT_STAT_DSD	By Age (Denominator): 20-24	2,440

PMTCT_STAT_DSD	By Age (Denominator): 25-49	4,025
PMTCT_STAT_DSD	By Age (Denominator): 50+	0
PMTCT_STAT_DSD	By Number of known positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of known positives: <10	0
PMTCT_STAT_DSD	By Number of known positives: 10-14	0
PMTCT_STAT_DSD	By Number of known positives: 15-19	16
PMTCT_STAT_DSD	By Number of known positives: 20-24	154
PMTCT_STAT_DSD	By Number of known positives: 25-49	262
PMTCT_STAT_DSD	By Number of known positives: 50+	0
PMTCT_STAT_DSD	By Number of new positives: Unknown Age	0
PMTCT_STAT_DSD	By Number of new positives: <10	0
PMTCT_STAT_DSD	By Number of new positives: 10-14	0
PMTCT_STAT_DSD	By Number of new positives: 15-19	10
PMTCT_STAT_DSD	By Number of new positives: 20-24	190
PMTCT_STAT_DSD	By Number of new positives: 25-49	321
PMTCT_STAT_DSD	By Number of new positives: 50+	0
PMTCT_STAT_DSD	By Number of new negative: Unknown Age	0
PMTCT_STAT_DSD	By Number of new negative: <10	0
PMTCT_STAT_DSD	By Number of new negative: 10-14	0
PMTCT_STAT_DSD	By Number of new negative: 15-19	32
PMTCT_STAT_DSD	By Number of new negative: 20-24	2,096
PMTCT_STAT_DSD	By Number of new negative: 25-49	3,442
PMTCT_STAT_DSD	By Number of new negative: 50+	0
PMTCT_STAT_DSD	By Age (Numerator): Unknown Age	0
PMTCT_STAT_DSD	By Age (Numerator): <10	0
PMTCT_STAT_DSD	By Age (Numerator): 10-14	0
PMTCT_STAT_DSD	By Age (Numerator): 15-19	58
PMTCT_STAT_DSD	By Age (Numerator): 20-24	2,440
PMTCT_STAT_DSD	By Age (Numerator): 25-49	4,025
PMTCT_STAT_DSD	By Age (Numerator): 50+	0
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions	1,261

	that are based on evidence and/or meet the minimum standards required	
KP_PREV_DSD	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	857
KP_PREV_DSD	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	404
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	34,100
HTC_TST_DSD	By Test Result: Positive	1,177
HTC_TST_DSD	Sum of Test Result disaggregates	1,177
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Negative	101
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Negative	144
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: <15, Male, Positive	1
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Negative	502
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Female, Positive	2
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Negative	344
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: 15+, Male, Positive	2
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient:	0

	Unknown Age, Female, Negative	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Inpatient: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Negative	960
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Female, Positive	38
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Negative	788
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: <15, Male, Positive	31
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Negative	2,860
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Female, Positive	119
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Negative	1,613
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: 15+, Male, Positive	72
HTC_TST_DSD	Service Delivery Point (Facility) Other PITC: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) Other PITC: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Pediatric : <5 Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15,	298

	Female, Negative	
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Female, Positive	15
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Negative	275
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: <15, Male, Positive	15
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Negative	1,396
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Female, Positive	88
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Negative	892
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: 15+, Male, Positive	117
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) TB: Unknown Age, Male, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: <1, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: <1, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 10-14, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 15-19, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 1-9, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 1-9, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 20-24, Positive	0

HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 25-49, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: 50+, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) VMMC: <15, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: <15, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: 15+, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: Unknown Age, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VMMC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Negative	851
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Female, Positive	31
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Negative	645
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: <15, Male, Positive	27
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Negative	2,259
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Female, Positive	130
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+, Male, Negative	1,771
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: 15+,	72

	Male, Positive	
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point Agg Age (Facility) Index: Unknown Age, Male, Positive	0
HTC_TST_DSD	By Key Population: FSW, Negative	0
HTC_TST_DSD	By Key Population: FSW, Positive	0
HTC_TST_DSD	By Key Population: MSM, Negative	0
HTC_TST_DSD	By Key Population: MSM, Positive	0
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Negative	0
HTC_TST_DSD	By Key Population: People in prisons and other enclosed settings, Positive	0
HTC_TST_DSD	By Key Population: PWID, Negative	8,109
HTC_TST_DSD	By Key Population: PWID, Positive	316
HTC_TST_DSD	By Key Population: TG, Negative	0
HTC_TST_DSD	By Key Population: TG, Positive	0
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Negative	0
HTC_TST_DSD	Service Delivery Point (Facility) Malnutrition: Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: <15, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: <15, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Negative	4,677
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: 15+, Positive	1,846
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Negative	0

HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) ANC: Unknown Age, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: <15, Male, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Negative	922
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Female, Positive	707
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Negative	529
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: 15+, Male, Positive	535
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Female, Positive	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Negative	0
HTC_TST_DSD	Service Delivery Point by Agg Age (Facility) VCT: Unknown Age, Male, Positive	0
TB_STAT_DSD	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.	334
TB_STAT_DSD	Total number of registered new and relapsed TB cases, during the reporting period.	337
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	38
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Numerator: Number of	153

	registered new and relapsed TB cases with documented HIV status, during the reporting period)	
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	25
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period)	118
TB_STAT_DSD	Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	38
TB_STAT_DSD	Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	154
TB_STAT_DSD	Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	25
TB_STAT_DSD	Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period)	120
GEND_GBV_DSD	Number of people receiving post-GBV care	8,575
GEND_GBV_DSD	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	6,995
GEND_GBV_DSD	By type of service: Sexual Violence (Post-Rape Care)	1,580
GEND_GBV_DSD	By PEP service provision (related to sexual violence services provided)	1,421
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	4,070
OVC_SERV_DSD	Age/Sex: 10-14 Male	825
OVC_SERV_DSD	Age/Sex: 15-17 Male	274
OVC_SERV_DSD	By: Age/sex: Male 18-24	66
OVC_SERV_DSD	Age/Sex: 10-14 Female	867
OVC_SERV_DSD	Age/Sex: 15-17 Female	302
OVC_SERV_DSD	By: Age/sex: 18-24 Female	69

OVC_SERV_DSD	Sum of Age/Sex disaggregates	2,268
OVC_SERV_DSD	Age/Sex: <1	44
OVC_SERV_DSD	Age/Sex: 1-9	1,623
OVC_SERV_DSD	Program Completion: Active	3,974
OVC_SERV_DSD	Program Completion: Graduation	56
OVC_SERV_DSD	Program Completion: Transferred	28
OVC_SERV_DSD	Program Completion: Exited without graduation	12
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	218
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	218
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	13
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	112
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	13
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period)	80
TB_ART_DSD	Aggregated Age/Sex: Male <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	13
TB_ART_DSD	Aggregated Age/Sex: Male 15+ (Denominator: The	112

	number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	
TB_ART_DSD	Aggregated Age/Sex: Female <15 (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	13
TB_ART_DSD	Aggregated Age/Sex: Female 15+ (Denominator: The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period)	80
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	846
PMTCT_EID_DSD	Number of infants with a positive virological test result within 2 months of birth	7
PMTCT_EID_DSD	Unknown, <= 2 months	0
PMTCT_EID_DSD	Unknown, 2 - 12 months	0
PMTCT_EID_DSD	Number of infants with a negative virological test result within 2 months of birth	624
PMTCT_EID_DSD	Number of infants with a positive virological test result between 2 and 12 months of birth	10
PMTCT_EID_DSD	Number of infants with a negative virological test result between 2 and 12 months of birth	205
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	26,953
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,168
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	7,889
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,178
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	16,718
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,346
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	24,607
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	26,953
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,953

TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	199
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	957
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	248
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,549
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,953
TX_NEW_DSD	Pregnancy status	406
TX_NEW_DSD	Breastfeeding status	38
TX_NEW_DSD	FSW	0
TX_NEW_DSD	MSM	0
TX_NEW_DSD	People in prisons and other enclosed settings	0
TX_NEW_DSD	TG	0
TX_NEW_DSD	By Key populations: People who inject drugs (PWID)	0
TX_PVLS_DSD	Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months.	23,969
TX_PVLS_DSD	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months.	26,904
TX_PVLS_DSD	Numerator: Indication: Routine	22,290
TX_PVLS_DSD	Numerator: Indication: Targeted	1,679
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Routine	727
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Routine	26
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Pregnant Targeted	85
TX_PVLS_DSD	Numerator: Preg/BF by Indication: Breastfeeding Targeted	7
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted	56
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted	707
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted	82

TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted	764
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Male Routine	924
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine	7,071
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: <15 Female Routine	908
TX_PVLS_DSD	Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine	13,387
TX_PVLS_DSD	Denominator: Indication: Routine	25,022
TX_PVLS_DSD	Denominator: Indication: Targeted	1,882
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Routine	761
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Routine	32
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Pregnant Targeted	93
TX_PVLS_DSD	Denominator: Preg/BF by Indication: Breastfeeding Targeted	9
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Targeted	82
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Targeted	930
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Targeted	90
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Targeted	780
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Male Routine	1,127
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Male Routine	8,612
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: <15 Female Routine	1,182
TX_PVLS_DSD	Denominator: Aggregate Age/Sex by Indication: 15+ Female Routine	14,101

TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_PVLS_DSD	<15, Routine, Unknown Sex	0
TX_PVLS_DSD	<15, Targeted, Unknown Sex	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Female	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Male	0
TX_PVLS_DSD	<15, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	15+, Routine, Unknown Sex	0
TX_PVLS_DSD	15+, Targeted, Unknown Sex	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Female	0
TX_PVLS_DSD	15+, Undocumented Test Indication, Male	0

TX_PVLS_DSD	15+, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Routine, Female	0
TX_PVLS_DSD	Unknown Age, Routine, Male	0
TX_PVLS_DSD	Unknown Age, Routine, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Targeted, Female	0
TX_PVLS_DSD	Unknown Age, Targeted, Male	0
TX_PVLS_DSD	Unknown Age, Targeted, Unknown Sex	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Female	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Male	0
TX_PVLS_DSD	Unknown Age, Undocumented Test Indication, Unknown Sex	0
TX_PVLS_DSD	Breastfeeding, Undocumented Test Indication	0
TX_PVLS_DSD	Pregnant, Undocumented Test Indication	0
TX_PVLS_DSD	Undocumented Test Indication	0
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,789
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	25,560
TX_RET_DSD	Numerator by Status: Pregnant	406
TX_RET_DSD	Numerator by Status: Breastfeeding	40
TX_RET_DSD	Denominator by Status: Pregnant	381
TX_RET_DSD	Denominator by Status: Breastfeeding	27
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	158
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	869
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	218

TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,406
TX_RET_DSD	Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,168
TX_RET_DSD	Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	7,612
TX_RET_DSD	Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,171
TX_RET_DSD	Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	15,609
TB_PREV_DSD	The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period	2,650
TB_PREV_DSD	The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period).	2,944
TX_TB_DSD	Number of ART patients who were started on TB treatment during the reporting period.	87

TX_TB_DSD	Number of ART patients who were screened for TB at least once during the reporting period	87
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Female	5
TX_TB_DSD	Numerator: By Aggregated Age/Sex: <15, Male	6
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Female	32
TX_TB_DSD	Numerator: By Aggregated Age/Sex: 15+, Male	44

Implementing Mechanism Details

Mechanism ID: 18517	**Mechanism Name: UOW Training**
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University of Washington	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 950,000	**Total Mechanism Pipeline: N/A**
Applied Pipeline Amount: 0	
Total All Funding Sources and Applied Pipeline Amount: 950,000	
Funding Source	**Funding Amount**
GHP-State	950,000

Cross-Cutting Budget Attribution(s)

Gender: GBV	12,500
Focus Area:	GBV Prevention
Sub Area:	Implementation
Focus Area:	Post GBV Care
Sub Area:	Capacity building
Human Resources for Health	100,000

Budget Code Information

Mechanism ID:	18517		
Mechanism Name:	UOW Training		
Prime Partner Name:	University of Washington		
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Care	HVTB	80,750	0
Strategic Area	**Budget Code**	**Planned Amount**	**On Hold Amount**
Treatment	HTXS	869,250	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 18670	**TBD: Yes**
REDACTED	

Agency Information - Costs of Doing Business
U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing		0		0	726,336	726,336
Computers/IT Services		0		0	579,500	579,500
ICASS		0		0	1,205,752	1,205,752
Institutional Contractors				0	905,424	905,424
Management Meetings/Professional Development		0		0	2,223,678	2,223,678
Staff Program Travel		0		0	1,241,340	1,241,340
USG Staff Salaries and Benefits - Internationally Recruited		0		0	1,571,636	1,571,636
USG Staff Salaries and Benefits - Locally Recruited		0		0	4,273,002	4,273,002
Total	**0**	**0**	**0**	**0**	**12,726,668**	**12,726,668**

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Computers/IT Services		11,363		11,363	2,647	14,010
ICASS		36,772		36,772	8,568	45,340
Institutional Contractors		1,663,660		1,663,660	0	1,663,660
Management Meetings/Professional Development		68,191		68,191	15,888	84,079
Non-ICASS Administrative Costs		213,955		213,955	437,464	651,419
Non-ICASS Motor Vehicles		92,702		92,702	21,598	114,300
Staff Program Travel		466,434		466,434	108,674	575,108
USG Staff Salaries and Benefits - Internationally Recruited		128,201		128,201	29,869	158,070
USG Staff Salaries and Benefits - Locally Recruited		0		0	0	0

Total	**0**	**2,681,278**	**0**	**2,681,278**	**624,708**	**3,305,986**

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Capital Security Cost Sharing		1,512,000		1,512,000	0	1,512,000
Computers/IT Services		750,000		750,000	0	750,000
ICASS		1,250,000		1,250,000	0	1,250,000
Institutional Contractors	0	375,000		375,000	0	375,000
Management Meetings/Professional Development		121,155		121,155	0	121,155
Non-ICASS Administrative Costs		1,404,800		1,404,800	0	1,404,800
Staff Program Travel	0	2,088,785		2,088,785	0	2,088,785
USG Staff Salaries and Benefits - Internationally Recruited	3,320,000	630,765		3,950,765	0	3,950,765
USG Staff Salaries and	0	6,314,560		6,314,560	0	6,314,560

Benefits - Locally Recruited						
Total	**3,320,000**	**14,447,065**	**0**	**17,767,065**	**0**	**17,767,065**

U.S. Department of Health and Human Services/Health Resources and Services Administration

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
Institutional Contractors				0	0	0
Peace Corps Volunteer Costs				0	0	0
Staff Program Travel		0		0	0	0
USG Staff Salaries and Benefits - Internationally Recruited		0		0	0	0
USG Staff Salaries and Benefits - Locally Recruited		0		0	0	0
Total	**0**	**0**	**0**	**0**	**0**	**0**

U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and Applied Pipeline Amount
ICASS		325,833		325,833	0	325,833
Management Meetings/Professional Development		136,000		136,000	0	136,000
Non-ICASS Administrative Costs		27,000		27,000	0	27,000
Staff Program Travel		35,000		35,000	0	35,000
USG Staff Salaries and Benefits - Internationally Recruited		252,136		252,136	0	252,136
USG Staff Salaries and Benefits - Locally Recruited		559,885		559,885	0	559,885
Total	**0**	**1,335,854**	**0**	**1,335,854**	**0**	**1,335,854**

U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Funding Source Total	Applied Pipeline	Total All Funding Sources and

						Applied Pipeline Amount
Non-ICASS Administrative Costs		19,538		19,538	0	19,538
Peace Corps Volunteer Costs		647,507		647,507	0	647,507
Staff Program Travel		22,210		22,210	0	22,210
USG Staff Salaries and Benefits - Internationally Recruited		0		0	0	0
USG Staff Salaries and Benefits - Locally Recruited		275,173		275,173	0	275,173
Total	**0**	**964,428**	**0**	**964,428**	**0**	**964,428**